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TELOMERE-DRIVEN TETRAPLOIDY
AND ITS RELEVANCE TO CANCER
Teresa Davoli, Ph.D.
The Rockefeller University 2013
Aneuploidy, i.e. the state of having an abnormal chromosome number, is a
hallmark of human solid tumors. A fraction of aneuploid tumors is near-diploid
and can be explained by individual chromosome gains and losses in mitosis.
The remaining fraction is subtetraploid, containing an increased chromosome
number, ranging from 60 to 90 chromosomes. Mounting evidence argues that
tetraploidization, i.e. whole genome doubling, followed by chromosome loss
is likely to represent an early event in the development of subtetraploid tu-
mors. The origin of tetraploidization in cancer is still unclear. Here we de-
scribe a new potential mechanism of tetraploidization in cancer, originating
from telomere dysfunction, a widespread phenomenon in early tumorigene-
sis. Prolonged telomere deprotection caused by inactivation of the telomeric
proteins POT1a and POT1b leads to tetraploidy in p53/Rb deficient mouse
cells. Irreversible telomere deprotection and other forms of persistent DNA
damage induce a prolonged G2 phase followed by by-pass of mitosis, re-entry
into S phase, and whole genome reduplication. Endoreduplication requires an
ATM and/or ATR-dependent DNA damage signal, blocking the activation of
Cdk1/CyclinB and mitosis. Furthermore, we demonstrate tetraploidization
through endoreduplication or mitotic failure in human fibroblasts and mam-
mary epithelial cells undergoing replicative telomere crisis in the absence of
p53 and Rb. Using an inducible system to generate transient telomere dam-
age, we show that telomere-driven tetraploidization enhances the tumorigenic
transformation of mouse cells. Finally we showed that breast cancer cell lines
with high chromosome numbers display higher frequency of telomeric fusions
compared to near-diploid lines, suggesting previous telomere crisis during their
development. Collectively, these data suggest a potentially widespread mecha-
nism for tetraploidization resulting from excessive telomere shortening in early
precancerous lesions, promoting the evolution of a subtetraploid cancer kary-
otype.
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Chapter 1
Introduction
1.1 Polyploidy in physiology and evolution
1.1.1 Organismal Polyploidy During Evolution
Organismal polyploidy is very common in plants (frequency estimated be-
tween 30 and 80%; Otto and Whitton, 2000), especially in the flowering plants
(angiosperms; Masterson, 1994), probably due both to frequent formation of
diploid gametes (0.5% of gametes are estimated to be diploid) and to frequent
species hybridization (Fig. 1.1A). In contrast, organismal polyploidy is rare
among animals, mainly due to problems in embryonic development and sex
determination (Otto and Whitton, 2000). Polyploidy is sporadically found in
insects (90 species) and some vertebrates (100 species among amphibians, rep-
tiles and fishes; Otto and Whitton, 2000, Fig. 1.1A). In mammals, organismal
polyploidy is poorly tolerated and it is responsible for 5-10% of spontaneous
abortions in humans (Creasy et al., 1976). The only tetraploid mammals
1
are the red vizcacha rat (Tympanoctomys barrerae) and its close relatives,
Fig. 1.1A).
Despite being rare in animals, polyploidy is thought to have played an
important role during evolution. Many plants and animals are considered an-
cient polyploids (or paleopolyploids), i.e. to have arisen through one or more
whole genome duplications during their evolution, followed by silencing, loss
and divergence of many of the duplicated genes (Wolfe, 2001; Pennisi, 2001).
For example, the genome of Arabidopsis thaliana contains many syntenic du-
plicated regions that have been proposed to derive from multiple genome-wide
polyploidization events (Ku et al., 2000). A longstanding hypothesis, dating
back to Ohno’s ideas in 1970, proposes that two events of polyploidization oc-
curred during the early evolution of the vertebrate lineage (’the 2R hypothesis’,
Ohno, 1970; Fig. 1.1B). One of the initial genetic observations supporting this
hypothesis was the fact that many invertebrate single-copy genes have four
vertebrate orthologues (’1:4 relationship’). For example, the single copy Hox
gene cluster in the Drosophila genome is present in four copies in mammals,
each located on a different chromosome (Graham et al., 1989; Schughart et
al.; 1989, Garcia-Fernandez and Holland, 1994). Other examples of the 1:4
relationship include genes encoding for the fibroblast growth factor receptors
and the major histocompatibility complex. Importantly, the quadruplicated
paralogous chromosomal regions frequently show collinear gene order and the
same centromere-to-telomere orientation, suggesting an en-bloc duplication,
instead of individual independent duplications. Recent studies have refined
the 2R model and specified the timing of whole-genome duplications at the
2
Figure 1.1: Examples of organismal polyploidy and the 2R hypothe-
sis. (A) Examples of natural polyploid species among plants and animals (from
http : //polyploidy.org/index.php/ParadeofP olyploids). The red vizcacha rat
(Tympanoctomys barrerae) and its close relatives are the only tetraploid mammals.
(B) Recent version of the 2R (3R) hypothesis, which assumes two rounds of genome
duplication, the first after the emergence of urochordates and the second before
the radiation of jawed vertebrates (from Kasahara, 2007). A third duplication is
thought to have occurred during the evolution of fishes.
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origin of vertebrates. The first duplication is supposed to have occurred after
the emergence of urochordates and the second before the radiation of jawed
vertebrates (Fig. 1.1B, Kasahara, 2007). A third genome duplication (3R) is
thought to have occurred during the evolution of ray-finned fishes (Jallion et
al., 2004).
The occurrence of paleopolyploidy argues that polyploidy does not neces-
sarily result in an evolutionary dead end. It has been argued that polyploidy
can confer an adaptive advantage because of mutational robustness. In the
polyploid genome, the consequences of gene deletions or inactivating muta-
tions can be buffered by the presence of the additional gene copies (Crow and
Wagner, 2006). By limiting loss of fitness or viability, polyploidy can reduce
the risk of extinction, especially of small and bottle-necked populations (as in
preneoplastic cell populations, see below). However, a drawback of increased
masking of gene mutations is a high mutational load (higher frequency of
gene mutations in the population), that can impair the survival of a polyploid
species compared to their diploid counterpart (Otto and Whitton, 2000). A
second advantage of polyploidy is the increased gene subfunctionalization and
neofunctionalization, leading to increased evolution rate and directional selec-
tion (Crow and Wagner, 2006). Moreover, doubling of the whole genome may
allow doubling of all the genes in the same pathway preventing unbalanced
effects that can result from duplication of single genes or single chromosomal
regions (Freeling and Thomas, 2006). On the other hand, the effect of a new
beneficial mutation can be lower in polyploids than in diploids since the num-
ber of remaining WT alleles is higher (Otto and Whitton, 2000). Finally, for
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partially unknown reasons, newly formed polyploids show greater genome in-
stability than the diploids counterpart, showing a higher rate of chromosome
missegregation and in some cases higher level of endogenous DNA damage
lesions and increased dependence on the DNA repair pathways (Hashimoto et
al., 1996; Comai et al., 2000; Andalis et al., 2004; Mayer and Aguilera, 1990;
Storchova et al., 2006). If high levels of genome instability can hamper survival
and fitness, an increased mutation rate is also able to promote development
of new gene functions and adaptive evolution especially in the presence of a
sustained selective pressure (Colegrave and Collins, 2008). Theoretical mod-
els of adaptive evolution have been developed to determine the conditions of
increased adaptive evolution of polyploids versus diploids. The prediction is
that polyploids can adapt more rapidly than diploids if the population size is
small and if the beneficial mutations that are selected for are at least partially
dominant (Otto and Whitton, 2000). This hypothesis has been experimentally
verified in yeast (diploids versus haploids; Paquin and Adams, 1983; Zeyl et
al., 2003; Anderson et al., 2003; Anderson et al., 2004; Thompson et al., 2006).
1.1.2 Cellular Polyploidy in Normal Physiology
Cellular polyploidy is frequently observed in terminally differentiated and spe-
cialized tissues of multicellular organisms from plants (Galbraith et al., 1991),
insects (such as gut, epidermis, salivary glands; Smith and Orr-Weaver, 1991)
and mammals (Biesterfeld et al., 1994). A common theme is the occurrence of
polyploidy in cells that provide nutrients, proteins or nucleotides to support
the developing embryo, as it happens in plant endosperm, in nurse and follic-
5
ular cells in the Drosophila ovary and in trophoblast giant cells of mammalian
placenta (Lee et al., 2009). Another common target of polyploidization are
tissues specialized in nutrient uptake and storage such as leaves and root hairs
in plants and intestinal cells in Drosophila and C. elegans.
In mammals, the conversion from diploidy to polyploidy is part of nor-
mal development and differentiation in at least three specialized cell types
(Fig. 1.2). A striking case of developmental polyploidization is the placental
trophoblast giant cell (TGC), which can reach a DNA content of up to 1000C
(Ullah et al., 2009a; Ullah et al., 2009b). TGC polyploidization begins with a
differentiation step induced when FGF4 signaling abates. The drop in FGF4
increases the expression of the Cdk inhibitor p57 (Ullah et al., 2008), which,
together with a reduction in the translation of Cyclin B (Palazon et al., 1998),
blocks Cdk1/CycB-mediated mitosis. The ensuing endocycles appear to in-
volve oscillation of Cdk2/CycE activity and p57 (Hattori et al., 2000), inducing
alternating S and G phases. TGCs have lowered amounts of geminin (Gon-
zalez et al., 2006), which may be a prerequisite for pre-RC formation in these
amitotic cycles. Because no mitosis occurs between S-phases, the replicated
chromatids are not separated, forming cohesin-linked polytene chromosomes
similar to those of Drosophila salivary glands (Ilgren, 1981). The endocycles
have been proposed to accelerate TGC growth by shortening the cell cycle and
simultaneously increasing the number of chromosomes (Gardner and Davies,
1993; Goncalves et al., 2003).
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Figure 1.2: Examples of developmentally programmed polyploidization.
Three mammalian cell types show prominent polyploidization under physiolog-
ical conditions: trophoblasts, megakaryocytes and hepatocytes. The schemat-
ics show the alterations in the cell cycle that allow polyploidization to occur.
Trophoblast giant cells from (Rossant and Cross, 2001); Megakaryocytes from
http : //blass.com.au/definitions/ megakaryocyte; Hepatocytes from http :
//www.vivo.colostate.edu/hbooks/pathphys/digestion/liver/histocytes.html. See
text for detailed discussion.
7
8
Whereas TGCs skip mitosis altogether, megakaryocytes become polyploid
through an abortive mitosis (endomitosis) in which anaphase and telophase can
occur but cytokinesis fails (Fig. 1.2). The abortive mitosis appears to be due to
suboptimal levels of Cdk1/CycB activity and premature degradation of Cyclin
B (Ravid et al., 2002). Although the clusters of duplicated chromosomes
temporarily separate and a mid-zone forms, the cleavage furrow regresses and
all chromosomes eventually end up in a single nucleus. The resulting cell is
in a G1-like state, progresses through S phase, and enters another round of
endomitosis, repeating the process several times to form polyploid cells up to
128N (modal ploidy of 16N; Winkelmann et al., 1987).
A third example of polyploidization involving an abortive mitosis is rep-
resented by hepatocytes (reviewed in (Celton-Morizur and Desdouets, 2010);
Fig. 1.2). During liver growth, there is a progressive increase in the frequency
of tetraploid (4N) and octoploid (8N) hepatocytes (Watanabe et al., 1978).
These cells often have two 2N (or 4N) nuclei and arise from a failure in cy-
tokinesis, perhaps due to an increase in insulin signaling (Celton-Morizur et
al., 2010; Guidotti et al., 2003; Margall-Ducos et al., 2007). Multi-nucleated
hepatocytes can also arise from cell-cell fusion (Duncan et al., 2009) and hepa-
tocytes with a single 4N or 8N nucleus readily arise when anaphase is inhibited
or telomeres are damaged (Wirth et al., 2006; Lazzerini Denchi et al., 2006).
Hepatocytes are particularly prone to increasing their ploidy in response to
DNA damage whereas most other cells undergo apoptosis. This attribute
may be related to the altered manner in which the hepatocyte p53 pathway
responds to DNA lesions (Fei et al., 2002).
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A fourth type of polyploidization is seen in skeletal muscle and osteoclasts
where cell fusion generates polynucleated terminally-differentiated cells (Yaffe
and Feldman, 1965; Vignery, 2000). Polyploidy has also been observed sporadi-
cally under physiological conditions in lactating mammary gland, urothelium,
mesothelium and Purkinje neurons (Biesterfeld et al., 1994), but how these
whole genome duplications arise is less clear.
The benefits of programmed polyploidy are not fully understood. Poly-
ploidy results in a decreased surface to volume ratio for both the whole cell
and the nucleus, thereby minimizing membrane requirements but also lower-
ing the efficiency of transport (Henery et al., 1992; Comai, 2005). Polyploid
cells, including hepatocytes and placental giant trophoblasts, often serve to
provide nutrients and metabolites. It has therefore been proposed that poly-
ploidization increases the metabolic capacity of a tissue, possibly by funneling
energy toward gene duplication and protein synthesis, instead of cell divi-
sion and membrane synthesis (Joubes and Chevalier, 2000; Lee et al., 2009).
Although megakaryocytes do not have a nourishing function, they can be sim-
ilarly viewed as a stockpile of components needed to generate platelets. A 32N
megakaryocyte can give rise to about 3,000 platelets (Ravid et al., 2002). As-
suming that for every 2-fold ploidy increase, there is an approximately 2-fold
increase in volume (Henery et al., 1992), at least 16 diploid megakaryocytes
would be necessary to deliver the same number of platelets. Considering the
diminished requirement for membrane synthesis in a single 32N cell versus
16 diploid cells, polyploidization of megakaryocytes might be an efficient way
to direct membrane synthesis towards the production of platelets and would
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avoid the energy expenditure of cell divisions. Recently, it has been proposed
that tetraploidization of hepatocytes has the benefit of generating genetic vari-
ability. During liver regeneration, tetraploid hepatocytes can undergo a reduc-
tive mitosis creating aneuploid daughter cells with a near-diploid chromosome
number (Duncan et al., 2010). These aberrant divisions are most likely the
consequence of multipolar mitoses generated by supernumerary centrosomes.
As the resulting aneuploid cells could carry re-assorted alleles, this genetic
variation might increase the chance of resistance to exogenous stress.
1.1.3 Tetraploidization with aging and stress
In several tissues, tetraploid or octoploid cells appear with aging and under
pathological conditions. For instance, the incidence of polyploidy increases
with age in hepatocytes and vascular smooth muscle cells (Celton-Morizur
and Desdouets, 2010; Hixon and Gualberto, 2003) and human fibroblasts and
endothelial cells become tetraploid with in vitro replicative aging (Wagner et
al., 2001; Walen, 2006). An increase in polyploidy is also observed in car-
diomyocytes with cardiac overloading, congenital heart disease, and hyperten-
sion (Staiger et al., 1975; Adler and Costabel, 1975) and in hepatocytes with
oxidative stress or telomere damage (Gorla et al., 2001; Lazzerini Denchi et
al., 2006). Furthermore, polyploidization occurs in inflammatory bronchial le-
sions (Lothschutz et al., 2002) and in wound healing (Oberringer et al., 1999).
The mechanisms and consequences of tetraploidization in these pathological
settings are largely unknown.
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1.2 Maintenance of the diploid mammalian
genome
The diploid state of mammalian somatic cells is guarded by control mecha-
nisms that act throughout the cell cycle to prevent the occurrence and/or pro-
liferation of cells with deviant DNA contents (Fig. 1.3). The cyclin-dependent
kinases (Cdks) and their cyclin subunits regulate key protein phosphorylation
events such that DNA replication and mitosis alternate, driving the cell cy-
cle forward; the initiation of DNA replication is controlled by a system that
prevents re-replication; and the integrity of the diploid genome and the cor-
rect separation of newly-replicated sister chromatids is ensured by two types
of checkpoints (the spindle assembly checkpoint or SAC and the DNA dam-
age checkpoints). These controls are highlighted in Figure 1.3 and discussed
briefly below.
Chromosome non-disjunction is prevented by regulatory pathways, gener-
ally known as ”error correction” pathways, which promote correct kinetochore-
microtubule attachments (for review see (Musacchio and Salmon, 2007)). An
additional level of control is exerted by the SAC on the cell cycle. The SAC
blocks anaphase until all chromosomes have achieved bi-oriented attachment to
the mitotic spindle (Fig. 1.3). The dissolution of sister chromatids in anaphase
requires activation of the APC/C (anaphase promoting complex/cyclosome,
referred to as APC here), a ubiquitin ligase that together with either Cdc20 or
Cdh1 targets mitotic proteins for degradation by the proteasome. APC/Cdc20
is inhibited by a signal emanating from unattached kinetochores. Once all
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Figure 1.3: How mammalian somatic cells maintain a diploid genome.
The schematic outlines the normal somatic cell cycle and highlights the three main
mechanisms by which the diploid genome is kept intact: assurance of correct chro-
mosome segregation in mitosis; regulation of DNA replication; and the DNA damage
checkpoint. See text for detailed discussion.
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chromosomes are correctly aligned on the spindle, the SAC is switched-off and
APC/Cdc20 becomes active, leading to degradation of securin. With securin
gone, separase can cleave the cohesin that holds the sister chromatids together
and one copy of each duplicated chromosome is segregated to the daughter
cells.
After mitosis, a regulatory pathway controls the initiation of DNA replica-
tion such that each sequence is only replicated once in the following S phase
(Fig. 1.3; for review see (Remus and Diffley, 2009)). Replication origins are
licensed at the end of mitosis and in the beginning of G1 by the formation of
the pre-replication complex (pre-RC). The formation of the pre-RC requires
Cdt1, which accumulates in G1 and is degraded upon entry into S phase after
a ubiquitinylation step that depends on the initiation of DNA replication. In
S and G2, origin re-licensing is prevented both by the degradation Cdt1 and
the expression of geminin, an inhibitor of Cdt1. This system is reset by the
APC/Cdh1-mediated degradation of geminin at the end of mitosis and the rise
of Cdt1 in G1. As a result, replication origin licensing is coupled to progression
through mitosis.
The integrity of the diploid chromosome complement is monitored by the
DNA damage response pathways (for review see (Ciccia and Elledge, 2010)).
Two related PI3-kinase-like protein kinases, the ATM and ATR kinases, can
initiate a DNA damage checkpoint. The ATM kinase is activated by double-
strand DNA breaks (DSBs) whereas ATR responds to pathological single-
stranded DNA (ssDNA), including ssDNA generated by DNA replication prob-
lems or resection of a DSB. ATM and ATR phosphorylate and activate down-
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stream effector kinases (Chk2 and Chk1, respectively), which in turn phospho-
rylate proteins that enforce cell cycle arrest. Replication of damaged DNA,
a potentially deleterious event, is prevented by blocking cell cycle progression
into S phase. This is achieved through inactivation of the Cdc25A phosphatase
(required for activation of Cdk2) and activation of the p53 pathway (result-
ing in upregulation of the Cdk inhibitor p21). Because the effect of Cdc25A
inactivation is transient, permanent arrest in G1 and induction of senescence
and/or apoptosis is absent from p53 deficient mouse cells. In human cells,
however, DNA damage also results in upregulation of p16, which can induce a
G1 arrest through preventing the phosphorylation of Rb (reviewed in (Gil and
Peters, 2006)). In G2, incompletely replicated DNA and broken chromosomes
activate the G2/M checkpoint. In this setting, ATM and/or ATR signaling
delays entry into mitosis primarily by inactivating Cdc25C, which is needed
for the activation of Cdk1/CycB. In p53/Rb-deficient cells, this is the main
checkpoint to prevent cell division in the presence of DNA damage. In addi-
tion to kinetochores and replication start sites, a third chromosomal element,
the telomere (see below) plays a critical role in the stability of the diploid
chromosome complement, as it is described below in detail.
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1.3 Mammalian telomeres: end-protection and
role in cancer
1.3.1 Telomere end-protection
Mammalian telomeres represent the ends of linear chromosomes and are com-
posed of double-stranded (TTAGGG)n tandem repeats, varying in length be-
tween 10-15 kb in humans (de Lange et al., 1990; Hastie et al., 1990) to
30-50 kb in laboratory mice (Kipling and Cooke, 1990) and end in a G-rich
single stranded 3’overhang (McElligott and Wellinger, 1997; Makarov et al.,
1997). Telomeres are maintained by telomerase, comprised of a telomere-
specific reverse transcriptase (TERT) and a TTAGGG RNA template (Terc),
which together mediate the sequential addition of telomeric repeats (Cong
et al., 2002). Telomeres are bound by a six-protein complex called shelterin
(Fig. 1.4; Palm and de Lange, 2008). Shelterin is anchored to the telomeres
through three DNA binding proteins which specifically recognize telomeric
DNA: the single-stranded DNA binding protein POT1 (POT1a and POT1b
in the mouse) and the two double-stranded DNA binding proteins TRF1 and
TRF2. TRF1 and TRF2 bind duplex telomeric DNA as homodimers through
their SANT/Myb domains (Chong et al., 1995; Bilaud et al., 1997; Broccoli et
al., 1997; Bianchi et al., 1997). POT1 contains two OB-folds through which it
can bind to single-stranded G-rich telomeric sequences (Baumann and Cech,
2001; Lei et al., 2004). The three DNA-binding components in shelterin are
bridged by TIN2 and TPP1. TPP1 heterodimerizes with POT1 and mediates
its localization at telomeres (Liu et al., 2004; Ye et al., 2004; Hockemeyer et
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al., 2007, Kibe et al., 2010). Moreover TPP1 interacts with TERT, and is
thought to mediate its recruitment to the telomeres (Xin et al., 2007). TIN2
can bind TRF1, TRF2 and TPP at the same time, bridging the TPP1/POT1
part of the complex to the ds DNA-bound TRF1/TRF2 (Houghtaling et al.,
2004; Ye et al., 2004; O’Connor et al., 2006). TIN2 also contributes to TRF2
localization and stability at the telomeres (Ye et al., 2004, Takai et al., 2011).
The sixth component of shelterin, Rap1, constitutively binds to TRF2 in a 1:1
stoichiometric ratio, and depends on TRF2 for its telomeric localization and
stability (Li et al., 2000; Celli and de Lange, 2005).
In addition to recruitment and regulation of telomerase, the main function
of shelterin is to prevent telomeres from being recognized as double-stranded
DNA breaks. Inactivation of specific components of the shelterin complex
leads to activation of one or multiple branches of the DNA damage signaling
and repair pathways. Inactivation of TRF2 results in ATM activation, Chk2
phosphorylation and cell cycle checkpoint activation (Karlseder et al., 1999;
Celli and de Lange, 2005; Denchi and de Lange, 2007). The activation of
the DNA damage response is evident by the accumulation of phosphorylated
histone H2AX and the DNA damage factor 53BP1 specifically at telomeres
(Takai et al., 2003). Loss of TRF2 also leads to NHEJ of telomeric ends
resulting in chromosome fusions that are incompatible with cell division and
survival (van Steensel and de Lange, 1998; Smogorzewska et al., 2002). The
mechanisms by which TRF2 inhibits ATM activation and NHEJ at telomeres
is not fully understood. The most widely accepted hypothesis is based on the
discovery that the 3’overhang can strand invade into the upstream double-
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stranded region, forming the t-loop structure and that TRF2 can promote
t-loop formation in vitro (Griffith et al., 1999; Stansel et al., 2001). The t-
loop based model proposes that TRF2 inhibits ATM activation and NHEJ
by promoting the formation of the t-loop configuration, which can hide and
protect the very end of telomeres. However, this hypothesis requires further
testing in vivo.
Figure 1.4: Telomere end protection. (A) Telomeres are bound to a multiprotein
complex called shelterin which prevents the activation of the DNA damage signaling
and repair pathways. (B) Deletion of POT1a/b at telomeres results in activation of
ATR-dependent DNA damage response at telomeres and polyploidization.
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The presence of POT1a (and to some extent POT1b) at the telomeres in-
hibits the activation of ATR at mouse telomeres (Fig. 1.4 B; Denchi and de
Lange, 2007; Gong and de Lange, 2010). In the absence of POT1a/b, telom-
eres are rendered dysfunctional as judged by the accumulation of 53BP1 and a
Chk1-dependent cell cycle checkpoint is induced (Wu et al., 2006 ; Denchi and
de Lange, 2007).The prevention of ATR signaling relies mainly on POT1a,
while POT1b has an additional independent role in preventing aberrant in-
crease of the telomeric overhang (Hockemeyer et al., 2006). As for the DNA
damage repair pathway, deletion of POT1a and POT1b results in a low level
of post-replicative telomere fusions (Hockemeyer et al., 2006; Wu et al., 2006).
TRF1 also contributes to the inhibition of the ATR pathway at telomeres, but
only indirectly, by promoting efficient replication of the telomeric DNA (Sfeir
et al., 2009). The homology-directed repair pathway at telomeres is prevented
by the general DNA damage factor Ku in combination with POT1 and Rap1
(Wu et al., 2006; Sfeir et al., 2010).
The mechanism of ATR inhibition by POT1a/b is not yet completely clear.
The ssDNA binding factor POT1 can bind to the telomeric overhang and to
the displaced G-strand of the D-loop present in the t-loop configuration. The
presence of POT1a (and POT1b) at the telomeric overhang is thought to
prevent the binding of RPA, the first step required for ATR activation (Gong
and de Lange, 2010). The low abundance of POT1 as compared to RPA
and its comparable in vitro binding affinity for telomeric DNA (even in the
presence of TPP1) cannot explain the ability of POT1 to prevent RPA binding
at the telomeric DNA in vivo (Takai et al., 2010; Takai et al., 2011). One way
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to explain the RPA exclusion model, is to assume that TIN2/TPP1 tether
POT1 to the telomeres, through their binding to the rest of the shelterin.
As a consequence, POT1 tethering would increase its local concentration at
the telomeres, allowing it to outcompete RPA for telomere binding (Kibe et
al., 2010; Takai et al., 2011). Theoretically this hypothesis could be tested
in vivo by tethering to mammalian telomeres a different factor able to bind
mammalian telomeric DNA, in the absence of POT1.
An additional consequence of POT1a/b deletion in mouse cells (when de-
ficient concomitantly for p53 and Rb) is the induction of polyploidization, ob-
served as multiple discrete peaks in the DNA profile (Hockemeyer et al., 2006).
The occasional metaphase spreads that can be harvested from POT1a/b de-
ficient cells, show diplo- and quadruplo-chromosomes, i.e. chromosomes com-
posed of four (or eight) chromatids held together at the centromere (Hocke-
meyer et al., 2006; Kibe et al., 2010). Similar to the loss of POT1, inactivation
of TPP1, which is required for localization of POT1 to the telomeres, results
in ATR-dependent DNA damage response at telomeres and polyploidization
(Kibe et al., 2010). Although TRF2 loss also leads to polyploidization, there
is an important difference compared to POT1 inactivation. In the absence
of TRF2, chromosome ends readily fuse by NHEJ, while in the absence of
POT1a/b, the percentage of chromosome fusions is very low (Celli and de
Lange, 2005; Hockemeyer et al., 2006). Therefore, while polyploidy after
TRF2 loss can be explained by mitotic failure due to chromosome fusions,
the prediction is that in the absence of POT1a/b, polyploidization is medi-
ated by a different mechanism, which does not require the block of mitosis by
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chromosome fusions.
1.3.2 Telomere shortening in human somatic cells
In humans and other primates (but not in rodents), telomerase activity is re-
stricted to the germline and some adult stem cell compartments (Shay and
Wright, 2005). As a consequence, telomeres of human somatic cells undergo
progressive shortening during cellular proliferation, which eventually limits the
cells’ lifespan (Fig. 1.5; Bodnar et al., 1998; Shay and Wright, 2005). Short
telomeres becomes unprotected, can be recognized as sites of DNA damage
and normally lead to apoptosis and senescence through activation the p53 and
Rb pathways (d’Adda di Fagagna et al., 2003). While in mouse cells, cell cycle
arrest (or apoptosis) after telomere dysfunction is primarily mediated by p53
and its target p21, in humans, inhibition of Rb pathway through the induc-
tion of the Cdk inhibitor p16INK4a contributes to the induction of the G1/S
arrest (Jacobs and de Lange, 2004; Smogorzewska and de Lange, 2002). In
the absence of proficient p53 and Rb pathways, human cells do not undergo
senescence and prolonged proliferation enhances telomere shortening until ex-
tremely short telomeres induce high genome instability and lead to cell death,
a stage called telomere crisis (Fig. 1.5; Wright and Shay, 1992; Shay et al.,
1993; Shay and Wright, 2005). The reason why short telomeres activate the
DNA damage response is still unclear. One possibility is that they are not
long enough to recruit a sufficient amount of shelterin factors necessary for
the inhibition of ATM and ATR.
Similarly to the context of telomere deprotection after shelterin inactiva-
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Figure 1.5: Telomere shortening during tumorigenesis. Telomere shortening
during cellular proliferation of human somatic cells occurs in early tumorigenesis
and normally leads to senescence or apoptosis. In the absence of functional p53
and Rb pathways, cells continue to proliferate until telomere crisis. Later in tumor
progression telomerase is reactivated allowing immortalization and evolution of the
tumor cells. See text for detailed discussion (PD: population doubling).
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tion, short telomeres in senescent cells and crisis cells can be processed by the
NHEJ pathway, leading to chromosome end-to-end fusion. As Barbara Mc-
Clintock first recognized in the 1940s, dicentric chromosomes (formed by the
terminal fusion of two broken chromosomes) can form anaphase bridges which
can in turn break and be rejoined again in the following cell cycle (McClintock,
1941). These Breakage-Fusion-Bridge (BFB) cycles can result in genomic rear-
rangements and curb cell proliferation. While senescence normally involves a
p53/p21 and Rb/p16 mediated permanent arrest in G1/S with minor genomic
instability (Benn, 1976; Saksela and Moorhead, 1963), BFB cycles and the
resulting chromosome rearrangements are frequently observed in cells in crisis
(Shay et al., 1993).
1.3.3 Role of telomere dysfunction during tumorigene-
sis
Telomere shortening is frequently observed in human tumorigenesis (de Lange
et al., 1990; Hastie et al., 1990). Although aberrant reactivation of telomerase
in cancer allows healing of telomeric ends, most of the advanced-stage cancers
show short telomeres (de Lange et al., 1990; Hastie et al., 1990), which bear
witness of the cellular replicative history. Telomere shortening is thought to
play a complex role during tumorigenesis. It can function either as a tumor
suppressor or as a tumor promoter, depending on the tumor stage and on the
integrity of cell cycle checkpoints, mainly the p53 and p16/Rb pathways.
By limiting the lifespan of human somatic cells, telomere shortening rep-
resents a tumor suppressor pathway. As a result of sustained proliferation,
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telomere shortening is frequently observed in the early pre-invasive stages of
human epithelial cancers, such as breast, colon and prostate cancers (Miura
et al., 1997; Meeker et al., 2004; Meeker et al., 2002; Zhang et al., 2004a). In
more advanced tumors, this barrier to cell survival and proliferation is usually
counteracted by telomerase reactivation, which occurs in 80-90% of human
cancers (Kim et al., 1994) or by an alternative mechanism of telomere elonga-
tion (Lundblad and Blackburn, 1993; Bryan et al., 1995; Bryan et al., 1997).
Inhibition of telomerase can impair the viability of human cancer cells, demon-
strating that their proliferation relies on telomere maintenance (Hahn et al.,
1999). Furthermore, modeling of telomere shortening in the mouse showed
that it is able to suppress tumorigenesis in some contexts through the acti-
vation of the p53 pathway (Gonzalez-Suarez et al., 2000; Greenberg et al.,
1999). Therefore, the combination of telomere shortening and the cell cycle
checkpoint pathways represents a barrier to tumorigensis. When the p53 (and
Rb in human cells) pathway is impaired the outcome is different. In this con-
text, telomere shortening can promote tumorigenesis and genome instability.
Late generation Terc-/- p53-/- or p53+/- mice (deficient for the telomerase
RNA component and for p53) show increased tumorigenesis as compared to
the telomerase proficient controls (Artandi et al., 2000). Interestingly, telomere
shortening can shift the tumor spectrum and the associated karyotype toward
the common tumor types of aged humans (Artandi et al., 2000). In Terc-/-
p53-/- mice the near-diploid lymphomas and sarcomas commonly observed in
p53+/- mice are replaced by epithelial carcinomas with a complex aneuploid
karyotype, resembling the karyotype of most human solid tumors (Artandi et
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al., 2000). These data indicate that once the checkpoint controls are inac-
tive, prolonged cell proliferation in the presence of very short telomeres can
promote tumorigenesis and genome instability (Fig. 1.5). Breakage-fusion-
breakage cycles result in gene mutation such as deletions, loss of heterozy-
gosity and amplifications but also in chromosomal rearrangements, especially
non-reciprocal translocations and inversions (de Lange, 2005). A large body
of evidence suggests that telomere deprotection contributes to genome insta-
bility in human cancer. Anaphase bridges are observed in the early cancer
stages when telomeres are short and telomerase activity is still undetectable
(Rudolph et al., 2001; O’Sullivan et al., 2002; Chin et al., 2004; Finley et al.,
2006). Analysis of the telomere length and the nature of the telomeric fusions
in tumor samples showed evidence of telomere crisis during the progression of
chronic lymphocytic leukemia (Lin et al., 2010). Finally, tumors arising from
telomerase competent cells, such as leukemias and some lymphomas usually
show very low levels of genome instability (Hilgenfeld et al., 1999; Broccoli et
al., 1995).
In the context of telomere-mediated tumorigenesis, it is important to high-
light that reactivation of telomerase, which occurs usually in the early invasive
lesions, is necessary for the tumor to progress to a full malignant state and
metastatic potential (Ding et al., 2012). In terms of genome instability, reac-
tivation of telomerase can limit genomic instability ongoing in early cancerous
lesions, stabilizing the cancer genome (Colegrave and Collins, 2008).
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1.4 Aneuploidy and tetraploidy in human can-
cer
1.4.1 Chromosome instability in human cancer
Most human solid tumors are aneuploid. Karyotypic analysis of cancer cell
lines has revealed a wide range of chromosome numbers ranging from hy-
podiploid to hypertetraploid. A substantial fraction of this aneuploidy, in
particular the near-diploid chromosome numbers, can be explained from indi-
vidual chromosome gains and losses due to defects in the segregation of sister
chromatids (Fig. 1.6, reviewed in (Holland and Cleveland, 2009). This type
of chromosome instability (CIN) leads to one chromosome gain or loss event
in approximately five cell divisions (Lengauer et al., 1997). In rare cases, the
cause of CIN has been assigned to defects in the SAC, cohesion, or the regula-
tion of kinetochore-microtubule attachment (see for review (Thompson et al.,
2010)). Mutations in Adenomatous Polyposis Coli in colon carcinoma can also
result in a CIN phenotype (Kaplan et al., 2001; Fodde et al., 2001) and loss
of Rb has been shown to cause aneuploidy and could therefore explain CIN in
many human cancers (Manning et al., 2010; van Harn et al., 2010; Coschi et
al., 2010). Aneupoloidy can also be caused by oncogene-induced replication
stress, which has been proposed to occur in many early neoplastic lesions or
defect in the DNA damage repair machinery (see for review (Negrini et al.,
2010)). In addition, cells with supernumerary centrosomes, formed through
a tetraploidization event or deregulation of the centrosome cycle, will often
mis-segregate chromosomes due to transient formation of multipolar spindles
26
(Ganem et al., 2009). Finally, the formation of micronuclei that derive from
chromosome missegregation, can result in chromosome pulverization and might
explain a recently described process of genomic instability called chromothryp-
sis (Stephens et al., 2011; Crasta et al., 2012).
An important but under-explored cause of CIN in the early stages of human
cancer is telomere dysfunction, as described earlier (reviewed in (de Lange,
2005)). A unique feature of this source of chromosome instability is that it is
episodic, ultimately resulting in aneuploid cancer genomes that are stabilized
once telomerase has restored telomere function. In this regard, it will be of
interest to understand which cancers show ongoing CIN and which have a
stable aneuploid chromosome complement.
1.4.2 Evidence for tetraploidization in human cancer
The CIN-type of chromosome mis-segregation does not, however, explain can-
cers with a triploid or near-tetraploid chromosome number (Fig. 1.6, Fig. 1.7).
At the mis-segregation rate of approximately 1 per 5 cell divisions observed in
colorectal cancer cell lines, it would require more than 200 PD to generate a
clone with close to 90 chromosomes. This number of cell divisions is very high
in the context of the etiology of human cancer. In addition, each intermediate
in the multi-step CIN pathway would have to be viable.
Data on the distribution of chromosome numbers in human cancer is consis-
tent with the proposal of a second, distinct pathway for tumors with high chro-
mosome numbers. For many tumors, the chromosome numbers are distributed
in two peaks, one representing tumors that are near-diploid and one represent-
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ing tumors with a chromosome number between triploid and tetraploid genome
, see examples in Fig. 1.6). This bimodal distribution argues against a sin-
gle mechanism underlying aneuploidy. To account for aneuploidy with high
chromosome numbers (arbitrarily set at >68 chromosomes in Fig. 1.7), it was
proposed that these cancers originate from an unstable tetraploid intermediate
(Shackney et al., 1989). As discussed above, tetraploid cells are known to fre-
quently mis-segregate chromosomes due to their supernumerary centrosomes
(Ganem et al., 2009). Tetraploid cells will therefore readily generate subclones
with the hypo-tetraploid or hyper-triploid chromosome numbers observed in
cancer.
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Figure 1.6: Evidence for tetraploidization in cancer. (A) First reported
evidence of polyploidy (Atkin and Richards, 1956) and diplochromosomes (Levan,
1956) in human cancer. (B, C) The bargraphs show the distribution of chromosome
numbers in pancreatic carcinoma (B) and in osteosarcoma (C). The data was derived
from the Mitelman database (http : //cgap.nci.nih.gov/Chromosomes/Mitelman).
The karyotype of all the pancreatic carcinoma and osteosarcoma tumors in the
database were retrieved and used for the frequency distribution shown. For the
monoclonal tumors, the average number of chromosomes is given. For multiclonal
tumors, if the difference between the chromosome numbers of the clones was less
than 10, the average is given. Otherwise, the 2 distinct clones were considered as
2 different karyotypes. Representative karyotype of pancreatic cancer from http :
//www.path.cam.ac.uk/index.html (Capan-2 cell line); representative karyotype of
osteosarcoma tumor from (Scheel et al., 2001).
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Consistent with an initial tetraploidization event preceding the final aneu-
ploid state, cells with supernumerary centrosomes have been observed in many
tumor types, including breast cancer (Lingle et al., 1998; Ottesen, 2003), pan-
creatic cancer (Sato et al., 1999), prostate cancer (Pihan et al., 2001), as well
as lung and colon carcinoma (Pihan et al., 1998). Multiple centrosomes appear
in pre-invasive carcinomas (Lingle et al., 2002; Pihan et al., 2003) and corre-
late with abnormal multipolar mitosis and chromosomal instability (Lingle et
al., 2005). In some tumor types, there is direct evidence for the development
of aneuploidy from a transient 4N state. In Barretts esophagus, which pre-
disposes to the development of esophageal adenocarcinoma, tetraploid cells
precede the development of further aneuploidy (Galipeau et al., 1996; Reid
et al., 1996). The tetraploid state is lost in 1-2 years, consistent with tran-
sient tetraploid cells that lose chromosomes at high frequency (Galipeau et al.,
1996). Similarly during the evolution of cervical, breast cancer and bladder
cancer, there is evidence for whole genome duplication followed by chromosome
losses (Kirkland et al., 1967; Olaharski et al., 2006; Dutrillaux et al., 1991;
Ottesen, 2003; Shackney et al., 1995b; Shackney et al., 1995a). Tetraploidiza-
tion also occurs in hyperplastic lesions of the pancreas (Tanaka et al., 1984),
in localized prostate cancer (Montgomery et al., 1990; Deitch et al., 1993; Pi-
han et al., 2001) and some colon adenomas (Hamada et al., 1988; Levine et
al., 1991). Collectively, these observations argue that tetraploidization in the
early stages of tumorigenesis is not a rare phenomenon.
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Figure 1.7: Incidence of hypertriploid karyotypes, inac-
tivation of p53 pathway and Rb pathway. a Based on
http://cgap.nci.nih.gov/Chromosomes/Mitelman. For each tumor type, a
search of the tumors containing a chromosome number >68 was performed and
the % of tumors >68 was calculated. The total number of tumors for each type
is indicated (n). b Frequency of inactivativation of the p53 pathway, including
p53 mutation (databases http://www-p53.iarc.fr/, http://p53.free.fr/index.html
and specific references) or LOH and MDM2 amplification (Momand et al., 1998)
c Frequency of inactivation of the Rb pathway, including mutation, LOH or
methylation of Rb, p16, p18 and amplification or overexpression of CyclinD or
CDK4/6 genes (Ruas and Peters, 1998; Sharpless and Chin, 2003) d In cervical
cancer p53 and Rb inactivation are mediated by HPV-E6 and HPV-E7 proteins,
respectively (Moody and Laimins, 2010). e The frequency of inactivation of p53
and Rb pathway in neuroblastoma is not completely clear since most studies have
been performed on cell lines (Brodeur, 2003; Van Maerken et al., 2009).
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1.4.3 Causes of tetraploidy in cancer
Two main mechanisms of tetraploidization in cancer have been proposed: cell
fusion, failure in cytokinesis or failure in other steps in mitosis (Fig. 1.8). Cell
fusion generates a bi-nucleate intermediate that can produce daughter cells
with single 4N nuclei in G1. Experimentally induced fusion of primary human
fibroblasts has been shown to enhance their in vitro transformation with potent
oncogenes (Duelli et al., 2007). Cell fusion can be caused by viral infection (see
for review (Duelli and Lazebnik, 2007)). For instance, infection with human
papilloma virus (HPV), which contributes to the etiology of cervical cancer,
has been shown to cause cell fusion (Hu et al., 2009; Gao and Zheng, 2010).
The virus that causes cell fusion could also be unrelated to cancer development
since the fusion partner could be a non-neoplastic infected cell that donates
its chromosomes to a cancerous neighbor.
Several types of failure in progression through, or exit from, mitosis can
give rise to a cell with double the chromosome number. Failure in cytokinesis
usually generates a transient bi-nucleate state, which will yield mono-nucleated
G1 daughter cells with 4N DNA content after the next cell division (Fig. 1.8).
This type of tetraploidization is observed upon increased expression of either
of two regulators of the anaphase promoting complex, Mad2 and Emi1 (Sotillo
et al., 2007; Lehman et al., 2006). Mad2 and Emi1 are overexpressed in a va-
riety of human cancers (Sotillo et al., 2007; Lehman et al., 2007), possibly due
to loss of the Rb pathway, which controls their transcription through E2F.
Furthermore, Mad2 overexpression might induce tetraploidization through in-
activation of MLKP2, a kinesin required for cytokinesis (Lee et al., 2010).
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Figure 1.8: Proposed mechanisms for tetraploidization in cancer. The
schematic shows the main mechanisms by which tetraploidization has been proposed
to arise in the early stages of tumorigenesis: cellular fusion, failure in cytokinesis,
in metaphase or anaphase. See text for discussion (OE: overexpression).
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Cytokinesis failure also occurs upon inhibition of LATS1, a kinase needed for
the regulation of actin polymerization in mitosis (Yang et al., 2004). LATS1 is
a tumor suppressor in Drosophila and is frequently lost in soft tissues sarcoma
(Hisaoka et al., 2002), astrocytoma (Jiang et al., 2006), and breast cancer
(Takahashi et al., 2005). Finally, failure in cytokinesis is associated with over-
expression of AuroraA, a kinase critical for mitosis (Bischoff et al., 1998; Zhou
et al., 1998; Meraldi et al., 2002; Zhang et al., 2004b). High levels of AuroraA,
in some cases due to gene amplification, are frequent in cancer (Lehman et
al., 2007). In light of these potential causes of cytokinesis failure, it will be of
interest to determine whether there is evidence for an initial tetraploidization
step in tumors with elevated Mad2/Emi1/AuroraA or defective LATS1.
Cells with lagging chromosomes or acentric fragments can show failure in
cytokinesis because the cleavage furrow can regress when there is chromatin
in the mid-zone (Mullins and Biesele, 1977). Since a myriad of pathways can
result in lagging chromosomes or acentric fragments, many genetic defects
could potentially result in a low frequency of tetraploidization through this
mechanism.
Problems earlier in mitosis are also likely to be responsible for some tetraploidiza-
tion events. Interestingly, tetraploidization occurs in cells with defects in the
Adenomatous Polyposis Coli, the colon carcinoma gene that is part of the
Wnt-signaling pathway (Fodde et al., 2001; Kaplan et al., 2001). This APC
protein (distinct from the anaphase promoting complex/cyclosome) binds to
microtubules and its absence affects the kinetochore-microtubule interaction in
a manner that induces disordered metaphases, lagging chromosomes, and chro-
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mosome mis-segregation responsible for CIN in APC-driven colon carcinoma
(Kaplan et al., 2001; Fodde et al., 2001; Dikovskaya et al., 2007; Dikovskaya et
al., 2004; Caldwell et al., 2007; Draviam et al., 2006). The function of the SAC
is not greatly affected by these APC mutations (Radulescu et al., 2010) nor
is the SAC strongly activated by the disordered metaphases in APC-mutant
cells (Draviam et al., 2006). Whether tetraploidization of APC-mutant cells
is a direct consequence of the lagging chromosomes is not yet clear.
1.4.4 Role of p53 in culling tetraploid clones
Tetraploid cells generated by experimentally-induced mitotic failure undergo
a p53-dependent arrest (Andreassen et al., 2001; Meraldi et al., 2002; Fu-
jiwara et al., 2005). This activation of the p53 pathway is also thought to
occur in other cases of tetraploidization, but the mechanism underlying this
phenomenon is not understood. It is unlikely that the p53 pathway is acti-
vated by tetraploidy per se or by the presence of extra centrosomes (Uetake
and Sluder, 2004; Wong and Stearns, 2005). Although the signal(s) that up-
regulate p53 remain to be determined, the challenges of navigating mitosis
with supernumerary centrosomes make tetraploid cells more prone to sustain-
ing DNA damage, explaining why they proliferate better in the absence of
p53 (Ganem et al., 2009). In agreement, the frequency of inactivation of the
p53 pathway inactivation and the occurrence of near-tetraploid karyotypes are
positively correlated ( Fig. 1.7 and Fig. 1.9A).
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Figure 1.9: Correlation between the frequency of p53 inactivation and
near-tetraploid karyotypes. The graphs shows the correlation between the fre-
quency of inactivation of the p53 pathway and the percentage of karyotypes with
high chromosome number (hypertriploid karyotypes, data from Fig. 1.7) for the indi-
cated cancers. Analysis of linear regression shows significant correlation (slope and
p-value are reported, from F-test using Prism-5 software). TCC: transitional cell
carcinoma; SCC: squamous cell carcinoma; ac: adenocarcinoma; carc: carcinoma
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1.4.5 Consequences of tetraploidy in cancer
The challenge for the incipient cancer cell is to evolve the right combination
of genetic alterations that support unbridled proliferation at inappropriate
sites. Aneuploidy per se does not confer an advantage in this regard but the
re-assortment of mutated alleles in the process leading to aneuploidy does.
Tetraploidization and its associated aneuploidy are particularly well-suited to
accelerate tumor genome evolution for two reasons. First, tetraploidy is likely
to enhance robustness in the face of a mutator phenotype as it will buffer
the consequences of chromosome losses, gene deletions, and inactivating mu-
tations. This idea was tested directly by comparing diploid and haploid yeast
(Thompson et al., 2006) and is likely to hold for diploid versus tetraploid
mammalian cells in which imprinting and haplo-insufficiency render part of
the genome functionally haploid. Thus, tetraploidy is expected to allow tumor
cells to sustain a higher incidence of mutations thereby increasing the chance
of adaptive changes. Second, tetraploid cells have an increased rate of chromo-
some mis-segregation (Mayer and Aguilera, 1990; Storchova et al., 2006) as a
consequence of supernumerary centrosomes and transient multipolar spindles
(Ganem et al., 2009, Silkworth et al., 2009). Supernumerary centrosomes can
limit the proliferation of newly formed tetraploid cells by inducing multipo-
lar mitoses, which usually result in an unviable progeny. Cells can negotiate
these problems through elimination/inactivation of centrosomes or by cluster-
ing them in two groups so that a bipolar spindle is formed (reviewed in (God-
inho et al., 2009)). In the latter case, a transient multipolar spindle can occur
before centrosome clustering, resulting in increased frequency of merotelic kine-
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tochore attachments and chromosome missegregation. Centrosome clustering
appears to be the dominant route by which (sub-) tetraploid cancer cells avoid
multipolar spindles and factors required for this clustering are potential targets
for cancer therapy (Kwon et al., 2008). Overall, tetraploidy has the potential
to increase the chance that an evolving tumorigenic clone will accumulate and
tolerate the mutations needed for its progression to a malignant state.
Finally, as described before, mathematical models predict that polyploids
can adapt more rapidly than diploids if the population size is small and if
the beneficial mutations that are selected for are at least partially dominant
(Otto and Whitton, 2000). From these conclusions we can derive some pre-
dictions about the effect of polyploidy during tumorigenesis. Most likely, a
polyploid state would be advantageous in bottle-neck phases when the cell
population is small due to high selective pressure and low cellular adaptation,
as precancerous cell populations, which are usually small at high risk of ex-
tinction. Other ’bottleneck’ phases during tumorigenesis probably involve the
initial steps of metastasis and of relapse after cancer treatment (such as surgery
or chemotherapy). Secondly, the prediction is that for tetraploid precancer-
ous cells dominant mutations activating oncogenes will be more advantageous
than recessive mutations inactivating tumor suppressor genes.
In this thesis I will describe a new potential mechanism of tetraploidiza-
tion during tumorigenesis. This mechanism is induced by prolonged telom-
ere dysfunction, both after deletion of POT1a/b in mouse cells and after ex-
tensive telomere shortening in human somatic cells during crisis. Persistent
telomere damage after deletion of POT1a/b activates the DNA damage re-
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sponse signaling pathway and lead to endoreduplication cycles where multiple
S-phases occur in the absence of intervening mitotic event. In human cells
during telomere crisis tetraploidization occurs through mitotic failure or en-
docycles. Tetraploid mouse cells derived after transient telomere dysfunction
show increased transformation potential in vitro and in vivo. Finally, we pro-
vide evidence of telomere crisis in breast cancer cell lines with an increased
chromosome number as compared to near-diploid cell lines.
40
Chapter 2
Results
2.1 Persistent telomere damage induces by-
pass of mitosis and tetraploidy
2.1.1 Polyploidy in response to persistent DNA damage
signaling
We used previously described SV40 large T antigen (SV40LT) immortalized
MEFs carrying conditional alleles for POT1a and POT1b from which both
POT1 genes can be deleted with Cre recombinase (POT1aF/-POT1bF/F; Hock-
emeyer et al., 2006). In these POT1a/b double knockout (DKO) cells, SV40LT
interferes with the function of p53, which can block polyploidization (Carder
et al., 1993; Andreassen et al., 2001; Margolis et al., 2003). As expected,
POT1a/b DKO cells showed a DNA damage response as shown by the accu-
mulation of 53BP1 foci and phosphorylation of Chk1 and Chk2 and displayed
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polyploidization characterized by FACS profiles with discrete 8N and 16N
peaks (Fig. 2.1A-D). The polyploid cell fraction (here defined as the fraction
of cells with a DNA content >4N) increases from a basal level of 7-8% to 20-
25% at day 4 after introduction of Cre, and to 35-40% at day 6 (Fig. 2.1A,
C). Consistent with polyploidization, depletion of the POT1 proteins resulted
in cells containing supernumerary centrosomes (Fig. 2.1E).
To determine whether the polyploidy of POT1a/b DKO cells was due
to a DNA damage signal, we generated POT1aF/-POT1bF/FATM-/- SV40LT-
immortalized MEFs and treated the cells with an shRNA to ATR (Denchi and
de Lange, 2007; Fig. 2.2A-C). As an ATM/ATR-proficient control, we used
littermate-derived, POT1aF/-POT1bF/FATM+/- SV40LT immortalized MEFs
infected with the shRNA vector. As expected, inhibition of ATM and ATR
affected the phosphorylation of Chk1 and Chk2 in response to deletion of
POT1a/b (Fig. 2.2B). Importantly, inhibition of ATM and ATR signaling di-
minished the induction of polyploidy (Fig. 2.2A, C). Consistent with the ATR
kinase being primarily responsible for the DNA damage signal in POT1a/b
DKO cells, inhibition of ATR alone reduced the fraction of polyploid cells,
whereas inhibition of ATM had a lesser effect (Fig. 2.2D, E). Measurement of
BrdU incorporation rates indicated that ATR knockdown did not affect DNA
replication per se (Fig. 2.2F). Polyploidization in the POT1a/b DKO cells
was also diminished by knockdown of Chk1 and Chk2 (Fig. 2.3A-C) or treat-
ment with UCN01 (Fig. 2.3D, E), which inhibits Chk1 and, to lesser extent,
Chk2. These data establish that a DNA-damage signaling cascade involving
ATM/ATR and Chk1/Chk2 is required for polyploidization in response to
42
Figure 2.1: Polyploidy is induced by telomere-specific or genome-wide
persistent DNA damage. (A) Polyploidization upon deletion of POT1a/b or
continuous zeocin treatment. POT1aF/-POT1bF/F MEFs were treated with Cre,
the vector control, zeocin, or left untreated and analyzed by FACS at the indi-
cated time points The % cells with DNA content >4N is given. Representative
FACS analyses are shown. (B) Immunoblotting showing POT1a/b deletion and
Chk1 and Chk2 phosphorylation in POT1aF/-POT1bF/F MEFs after introduction
of Cre. (C) Quantification of polyploidy induced by POT1a/b deletion or continu-
ous zeocin. POT1aF/-POT1bF/F MEFs were treated and analyzed as in (A). The
bars show the average values and SDs of 3 independent experiments. (D) 53BP1 foci
in POT1a/b DKO cells and zeocin-treated cells. POT1aF/-POT1bF/F MEFs were
treated with Cre, zeocin, or left untreated as in (A) and processed for IF for 53BP1
(red; DNA stained with DAPI (blue)). Average 53BP1 foci/nucleus and SEMs are
given (n>50). (E) Supernumerary centrosomes in POT1a/b DKO cells. Centro-
somes were detected by immunofluorescence for pericentrin in POT1a/b knockout
cells and controls (no Cre). The percentage of cells containing more than 2 centro-
somes was scored on >50 cells for each group.
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telomere dysfunction.
The telomere damage in the POT1a/b DKO cells is unusual because it is
not efficiently repaired and therefore elicits a DNA damage signal that persists.
Irreparable telomere damage, and an accompanying persistent ATM kinase
signal, also occurs when TRF2 is deleted from cells that are NHEJ-deficient due
to lack of DNA ligase IV (Lig4-/-; Celli and de Lange, 2005). Consistent with
the findings in the POT1a/b DKO cells, Cre-mediated deletion of TRF2 from
TRF2F/-Lig4-/-p53-/- MEFs induced endoreduplication and diplochromosomes,
although the magnitude of the phenotype was less than for POT1a/b DKO
cells (Fig. 2.4 A, B).
To further test the idea that polyploidization is induced under conditions
where the DNA damage signal persists, we monitored the effects of continu-
ous treatment with the DSB-inducing agent zeocin. As expected, persistent
treatment with zeocin induced the accumulation of DNA damage lesions as
judged by 53BP1 foci (Fig. 2.1D) and, similarly to the deletion of POT1a/b,
the DNA damage appeared similar over several days. After continuous zeocin
treatment for 2 or 4 days, MEFs became polyploid, showing a DNA profile
characterized by discrete 8N and 16N peaks (Fig. 2.1A). Polyploidy was also
induced by treatment of mouse cells with continuous doxorubicin, continuous
bleomycin, or repeated UV irradiation (Fig. 2.4C-E). Moreover, tetraploidiza-
tion occurred in response to activation of ATR by tamoxifen-induced expres-
sion of the TopBP1 ATR-activating domain (Fig. 2.4C). Since overexpression
of this TopBP1 domain has been shown to activate ATR in the absence of DNA
lesions (Toledo et al., 2008), this result argues that the DNA damage signaling
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Figure 2.2: Polyploidization depends on ATR and ATM. (A, B, C) Dimin-
ished polyploidy after inhibition of ATM and ATR. POT1aF/-POT1bF/FATM-/-
and POT1aF/-POT1bF/FATM+/- were treated with ATR shRNA or vector control.
Polyploidy was measured as in Fig. 2.1C. FACS profiles from a representative exper-
iment (A) and quantification of the percentage of polyploid cells in 3 independent
experiments with SDs (C) are shown. Immunoblotting for ATR, P-Chk1 and Chk2
in the indicated cells is shown in (B). (G) Role of ATR in the induction of polyploidy.
POT1aF/-POT1bF/F MEFs were treated with ATR shRNA or vector control and
polyploidy was measured by FACS after Cre expression (4 days after), zeocin treat-
ment (48 hours after) or in cells left untreated. Quantification of the percentage of
polyploid cells in 3 experiments and SDs are shown. (H) Role of ATM in the induc-
tion of polyploidy. POT1aF/-POT1bF/FATM-/- and POT1aF/-POT1bF/FATM+/-
MEFs were treated with Cre, zeocin, or left untreated and the percentage of poly-
ploidy was measured by FACS. Quantification of the percentage of polyploid cells
in 4 independent experiments with SD is shown. (I)The indicated cells were treated
as in (A). Cells were pulsed with BrdU for one hour and the percentage of BrdU
positive cells was measured. Average values and SD are shown.
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Figure 2.3: Polyploidization depends on Chk1 and Chk2. (A, B, C) Dimin-
ished polyploidy after impairment of Chk1 and Chk2. POT1aF/-POT1bF/F MEFs
were treated with Chk1 and Chk2 shRNAs (set 1) or vector control. FACS profiles
from a representative experiment (A) and quantification of the percentage of poly-
ploid cells in 3 independent experiments with SD (C) are shown. Immunoblotting
showing Chk1 and Chk2 knockdown is in (B). (D, E) UCN01 decreases polyploidiza-
tion in POT1a/b DKO cells. POT1aF/-POT1bF/F MEFs were treated with Cre or
vector and after 2 days were synchronized in G1/S by double thymidine block and
released. Cells were pulsed for 1 hour (t=0h to t=1h) with BrdU in order to mark
a cell population and washed. After 2 hours from release (t=2h) UCN01 (2 µ M)
or vehicle was added and FACS was performed at the indicated time points (D).
Bargraphs showing the average percentage of tetraploid BrdU-positive cells after
treatment with 2 or 5 µM UCN01 are in (E).
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rather than DNA damage per se is the primary cause of polyploidization. DNA
damage induced polyploidization was not a peculiarity of the mouse cells used
for generating telomere damage, as prolonged zeocin treatment of HPV-E6/E7-
transformed human BJ fibroblasts also resulted in tetraploidy (Fig. 2.4F, G).
Furthermore, the polyploidization was not due to the expression of viral onco-
proteins since it also occurred in p53-/- MEFs treated with zeocin (Fig. 2.4H)
and in TRF2F/-Lig4-/-p53-/- MEFs treated with Cre (Fig. 2.4A, B). In con-
trast, primary MEFs and BJ fibroblasts with an intact p53 pathway showed
the expected cell cycle arrest in response to DNA damage and polyploidization
was absent.
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Figure 2.4: Polyploidy after activation of DNA damage signaling by dif-
ferent sources. (A) FACS analysis of TRF2F/-Lig4-/- SV40 MEFs treated with
Cre showing a mild endoreduplication phenotype. (B) Metaphase spread from
TRF2F/-Lig4-/-p53-/- MEFs treated with Cre showing diplochromosomes. DAPI,
red; Telomeric FISH, green. (C-E) Induction of polyploidy in mouse cells using
various treatments to induce persistent DNA damage. POT1aF/-POT1bF/F MEFs
were continuously treated with the indicated drugs or with UV (20J2/m every 2
hours for two periods of 12 h with 12 h in between) and the percentage of polyploid
cells was measured by FACS at the indicated time points. Alternatively, mouse cells
expressing TopBP1-ER (Toledo et al., 2008) were treated or not with OHT for 72
hours. Representative experiments (C) and quantification in two or more indepen-
dent experiments (E) are shown. Immunoblotting showing phosphorylation of Chk2
after drug treatment at the indicated time points is shown in (D). (F, G) Persistent
DNA damage induces polyploidy in human cells. Human BJ fibroblasts expressing
HPV E6 and E7 proteins were treated with the indicated drugs and polyploidy was
measured by FACS at the indicated time points. Representative experiment (F) and
quantification in 3 independent experiments (G) are shown. (H) Absence of p53 is
sufficient to allow polyploidization in MEFs. p53-/- MEFs were treated with zeocin
and polyploidy was measured by FACS at the indicated time points. Average values
from 2 independent experiments with standard error of the mean (SEM) are shown.
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Consistent with the data obtained with POT1a/b DKO cells, the induc-
tion of polyploidy by zeocin was strongly impaired when either ATR/ATM
or Chk1/Chk2 were inhibited (Fig. 2.2A-F, Fig. 2.3A-C). As expected, the
absence of ATM, which transduces the initial response to the DSBs, had a
stronger effect than knockdown of ATR (Fig. 2.2D, E). In these experiments
and those discussed below, zeocin-treated cells show a more complete deple-
tion of 2N cells and a stronger induction of polyploidization than the POT1a/b
DKO cells. This difference could be due to incomplete Cre-mediated deletion
of the POT1 genes or may signify a qualitative difference, such as the nature of
the DNA damage signal. Collectively, these data established that polyploidy
can be induced by a persistent DNA damage signal originating from either
deprotected telomeres or DNA lesions elsewhere in the genome.
2.1.2 Lack of Cdk1/CyclinB activation and stabilization
of APC/Cdc20 targets
In order to determine the cell cycle alterations giving rise to polyploidization
in POT1a/b DKO cells, we analyzed the kinetics of several cell cycle regulated
proteins after synchronization in G1/S. Specifically, we determined the status
of APC/Cdc20 targets, which are normally degraded during mitosis. Cells were
synchronized in G1/S and mitotic APC targets were analyzed after release into
S-phase (Fig. 2.5A). Both control and POT1a/b DKO cells entered S phase, as
shown by the increase in incorporation of BrdU, although POT1a/b DKO cells
progressed into S-phase somewhat slower (Fig. 2.5B). Each of the nine APC
targets tested, including securin, were abnormally stabilized in POT1a/b DKO
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cells (Fig. 2.5A). Thus, APC/Cdc20-mediated degradation of mitotic targets
was defective and/or significantly delayed. In contrast, CyclinE, a target of
SCF ubiquitin ligase, was degraded with normal kinetics in POT1a/b DKO
cells (Fig. 2.5A).
We next analyzed the activity of Cdk1/CyclinB, which is required for
entry into mitosis and contributes to the activation of APC/Cdc20 (Peters,
2002). Cdk1/CyclinB activation can be blocked by ATM/ATR kinase signal-
ing through Chk1/Chk2-mediated inactivation of Cdc25 phosphatases, which
removes inhibitory phosphates from Tyr14/15 of Cdk1 (Walworth, 2001). The
Cdk1/CyclinB activity in synchronized POT1a/b DKO cells released into
S/G2 was ∼4-fold lower than in the control and phosphorylation of Tyr14/15
was increased (Fig. 2.6A-C). Furthermore, the Cdk1/CyclinB kinase activity
remained low for at least 6 days after POT1a/b deletion and during 72 hours
of zeocin treatment (Fig. 2.6B). In contrast, the Cdk2/CyclinE activity was
not obviously altered (Fig. 2.6D). Knockdown of Chk1 and Chk2 in POT1a/b
DKO cells resulted in an increase in Cdk1/CyclinB activity and the phospho-
rylation of Tyr14/15 was diminished (Fig. 2.6C-E). In addition, when Chk1
and Chk2 were knocked down (Fig. 2.6C) or inhibited with UCN01 (Fig. 2.6F),
the level of several APC/Cdc20 targets decreased, suggesting that APC/Cdc20
was more active. These data indicate that the activation of Chk1 and Chk2
upon POT1a/b deletion results in a failure in activation of Cdk1/CyclinB and
APC/Cdc20-mediated degradation of mitotic targets.
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Figure 2.5: Impaired activity of APC/Cdc20 in POT1a/b DKO cells.
(A) Abnormal stabilization of mitotic APC targets in POT1a/b DKO cells.
POT1aF/-POT1bF/F MEFs were treated with Cre and 2 days later synchronized
in G1/S by double thymidine block. The indicated proteins were analyzed by im-
munoblotting and the cell number at the corresponding time points is indicated
below the blots. (B) S phase progression of cells used in (A). FACS analysis of
BrdU positive cells at 0 and 4 hours after release from double thymidine (G1/S)
block.
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Figure 2.6: Impaired activity of Cdk1/CyclinB in POT1a/b DKO cells and
zeocin treated cells. (A, B, D) Reduced Cdk1/CyclinB activity in POT1a/b DKO
cells. POT1aF/-POT1bF/F MEFs were treated as in Fig. 2.5A and the activity of
Cdk1/CyclinB (A) and Cdk2/CyclinE (D) complexes was measured by histone H1-
kinase assay. Phopho-histone-H1, Coomassie staining of histone H1, immunoblot-
ting showing Cdk1 (A) and Cdk2 (D) in IPs and quantification of kinase activity
are shown. (B) Low Cdk1/CyclinB activity in POT1a/b DKO and zeocin treated
cells. POT1aF/- POT1bF/F MEFs were treated with Cre or with continuous zeocin
and Cdk1/CyclinB activity was measured at the indicated time points. Phopho-
histone-H1, Coomassie staining of histone H1, immunoblotting showing Cdk1 and
quantification of kinase activity are shown. (C, E) Impairment in Cdk1/CyclinB
and APC/Cdc20 activation in POT1a/b DKO cells is dependent on Chk1 and/or
Chk2. POT1aF/-POT1bF/F MEFs were treated with Cre and two sets of Chk1 and
Chk2 shRNAs. Immunoblotting for the indicated proteins is shown (C). Quantifica-
tion of Cdk1/CyclinB kinase activity after knockdown of Chk1 and Chk2 (set 1) in
two independent experiments is shown (E). (F) Role of Chk1/Chk2 in stabilization
of mitotic APC targets. POT1aF/-POT1bF/F MEFs were treated as in Fig. 1.1 and
immunoblotting for the indicated proteins at the indicated time points is shown.
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2.1.3 By-pass of mitosis in POT1a/b DKO and zeocin
treated cells
To gain further insight into the cell cycle alterations during polyploidiza-
tion, we used time-lapse live-cell imaging. Asynchronously growing POT1a/b
DKO cells and zeocin-treated cells were imaged for two days, acquiring phase-
contrast images every 15 minutes. As expected, a fraction of the cells became
polyploid during this period whereas control cells divided normally, reaching
confluence at the end of the 48 hours imaging period and retaining their diploid
DNA content (Fig. 2.7A, B and Movie 1). On average, each cell in the control
cultures went through mitosis twice (Fig. 2.7A, C). In contrast, 72% of the
POT1a/b DKO cells and 86% of the zeocin-treated cells did not divide during
the imaging period (Fig. 2.7A, C, Movie 1). Furthermore neither the POT1a/b
DKO cells, nor the zeocin-treated cells showed signs of entering mitosis such as
nuclear envelope breakdown and chromosome condensation (Fig. 2.7A, Movie
1). In comparison with control cells, POT1a/b DKO and zeocin-treated cells
became larger and more flattened, displaying a senescent-like phenotype. The
POT1a/b DKO cells and zeocin-treated cells showed a ∼2-fold increase in the
nuclear area (p<0.001; Fig. 2.7D), consistent with the increase in their DNA
content. We also monitored cells expressing a CyclinE-eGFP fusion in the
POT1a/b DKO and zeocin-treated cells (Fig. 2.7C, Movie 2). Although the
CyclinE-eGFP signals were hard to discern, ∼35% of the cells showed clear
evidence of two waves of CyclinE-eGFP without intervening mitosis over a pe-
riod of 48 hours. These experiments and the FUCCI imaging data presented
below indicated that POT1a/b DKO and zeocin-treated cells frequently fail
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to enter mitosis under conditions that induce polyploidization.
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Figure 2.7: By-pass of mitosis in POT1a/b DKO and zeocin treated
cells. (A) Time-lapse imaging of POT1aF/-POT1bF/F MEFs treated with Cre,
cells treated with zeocin, and the untreated controls. After 72 hours, phase contrast
microscope images were taken every 15 minutes for 48 hours (Movie 1). Selected
time points stills are shown. Arrows of the same color highlight the same cell over
the course of the imaging session. In POT1a/b DKO and zeocin-treated cells, ar-
rows highlight representative cells not undergoing mitosis. (B) FACS profiles of cells
used in the live-cell imaging shown in (A) at the beginning (t =0h) and at the end
(t = 48h) of the imaging session. Percentage of polyploid cells is shown. (C) Quan-
tification of cells not undergoing mitosis and the average number of mitoses per cell.
Cells were treated and imaged as in (A) and the movies were analyzed for the % of
cells not undergoing mitosis. Cells expressing CyclinE-eGFP were also analyzed by
time lapse as in (A) (Movie 2) and the percentage of cells showing CyclinE rising
twice without an intervening mitosis in 48 hours is shown. At least 100 cells in each
movie were analyzed for each condition. Average values and SDs were obtained
from 3 independent experiments. (D) Increased nuclear area of POT1a/b DKO and
zeocin treated cells. Cells were treated and imaged as in (A). For each condition,
the nuclear area of 100 cells was measured at the beginning (0 h) and at the end (48
h) of the imaging session and displayed as a frequency distribution. P values based
on non-parametric Krustal-Wallis test.
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2.1.4 Alternating geminin and Cdt1 expression without
mitosis
The ability of POT1a/b DKO cells to enter S phase without progression
through mitosis was unexpected as the initiation of DNA replication requires
degradation of the DNA replication inhibitor geminin (Blow and Dutta, 2005).
In S/G2 geminin is present and inhibits re-licensing of replication origins by
Cdt1. Geminin is degraded at the end of mitosis, allowing Cdt1, which rises in
G1, to license replication origins. Once DNA replication is initiated, Cdt1 is
degraded by SCF. This alternating expression of Cdt1 and geminin expression
ensures that cells execute only one round of DNA replication per cell division
cycle, a rule that is broken in the endoreduplicating cells.
To examine the fluctuations of geminin and Cdt1 in POT1a/b DKO and
zeocin-treated cells, we used the FUCCI (Fluorescent Ubiquitination-based
Cell Cycle Indicator) live-cell imaging system (Sakaue-Sawano et al., 2008).
FUCCI imaging relies on fluorescently-tagged, truncated forms of geminin and
Cdt1 (green and red, respectively) that recapitulate the degradation of the
endogenous proteins. Normally cycling cells are red in G1, reflecting Cdt1
expression, become yellow upon entry into S phase when geminin begins to
accumulate before Cdt1 is degraded and then are green throughout S phase and
G2, due to the presence of geminin. Geminin is degraded at the end of mitosis
and upon entry into G1, resulting in a brief period without either marker
in early G1 before Cdt1 rises again. This sequence of events was observed
in POT1aF/-POT1bF/F cells not treated with Cre, showing G1 (red, ∼12 h),
beginning of S phase (yellow, ∼1 h), S/G2 (green, ∼6 h), and disappearance
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of geminin during mitosis (Fig. 2.8, Fig. 2.9A, B and Movie 3). Cre-treated
POT1a/b DKO cells showed a similar Cdt1-positive G1 phase of 12-14 h,
but then showed a prolonged geminin-positive S/G2 phase (∼20 h; Fig. 2.8,
Fig. 2.9A, B). Importantly, S/G2 was followed by loss of geminin without
mitosis, suggesting that cells returned to a G1-like state (Fig. 2.8, Fig. 2.9A,
B and Movie 3). Cdt1 was undetectable until geminin was degraded but then
increased over the next 12-14 h. Eventually, the POT1a/b DKO cells attained
features of early S-phase, expressing both geminin and Cdt1, followed by a
second period of geminin expression without Cdt1 (Fig. 2.8, Fig. 2.9B and
Movie 3). Thus, the endoreduplicating POT1a/b DKO cells showed a much
slower cell cycle but preserved the alternating geminin and Cdt1 expression
despite the absence of mitosis.
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Figure 2.8: Geminin and Cdt1 alternate in POT1a/b DKO and zeocin
treated cells. FUCCI imaging of geminin and Cdt1. Time lapse imaging of
POT1aF/-POT1bF/F MEFs transduced with FUCCI lentiviral vectors, expressing
mKO2-hCdt1 (red) and mAG-hgeminin (green). Cells were treated with Cre or
vector control and imaged after 72 h. Alternatively, cells were treated with zeocin
during the imaging time. Phase contrast images and fluorescent images using GFP
and rhodamine filters were taken every 15 min (Movie 3). Selected time points
are shown. Arrows with the same orientation highlight the same cell at different
times. In control cells, arrows highlight one cell progressing through a normal cell
cycle (red-yellow-green, mitosis) and its daughters until they move out of the field.
In Cre-treated cells, arrows highlight two representative cells showing the color se-
quence red-yellow-green-red-yellow-green without intervening mitotis.
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The same prolonged S/G2 and mitosis-independent alternation of geminin
and Cdt1 was observed with cells continuously treated with zeocin (Fig. 2.8,
Fig. 2.9A, B and Movie 3). The aberrant cell cycle patterns were observed in
∼70% of the POT1a/b DKO cells and ∼83% of zeocin-treated cells compared
to 1% of the controls (Fig. 2.9A). In addition, FUCCI imaging showed that
zeocin treatment induced mitosis-independent geminin degradation in human
BJ fibroblasts overexpressing HPV-E6/E7 or SV40-LT (Fig. 2.9C and Movie
4). During persistent treatment with zeocin, BJ cells showed an increase
in mitosis-independent geminin degradation and proceeded into a second G1
phase as compared to the untreated control cells displayed a normal mitotic
cycle.
Degradation of geminin without progression through mitosis and reap-
pearance of Cdt1 was also observed in cells that were first synchronized in
G1 and then allowed to progress through G1/S/G2 in the presence of zeocin
(Fig. 2.10A, Movie 5). Immunoblotting of G1/S-synchronized zeocin-treated
cells and POT1a/b DKO cells showed that the FUCCI system faithfully re-
ported on the rise and fall of the endogenous Cdt1 and geminin (Fig. 2.10B,
C). Data from FACS analysis was consistent with a prolonged G2 phase fol-
lowed by entry into S-phase (Fig. 2.10D, E). Furthermore, zeocin-treated cells
and POT1a/b DKO cells showed degradation of the APC targets CyclinA, Cy-
clinB, and securin (Fig. 2.10B, C). However, the cohesin subunit Scc1 was sta-
ble, consistent with the occasional observation of metaphases with diplochro-
mosomes in which the original cohesion of the sister chromatid is preserved
(Hockemeyer et al., 2006). These data establish that persistent telomere-
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Figure 2.9: Geminin and Cdt1 alternate in POT1a/b DKO and zeocin
treated mouse and human cells. (A) Quantification of geminin degradation in
the absence of mitosis. POT1aF/-POT1bF/F MEFs treated with vector control, Cre,
(POT1a/b DKO) or zeocin (Movie 3) were imaged as in Fig. 2.8 and the movies
were analyzed for cells showing at least one event of geminin degradation in the
absence of mitosis. >100 cells were scored for each condition. Average values and
SDs were obtained from 4 independent experiments. (B) Duration of alternating
geminin and Cdt1 expression in endoreduplicating cells. Cells were treated and
imaged as in Fig. 2.8. The indicated number of cells was followed throughout the
imaging session and the length of G1 (red), entry into S phase (yellow) and S/G2
(green) was measured. Average values (h) are shown. (C) Geminin degradation in
the absence of mitosis in BJ cells treated with zeocin. BJ cells were transduced
with FUCCI lentiviral vectors and imaged in the absence (control) or presence of
zeocin for 96 hours. The percentage of cells showing at least one event of geminin
degradation in the absence of mitosis during the imaging was analyzed by scoring
at least 100 cells for each condition.
64
derived or genome-wide DNA damage signaling induces a prolonged S/G2
after which geminin is degraded without progression through mitosis, allowing
reduplication of the whole genome.
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Figure 2.10: Fluctuations of geminin, Cdt1 and other proteins
in endoreduplicating cells. (A) FUCCI imaging of synchronized cells.
POT1aF/-POT1bF/F MEFs expressing FUCCI vectors were synchronized in G1 by
mitotic shake-off and were imaged for 72 hours in the presence or absence of zeocin,
Imaging was started 10 hours after the mitotic cells were plated. Selected time points
(every 6 hours) are shown from a representative experiment (Movie 5). (B) Anal-
ysis of the indicated cell cycle regulated proteins over time in zeocin treated cells.
POT1aF/-POT1bF/F MEFs were synchronized in G1/S by double thymidine block
and released in the presence of zeocin. Immunoblotting for the indicated proteins at
the indicated time points is shown. (C) Analysis of the indicated cell cycle regulated
proteins in POT1a/b DKO cells. POT1aF/-POT1bF/F MEFs were treated with Cre,
synchronized in G1/S by double thymidine block and released. Immunoblotting for
the indicated proteins is shown. (D) FACS analysis of cells treated as in (B). FACS
analysis at the indicated time points is shown and the percentage of polyploid cells
is indicated. (E) POT1aF/-POT1bF/F MEFs were treated as in (C). FACS analysis
at the indicated time points is shown and the percentage of polyploid cells is shown.
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2.1.5 Involvement of APC/Cdh1
We next determined whether APC/Cdh1, the ubiquitin ligase responsible for
degradation of geminin during normal cell cycles (McGarry and Kirschner,
1998), is involved in the endoreduplication. For both POT1a/b DKO cells
and zeocin treated cells, polyploidy was decreased by knockdown of Cdh1
with an shRNA (Fig. 2.11A-C). FUCCI imaging showed that after knock-
down of Cdh1, most of POT1a/b DKO cells remained blocked in G2 (green)
and geminin was not degraded in these cells whereas a parallel culture of
POT1a/b DKO cells showed the mitosis-independent loss of geminin noted
above (Fig. 2.12A-C and Movie 6). Most of the POT1a/b DKO cells treated
with Cdh1 shRNA remained blocked in G2 for 30-40 h and eventually un-
derwent apoptosis (Fig. 2.12A, B and Movie 6). Cdh1 shRNA also had this
effect on zeocin-treated cells (Fig. 2.13A-C, Movie 7) and similar results were
obtained with a second Cdh1 shRNA.
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Figure 2.11: Involvement of Cdh1 in polyploidization. (A-C) Knockdown
of Cdh1 inhibits polyploidization. POT1aF/-POT1bF/F MEFs were treated with
shRNA to knockdown Cdh1 and polyploidy was measured after POT1a/b deletion
by Cre expression, zeocin treatment, or in untreated cells. Immunoblot is shown in
(A). FACS profiles from a representative experiment (B) and quantification of the
percentage of polyploid cells in 3 independent experiments with SDs (C) are shown.
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Figure 2.12: Involvement of Cdh1 in endoreduplication in POT1a/b
DKO cells. (A) Diminished geminin degradation after Cdh1 knockdown.
POT1aF/-POT1bF/F MEFs transduced with FUCCI vectors were treated with Cre,
followed by Cdh1 shRNA or vector control infections a day later. Two days later,
the cells were imaged for 60 hours (Movie 6) and selected time points of a repre-
sentative experiment are shown. Arrows with the same orientation highlight the
same cell over time. In Cre-treated cells two representative cells showing geminin
degradation without mitosis are highlighted. In cells treated with Cre and Cdh1
shRNA, arrows highlight two cells showing prolonged arrest in G2 and persistence
of geminin. (B) Schematic of FUCCI imaging data obtained on POT1a/b DKO cells
treated with Cdh1 shRNA. Cells were treated and imaged as in (A). Cells treated
with Cdh1 shRNA only were imaged separately (Movie 6). The indicated number
of cells were followed throughout the imaging session to determine the length of G1
(red), entry into S phase (yellow), and S/G2 (green). Average values (h) are shown.
(C) Table showing the effect of Cdh1 knockdown on mitosis-independent geminin
degradation. Cells were treated and imaged as in (A) and (B). At least 100 cells
were followed throughout the movie and the percentage of cells showing at least one
event of geminin degradation without mitosis was determined. Average values and
SDs were obtained from 3 independent experiments.
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The occurrence of a prolonged G2 arrest is consistent with the FACS pro-
files in which the ratio between the 4N and 8N peaks is higher in cells treated
with Cdh1 shRNA than in the control. (Fig. 2.11B). In contrast, Cdh1 knock-
down in cells that were not experiencing persistent DNA damage resulted in a
nearly normal progression through the cell cycle (Movie 6 and Fig. 2.12A, B).
The role of APC/Cdh1 in the degradation of geminin and endoreduplication
was further confirmed with an shRNA to the APC1 subunit of the APC, which
gave results similar to those with the Cdh1 shRNA in inhibiting polyploidiza-
tion in POT1a/b DKO cells and zeocin-treated cells (Fig. 2.14A-C).
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Figure 2.13: Involvement of Cdh1 in endoreduplication in zeocin-treated
cells. (A) Cells were treated with Cdh1 shRNA or the vector control and imaged
as in Fig. 2.12A in the presence of zeocin (Movie 7). Selected time points (every 4
hours) are shown. Arrows with the same orientation highlight the same cell during
time. (B) Table showing the effect of Cdh1 knockdown on mitosis-independent
geminin degradation in zeocin-treated cells. Cells were treated and imaged as in (A).
At least 100 cells were followed throughout the movie and the percentage of cells
showing at least one event of geminin degradation without mitosis was determined.
Average values obtained from 3 independent experiments with SD are shown. (C)
Prolonged G2 phase after Cdh1 knockdown in zeocin-treated cells. Cells were treated
and imaged as in (A) and the indicated number of cells were followed throughout
the imaging session to determine the length of G1 (red), entry into S phase (yellow),
and S/G2 (green). Average values (h) are shown.
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Figure 2.14: Involvement of APC1 in endoreduplication in POT1a/b
DKO and zeocin-treated cells. (A-C) Diminished polyploidy after knockdown of
APC1. POT1aF/-POT1bF/F MEFs were treated with APC1 shRNA and polyploidy
was measured after POT1a/b deletion with Cre, after continuous zeocin treatment,
or in untreated cells. FACS profiles from a representative experiment (A) and quan-
tification of the percentage of polyploid cells in 3 independent experiments (C) are
shown. Immunoblotting showing APC1 knockdown is shown in (B).
2.2 Tetraploidization in human cells during
telomere crisis
2.2.1 Telomere-driven tetraploidization occurs in
human cells undergoing crisis
The data presented so far suggest that a prolonged state of telomere dys-
function, which is widespread in early tumorigenesis, may represent a source
of tetraploidization. In the previous experiments, we used a genetic system
where telomere dysfunction was induced by genetic inactivation of the shel-
tering components POT1a/b in mouse cells. We next set out to determine
whether tetraploidy occurs in the cancer-relevant context of telomere crisis
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(Fig. 1.5), the final stage of the last phase of human cells’ lifespan, where
cells experience extensive telomere shortening in the absence of p53 and Rb
pathways.
To generate cells in telomere crisis, telomerase-negative human IMR90 and
BJ fibroblasts were rendered p53- and Rb-deficient through expression of SV40
large T antigen (SV40-LT). As expected, the telomeres shortened progressively
in these cultures (Fig. 2.15A, B), resulting in telomere crisis at PD 80-90
for IMR90-SV40LT and at PD 105-110 for BJ-SV40LT. Telomere crisis was
evident from the plateau in the growth curve (Fig. 2.15A, B), the increased
number of 53BP1 DNA damage foci (Fig. 2.16A), and the phosphorylation
of Chk1 and Chk2 (Fig. 2.16B). FACS analysis showed that the fraction of
tetraploid cells (estimated based on the fraction of cells with a DNA content
>4N) progressively increased from 2-3% at early PDs to 30-35% at the time of
telomere crisis (Fig. 2.16C). Similarly, BJ fibroblasts expressing HPV E6 and
E7 displayed hallmarks of telomere crisis and accompanying tetraploidization
at PD 90-100 (Fig. 2.17A-D).
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Figure 2.15: Telomere shortening and crisis in BJ-SV40 and IMR90-SV40.
(A) Genomic blot for telomere restriction fragments of SV40-LT expressing IMR90
and BJ human fibroblasts at the indicated PD.(B) Growth curve of IMR90-SV40
and BJ-SV40 from PD 20 or 38 respectively until crisis (105-110 PDs for BJ-SV40
cells and at 80-90 for IMR90-SV40).
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Figure 2.16: Tetraploidization of BJ-SV40 and IMR90-SV40 in telomere
crisis (A) IF analysis of 53BP1 foci in the cells at the indicated PDs. The average
number of 53BP1 foci per cell and the % of cells with >3 foci are shown with
standard deviation (SD). (B) Immunoblots for P-Chk1 and P-Chk2 in the BJ-SV40
and IMR90-SV40 cells at the indicated PD. (C) FACS profiles (PI staining) of
IMR90-SV40 and BJ-SV40 cells at the indicated PD. The % of cells with >4N DNA
content is indicated.
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Figure 2.17: Tetraploidization of BJ-E6E7 in telomere crisis. (A) Genomic
blot of telomere restriction fragments of BJ-E6E7 cells at the indicated PDs. (B)
IF for 53BP1 foci in BJ-E6E7 cells at the indicated PDs. The average number
of 53BP1 foci per cells and % of cells with >3 foci at the indicated PD is given.
(C) Immunoblot showing phosphorylation of Chk1 and Chk2 in BJ-E6E7 at the
indicated PD. (D) FACS analyis of BJ-E6E7 at the indicated PD. The % of cells
with DNA content >4N is indicated.
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Telomere crisis was also induced in two telomerase-negative human mam-
mary epithelial cell strains (hMECs), 184BB-GSE22 and 48RS-GSE22, which
lack a functional Rb pathway and express the p53 inhibitory peptide GSE22
(Romanov et al., 2001; Garbe et al., 2007). When these cells divide beyond
senescence, they continue to erode their telomeres and enter a telomere cri-
sis that is accompanied by genome instability (Romanov et al., 2001). The
p53-proficient 184B and 48RS precursors were used as controls. The 184B-
GSE22 and 48RS-GSE22 cultures entered telomere crisis at passage 18-20 and
passage 28-32, respectively, showing shortened telomeres, an increase in the
frequency of 53BP1 foci, and phosphorylation of Chk1 and Chk2 (Fig. 2.18A-
D). FACS analysis showed an increase in the fraction of cells with >4N DNA
content upon entry into telomere crisis in the two p53/Rb negative hMEC
cultures, whereas the parallel p53-proficient counterparts showed a G1/S ar-
rest without tetraploidization (Fig. 2.19A-D). The GSE-22 expressing hMECs,
but not their p53-proficient counterparts, showed evidence for tetraploidization
when pre-crisis cultures were treated with zeocin for 96 hours (Fig. 2.19A-D).
Tetraploidization in telomere crisis was confirmed by analyzing the chromo-
some numbers of metaphase spreads (Fig. 2.20A).
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Figure 2.18: Telomere crisis in hMECs. (A) Genomic blot for telomere restric-
tion fragments of 184B-GSE22 and 48RS-GSE22 at the indicated passage during
the progression toward crisis. (B) Growth curves of 184B-GSE22 and 48RS-GSE22.
(C) Immunoblots for Chk1 and Chk2 phosphorylation in 48RS-GSE22 and 184B-
GSE22 at the indicated passage and after zeocin treatment. (D) IF for 53BP1 foci
in 184B-GSE22 and 48RS-GSE22 hMECs at the indicated passages. The average
number of 53BP1 foci per nucleus and the % of cells with >3 foci are given.
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Figure 2.19: Tetraploidization of hMECs in telomere crisis. (A, B) FACS
analysis of the indicated hMECs at the indicated passage. The % of cells with DNA
content >4N is indicated. Quantification of averages of two or three independent
experiments is shown in (B). (C, D) FACS analysis of 184B-GSE22 and 48RS-GSE22
at the indicated (early) passage treated with zeocin. The % of cells with a DNA
content >4N is indicated. Quantification of three independent experiments is shown
in (D).
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Figure 2.20: Chromosomal abnormalities in crisis cells. (A) Chromosome
numbers of the indicated hMECs at the indicated passage (before and at crisis).
(B) Examples of diplochromosomes and chromosome end fusions from metaphase
spreads derived from BJ-SV40 and 184B-GSE22 in telomere crisis.
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Figure 2.21: DNA damage signal in polyploid cells. BJ-SV40 cells at the
indicated PD were stained for 53BP1 and DAPI by immunofluorescence, pictures
were captured (40X objective) and analyzed using Metamorph software for nuclear
area and number of 53BP1 foci per nucleus. A positive correlation (p<0.0001)
between the nuclear area and the number of 53BP1 foci per cell was found in BJ-
SV40 cells in crisis (PD 100), but not in BJ-SV40 cells at PD 50 (linear regression
analysis of the data was performed using Prism 5 software).
Thus, in epithelial cells as well as in fibroblasts, telomere crisis and pro-
longed genome-wide DNA damage is accompanied by polyploidization result-
ing in tetraploid cells. While the formation of tetraploid cells is readily demon-
strable, we note that the 8N peak in the FACS profiles of cells in crisis could
represent octoploid cells in G1 as well as tetraploid cells in G2. As two succes-
sive aberrant cell cycles are required to generate octoploid cells, octoploidiza-
tion might be too infrequent to result in a clear 16N peak in the FACS profiles.
In the heterogeneous cell population in telomere crisis, tetraploidization is ex-
pected to be more frequent in cells with greater (telomeric) DNA damage
signaling. In agreement, we found a positive correlation between the num-
ber of 53BP1 foci and the nuclear area of BJ-SV40 cells in telomere crisis
(p<0.0001) but not in the same cell population at an earlier PD (Fig. 2.21).
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2.2.2 Endoreduplication and mitotic failure in telomere
crisis
The increased ploidy of cells in telomere crisis could be due to either endoredu-
plication or a failure in the late stages of mitosis, since dicentric chromosomes
formed by telomere fusions (Fig. 2.20B) hinder the completion of cytokine-
sis. In fact if the two centromeres of a dicentric chromosome are pulled to-
ward opposite poles of the mitotic spindle, the resulting lagging chromosome
can prevent completion of mitosis (Mullins and Biesele, 1977). To distin-
guish between these events, we performed live-cell imaging using the FUCCI
system (Sakaue-Sawano et al., 2008). In a normal mitotic cycle, geminin is
degraded during mitosis, thereby re-establishing a state that is permissive to
origin licensing in the daughter cells. However, as shown before, in POT1a/b
DKO cells undergoing endoreduplication, geminin degradation takes place in
the absence of mitosis, allowing cells to enter a G1-like state in which Cdt1
can mediate a second round of DNA replication. Thus, mitosis-independent
geminin degradation is an indicator for endoreduplication (Fig. 2.22A,B and
Fig. 2.23A; Movie 8). In addition, FUCCI imaging can be used to detect
mitotic failure based on the breakdown of the nuclear envelope that signifies
entry into mitosis and the binucleated or multinucleated cells that result from
a failure in cytokinesis (Fig. 2.23A; Movie 8).
As expected, FUCCI imaging at early PDs (PD<50) of BJ-SV40 and
BJ-E6/E7 fibroblasts showed that in most cells geminin degradation coin-
cided with mitosis, whereas endocycles and mitotic failure were rare (<5%;
Fig. 2.22A, B and Fig. 2.23A, B; Movie 8). However, at the late PDs when the
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cells entered telomere crisis, the fraction of BJ-SV40, BJ-E6E7 and IMR90-
SV40 cells undergoing geminin degradation in the absence of mitosis increased
to 12-17% (Fig. 2.22A, B and Fig. 2.23A-C; Movies 8 and 9). After loss of
geminin, most of these cells expressed Cdt1 and entered a second S phase as
deduced from the degradation of Cdt1 and re-appearance of geminin. Dur-
ing these endocycles there was no evidence of nuclear envelope breakdown.
The BJ-SV40 fibroblasts in telomere crisis also displayed a prolonged S/G2
phase whereas G1 was only minimally affected (Fig. 2.23C; Movie 8). In addi-
tion, the cells showed occasional metaphase spreads with diplochromosomes, a
characteristic consequence of endoreduplication representing duplicated sister
chromatids that are held together by the centromeric cohesin (Fig. 2.20B).
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Figure 2.22: Endoreduplication and mitotic failure in fibroblasts in telom-
ere crisis. (A, B) FUCCI live-cell imaging of BJ-SV40 cells (A) and IMR90-SV40
(B) at the indicated PD (Movies 8 and 9). Arrows with the same orientation high-
light the same cell over time. In BJ-SV40 PD 45, the arrow highlights one cell
progressing through a normal cell cycle. In BJ-SV40 cells PD 105, the white arrows
highlight two cells undergoing endoreduplication; the black arrow highlights mitotic
failure.
86
87
Figure 2.23: Quantification of endoreduplication and mitotic failure in
fibroblasts in crisis. (A) Enlarged images exemplifying endoreduplication and
mitotic failure. (B) Table summarizing the data derived from FUCCI imaging and
FACS of BJ-SV40, IMR90-SV40, and BJ-E6E7. The average values and SD obtained
from three independent experiments is given (n is the total number of cells analyzed
in each case). (B) BJ-SV40 cells at the indicated PDs were imaged as in Fig. 2.22.
The indicated number of cells was followed during the imaging session and the
duration (hours) of the presence of geminin and Cdt1 was analyzed (average values
are indicated).
In addition to endoreduplication, fibroblasts in telomere crisis showed a
considerable level of mitotic failure (Fig. 2.22A, B and Fig. 2.23A, B; Movie
8 and 9). Their aberrant mitosis was presumably due to the dicentric chro-
mosomes resulting from telomere fusions (Fig. 2.20B). The cells attempted
mitosis as evidenced by their rounding up and breakdown of the nuclear en-
velope leading to the presence of geminin throughout the cells. However, the
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execution of cytokinesis appeared to fail, resulting in binucleated or multi-
nucleated cells (Movie 8 and 9). Endoreduplication and mitotic failure was
also observed in the hMEC lines 48RS-GSE22 and 184B-GSE22 in telomere
crisis and upon continuous treatment with zeocin (Fig. 2.24 and Fig. 2.25 A,
B; Movie 10). Mitotic failure appeared to be more frequent in the hMECs
compared to the BJ and IMR90 fibroblasts. For instance, in the presence of
zeocin, BJ fibroblasts predominantly show endoreduplication whereas hMECs
also show mitotic failure events (Fig. 2.25A, B; Movie 10).
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Figure 2.24: Endoreduplication and mitotic failure in hMECs in telomere
crisis and after zeocin. FUCCI imaging of 48RS-GSE22 at the indicated passages
untreated or treated with zeocin. Indicated time points are from Movie 10. Arrows
with the same orientation highlight the same cell over time. In 48RS-GSE22 p32,
the white arrows highlight cells showing endoreduplication and the black arrows
highlight cells undergoing mitotic failure.
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Figure 2.25: Quantification of endoreduplication and mitotic failure in
hMECs in telomere crisis and after zeocin. Table summarizing data derived
from FUCCI imaging (Movie 10) and FACS (Fig. 2.24). The average and SD ob-
tained from three independent experiments is given.
2.2.3 Role of Rb in blocking telomere-driven tetraploidiza-
tion
In human cells, activation of the Rb pathway contributes to the cell cycle arrest
in response to a genome-wide or telomere-derived DNA damage signal (Jacobs
and de Lange, 2004; Shay et al., 1991; Smogorzewska and de Lange, 2002;
Shay and Wright, 2005). In order to determine whether the Rb pathway can
block tetraploidization, we analyzed telomerase-negative BJ fibroblasts with
an unaltered Rb pathway. The p53 dominant negative allele (p53dn, p53175H)
was used to abrogate the p53 response to DNA damage (p53dn, (Baker et al.,
1990; Jacobs and de Lange, 2004).
To measure their propensity for tetraploidization, the BJ-p53dn cells were
either subjected to continuous zeocin treatment or extensive replicative telom-
ere shortening (PD 70-80; Fig. 2.26A-C; Fig. 2.27A-C). As compared to PD
30, at PD 70-80 the BJ-p53dn cells showed a small increase in the fraction
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of tetraploid cells (<1% to ∼7%; Fig. 2.26A, B). The DNA damage response
was active in BJ-p53dn cells at PD 70-80, as shown by Chk1 phosphorylation
and an increased number of 53BP1 foci compared to earlier PDs (Fig. 2.26C,
Fig. 2.27C). FACS analysis indicated that BJ-p53dn showed fewer tetraploid
cells and a lower fraction of cells in G2 compared to BJ-SV40 at the same
PD (Fig. 2.16C, Fig. 2.26A, B). Furthermore, after 96 hours of zeocin treat-
ment, only ∼9% of BJ-p53dn cells had a DNA content >4N, whereas 20-25%
of BJ-SV40 became tetraploid after zeocin treatment (Fig. 2.26A, B).
Figure 2.26: Rb-mediated inhibition of tetraploidization in BJ cells. (A)
FACS analysis of BJ cells expressing p53175H (p53dn) or SV40-LT at the indicated
PD with or without treatment with zeocin. (B) Quantification of the FACS data in
(A). (C) Immunoblot for Chk1 phosphorylation and p16 expression in BJ-p53dn at
the indicated PD or after treatment with zeocin.
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Figure 2.27: Telomere shortening and DNA damage after prolonged pro-
liferation in BJ-p53dn. (A) Genomic blot of telomere restriction fragments of
BJ-p53dn cells at the indicated PDs. (B) Growth curve of BJ-p53dn cells. (C) IF
for 53BP1 foci in BJ-p53dn cells at the indicated PD. The average number of 53BP1
foci per nucleus is indicated.
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Similar data were obtained using RPE (retinal pigment epithelial) cells
lacking p53 function (Fig. 2.28A, B) whereas tetraploidy was not induced in
primary cells, which arrested in G1/S (Fig. 2.28 A, B). Consistent with a role
of the Rb pathway in mediating a G1/S arrest in response to telomere and
genome-wide DNA damage, the level of p16 increased at increasing PDs and
after zeocin treatment (Fig. 2.26C). These data suggest that the activation of
the Rb/p16 pathway contributes to the repression of tetraploidization in cells
experiencing a persistent DNA damage response.
The low level of residual tetraploidization in the Rb-proficient cells could be
explained if the Rb pathway led to a block in G1 but not in G2. We therefore
isolated FACS-sorted G1 and S/G2 cells, subjected them to zeocin treatment
soon after plating, and then used FUCCI imaging to determine their tendency
to undergo cell cycle progression and/or tetraploidization. Approximately 60%
of the G1-sorted BJ-p53dn cells treated with zeocin remained in G1/S phase of
the cell cycle (red or yellow) throughout the 96 hour imaging session (Fig. 2.29;
Movie 11) whereas only 25-30% of G1-sorted BJ-SV40 cells arrested in G1/S
after zeocin treatment (Fig. 2.29; Movie 11). In contrast, approximately 75%
of the BJ-p53dn S/G2 cells underwent endoreduplication, showing mitosis-
independent geminin degradation and re-entry into G1 (Fig. 2.29; Movie 12).
BJ-SV40 cells in S/G2 showed the same percentage of endoreduplication, in-
dicating that Rb status does not affect tetraploidization of cells experiencing
prolonged DNA damage in S/G2. Although we cannot exclude other aspects
of SV40 large T antigen expression, these data suggest that activation of the
Rb/p16 pathway blocks entry into S phase in cells that experience a DNA
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Figure 2.28: Rb-mediated G1 arrest represses of tetraploidization in RPE
cells. (A, B) Human retinal pigment epithelial (RPE) cells at PD 10 were trans-
duced with vectors expressing p53 shRNA or SV40-LT or an empty vector. The
indicated cells were treated for 96 hours with zeocin or left untreated and were ana-
lyzed by FACS. The % of cells with a >4N DNA content is indicated. Quantification
of three independent experiments is shown in B.
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damage signal in G1, thereby limiting the occurrence of tetraploidization. In
contrast, the Rb/p16 pathway alone is not capable of preventing endoredupli-
cation when the DNA damage takes place in G2.
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Figure 2.29: Rb-mediated G1 arrest inhibits tetraploidization. FUCCI
imaging of BJ-p53dn PD 35 and BJ-SV40 PD 40 cells that were first FACS sorted
for G1 (Cdt1, red) or S/G2 (geminin, green) and then imaged in the presence of
zeocin (Movie 11, Movie 12). Selected time points are shown. Quantification of
the Movie is shown below the images. The number of cells that remain arrested
in G1/S (red/yellow color) throughout the imaging session and the cells showing
geminin degradation in the absence of mitosis were scored in the indicated cases.
Average numbers obtained in two experiments are shown.
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2.2.4 DNA damage signal threshold for the induction
of tetraploidy.
A question relevant to the induction of polyploidization during telomere crisis
is how many dysfunctional telomeres are required for this phenomenon and,
in more general terms, whether there is a threshold for the induction of en-
doreduplication by DNA damage. This point was addressed by the work of
Gloria Wu, an MD. PhD. student who rotated in the lab under my guidance.
We treated mouse or human cells with increasing amounts of zeocin from 2 to
50-100 ug/ml for 72 hours and then analyzed the cells for polyploidy (fraction
of cells with a DNA content >4N) and number of 53BP1 foci, as a quantifi-
cation of the DNA damage level (Fig. 2.30 and Fig. 2.31). We noticed that
the FACS profile of MEFs SV40 treated with 2 or 5 ug/ml was very similar to
the untreated cells, with almost no increase in the cells with a DNA content
>4N. At zeocin concentration of 10 ug/ml, we started to detect a significant
increase in polyploidy from 3 to 11%, corresponding to a clear tetraploid peak
in the FACS profile. Higher concentration of 20 ug/ml zeocin further increased
the fraction of polyploid cells, and finally, at 50 ug/ml extensive polyploidiza-
tion in almost half of the cell population (45%) was observed. The number
of 53BP1 foci per cell was analyzed in the same cells after 12-16 hours from
the beginning of the zeocin treatment as a quantification of the DNA damage
level (Fig. 2.30). MEFs treated with zeocin concentrations of 2 and 5 ug/ml
showed an homogeneous distribution of around 3 53BP1 foci per cell, with
very few cells showing more than 10 foci. At higher concentrations of 10 and
20 ug/ml, the fraction of cells with more than 10 foci increased, accordingly
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to the increase in polyploidy. In MEFs treated with the 50 ug/ml of zeocin
almost half of the cells showed more than 10-15 foci, and these cells most
likely represent the fraction of polyploid cells seen in the FACS profile (45%)
Thus, from this data we can infer that, in mouse cells a minimum level of
10-15 53BP1 foci is necessary for the induction of endoreduplication in mouse
fibroblasts (Fig. 2.30).
A similar experiment was performed in human BJ SV40 fibroblasts at
PD30. We noticed that in BJ SV40 cells, the lowest zeocin concentration
necessary for polyploidy was higher than in mouse cells (Fig. 2.31). In fact,
for zeocin concentration up to 10 ug/ml, the fraction of polyploid BJ SV40
cells was not significantly higher than untreated cells. Overt polyploidization
was observed only at 50 and 100 ug/ml of zeocin. The distribution of 53BP1
foci in zeocin-treated BJ SV40 cells seemed to be more homogeneous than in
mouse cells, with less clear distinction of the population with high number
of 53BP1 foci, most likely representing polyploid cells. Nevertheless, we were
able to estimate a threshold of 15-20 DNA damage foci for the induction of
polyploidy in human fibroblasts. These data indicate that a DNA damage
threshold for the induction of polyploidy indeed exists, since even a prolonged
treatment with low zeocin concentrations is not sufficient for polyploidy to
occur. Most likely, in this case the balance between the induction of DNA
lesions by zeocin and the activity of the repair machinery results in a net level
of damage that is not sufficient to induce a prolonged G2 cell cycle arrest.
It is likely that these cells experience a delay in G1 and/or G2 phases of the
cell cycle, still being able to complete a regular mitotic cycle. Similarly, the
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Figure 2.30: DNA damage threshold for tetraploidization in MEF SV40.
(A) MEF SV40 were continuously treated with zeocin at the indicated concentration
and analyzed by FACS after 72 hours (representative experiment is shown). (B)
MEF SV40 were treated as in (A) and analyzed by IF for 53BP1 foci. The grey
bar show the estimated threshold of the number of 53BP1 foci necessary to induce
tetraploidy.
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lower fraction of polyploid cells in human fibroblasts as compared to mouse
cells treated with the same zeocin concentration might reflect differences in
the regulation of the cell cycle checkpoint in G2 and/or in the re-entry into S
phase, necessary for tetraploidization.
We next asked whether in BJ SV40 cells in crisis, the level of DNA dam-
age required for polyploidization was reached in a certain fraction of cells,
and whether this value is in agreement with the percentage of polyploid cells
measured by FACS. Due to the low amount of telomeric DNA in crisis cells,
colocalization analysis of 53BP1 DNA and telomeric DNA is very difficult.
Thus, we considered the number of 53BP1 foci as an estimate of the num-
ber of dysfunctional telomeres in crisis cells (d’Adda di Fagagna et al., 2003).
Quantification of 53BP1 foci in BJ SV40 cells in crisis (PD100) showed that
about 15-20% of cells displayed a number of 53BP1 foci higher than 15-20 foci
(Fig. 2.31), the previously estimated threshold for the induction of polyploidy
in human cells. The fraction of polyploid cells in BJ SV40 in crisis measured
by FACS is about 30%, higher than this value (Fig. 2.23). However, poly-
ploid cells include both endoreduplicating cells and cells undergoing mitotic
failure, in almost similar ratio (Fig. 2.23) and it is plausible that endoredu-
plicating cells will have more ongoing damage than cells undergoing mitotic
failure. Based on this consideration, the estimated fraction of cells with high
number of 53BP1 foci seems to be consistent with the % of cells undergoing
endoreduplication in this context. Finally, it is also important to note that our
way to assess polyploidy might be an underestimate, as the tetraploid G1 cells
are not included in the polyploid fraction, therefore the threshold of 53BP1
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Figure 2.31: DNA damage threshold for tetraploidization in BJ-SV40.
(A) BJ-SV40 were continuously treated with zeocin at the indicated concentration
and analyzed by FACS after 72 hours (representative experiment is shown). (B) BJ
SV40 were treated as in (A) and analyzed by IF for the number 53BP1 foci. BJ-SV0
before and during crisis were also analyzed in the same way. The grey bar show the
estimated threshold of the number of 53BP1 foci necessary to induce tetraploidy.
The fraction of predicted tetraploid cells in BJ SV40 in crisis is shown.
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foci required for tetraploidy may be lower. This would be particularly true for
the short term damage in zeocin-treated cells, where some cells might not have
enough time to endoreduplicate during the 72-hours experiment, as compared
to the ’long-term’ telomere damage during crisis.
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2.3 Telomere-dependent tetraploidy promotes
transformation in mouse cells.
2.3.1 Re-establishment of cell division cycles after telomere-
dependent tetraploidization
To address the trasformation potential of telomere-dependent tetraploidiza-
tion, we created a POT1atet-OFF system to elicit transient telomere dys-
function, mimicking the temporary loss of telomere protection that is thought
to occur early in tumorigenesis before telomerase activation. A tetracycline-
inducible system was used to control POT1a expression in POT1aF/-POT1bF/F
MEFs. After induction of POT1a, the endogenous POT1a/b proteins were re-
moved with Cre, clones were derived and two of them were chosen for further
analysis, clone 19 and 26. Cells lacking POT1b have excessive single-stranded
DNA at their telomeres but the telomeres do not elicit a DNA damage re-
sponse and the cells proliferate normally (Hockemeyer et al., 2006). As ex-
pected, the loss of POT1a was accompanied by the accumulation of 53BP1
at telomeres as judged by the increase in number of colocalizations between
telomeric DNA and 53BP1 or TIFs (telomere-dysfunction induced foci), phos-
phorylation of Chk1 and tetraploidization as measured by FACS (Fig. 2.32A,
B). Tetraploidization was also evident in these cells from the supernumerary
centrosomes and telomere clustering in interphase which are consistent with
chromosome reduplication without chromosome segregation (Hockemeyer et
al., 2006; Fig. 2.33A, B).
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Figure 2.32: Tet-OFF system for inducible expression of POT1a in MEFs.
(A, B) Immunoblot for Chk1 phosphorylation and POT1a in POT1a-tetOFF-19 and
-26 cells (SV40-LT expressing MEFs) at the indicated time points after treatment
with doxycycline and after release of the FACS-sorted diploid and tetraploid cells.
POT1a-tetOFF clones 19 and 26 were treated with doxycycline for 10 days, FACS
sorted after Hoechst 33342 staining, and cultured in the absence of doxycycline. (B)
FACS analysis of POT1a-tetOFF-19 and -26 cells treated as in (A). The % of cells
with >4N DNA content is indicated.
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Figure 2.33: Analysis of diploid and tetraploid cells derived from POT1a-
tetOFF-19 and -26 (A) IF-FISH to detect telomere dysfunction in POT1a-
tetOFF-19 and -26. Cells were treated with doxycycline and analyzed by IF for
53BP1 and telomeric FISH. Representative IF-FISH image and average % of cells
with > 5 TIFs (Telomere Dysfunction Induced foci) for the indicated cells is shown.
Examples of cells showing telomere clusters after doxycycline treatment are also
shown for the two POT1atetOFF cell lines (right panels). (B) Centrosome amplifi-
cation in tetraploid cells derived from POT1a-tetOFF-19 cells treated with doxycy-
cline. Cells were analyzed by IF for centrin-2 staining and the average centrosome
number is indicated. (C) Diploid and tetraploid cells derived from POT1a-tetOFF-
19 and -26 were derived as in Fig. 2.32 and the shown growth curve was started
after 5-7 days after sorting.
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This system was used to test the ability of diploid and tetraploid cells to
proliferate after restoration of telomere protection by POT1a. After 7 days of
doxycycline treatment to repress POT1a, diploid (2N) and tetraploid (8N) cells
were isolated by FACS-sorting (Fig. 2.34A). Removal of doxycycline allowed
re-expression of POT1a and repressed Chk1 phosphorylation (Fig. 2.32A, B),
indicative of restoration of telomere protection. The cell division cycles of the
tetraploid and diploid populations were monitored by time lapse imaging us-
ing H2B-GFP to visualize chromatin (Fig. 2.34B, Movie 13). Approximately
90% of the diploid cells and ∼70% of tetraploid cells were able to progress
through an apparently normal cell division cycle and gave rise to a viable
progeny. Tetraploid cells proliferate at a slightly lower rate than diploid ones
(Fig. 2.33C). Thus, the tetraploid cells generated by persistent telomere dam-
age can re-establish normal cell division cycles and proliferate. As expected
from the presence of supernumerary centrosomes in these cells (Fig. 2.1E and
Fig. 2.33B), some of the tetraploid cell divisions showed multipolar spindles
(Fig. 2.34B), predicting a greater rate of chromosome mis-segregation in these
clones and higher rate of cell death.
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Figure 2.34: Re-establishment of cell division cycles after tetraploidiza-
tion. (A) Schematics of the experimental approach. H2B-GFP expressing POT1a-
tetOFF-19 cells were treated with doxycycline for 7 days to repress POT1a and
stained with Hoechst and FACS-sorted for DNA content. G1 diploid cells (2N
peak) and G2 tetraploid cells (8N peak) were separated, plated in the absence of
doxycycline and monitored by time lapse imaging. (B) Cell divisions of diploid and
tetraploid cells derived from clone 19 after re-expression of POT1a. Time lapse
imaging of diploid and tetraploid cells expressing H2B-GFP was started 24 hours
after doxyxcycline removal. Phase contrast and GFP-fluorescent images were taken
every 15 minutes (Movie 13). Selected time points are shown. Arrows highlight
a cell performing multiple cell divisions during the imaging session. Insets show
evidence for multipolar mitoses.
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2.3.2 Telomere-driven tetraploidization promotes
transformation in mouse cells
We next used the POT1a-tetOFF system to determined the transformation
potential of tetraploid cells generated after transient telomere damage. Af-
ter doxycycline treatment, POT1a-tetOFF-19 and -26 cells were FACS-sorted
based on Hoechst-staining for DNA content to derive tetraploid and diploid
cells. The diploid and tetraploid cells were cultured for either 2 or 5-6 weeks
in the absence of doxycycline, allowing POT1a re-expression (Fig. 2.32A). The
results at these two time points were essentially the same.The resulting diploid
and tetraploid cultures were tested for their ability to form colonies in soft-agar
and tumors in nude mice (Fig. 2.35A, B). For both POT1a-tetOFF-19 and -26,
the tetraploid descendants were more transformed based on both assays. The
transformation efficiency after long term culture (5-6 weeks) was slightly higher
than the one after short term culture (2 weeks). Overexpression of c-Myc fur-
ther enhanced the transformation of diploid and tetraploid POT1a-tetOFF
cells but even without this oncogene, the greater tumorigenic potential of the
tetraploid population was significant (Fig. 2.32A, B). POT1atetOFF control
cells not treated with doxycycline transformed at a rate similar to the sorted
diploid cells. The increased transformation potential in the tetraploid cells was
not due to increased proliferation rate, since the tetraploid cells grew slower
than their diploid counterparts (Fig. 2.33C).
112
Figure 2.35: Telomere-driven tetraploidy promotes cellular transforma-
tion in mouse cells. (A, B) POT1a-tetOFF-19 and -26 with or without pBabe-
Myc-ER were treated as in Fig. 2.32. FACS sorted diploid and tetraploid cells were
expanded for 2 weeks or for 6-8 weeks and plated in soft-agar (A) or injected into
nude mice (B). The soft-agar colonies were counted after 4 to 6 weeks. Myc-ER
was induced with 0.5 µ M OHT. The average frequencies of tumor formation and
latencies are indicated with standard deviation (3 or 4 experiments, 5 or 10 mice
per experiment). Stars indicate a statistically significant difference (p<0.05 after
paired Students t-test). (C, D) POT1a-tetOFF-19 cell line was stably transduced
with H2B-GFP and treated as in (B). Tumors derived from diploid or tetraploid
cells were harvested and GFP+ cells were FACS sorted. FACS analysis of unsorted
cells derived from tumors formed by diploid or tetraploid cells (C) and sorted (GFP-
positive and -negative) cells derived from a tumor formed by tetraploid cells (D) are
shown. The GFP-negative cells are most likely cells derived from the host.
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2.3.3 Evolution of sub-tetraploid karyotypes
In order to monitor the karyotypic changes during tumor outgrowth, we estab-
lished cell lines from tumors formed upon injection of diploid and tetraploid
mouse cells. Prior to injection into nude mice, the cells were infected with
the histone H2B-GFP construct allowing separation of tumor cells from host-
derived cells present in the tumor mass. GFP-positive cells of tumors de-
rived from injected tetraploid cells showed a tetraploid-like profile, consistent
with their cells of origin (Fig. 2.35C, D). As expected, the host-derived GFP-
negative cells showed a diploid-like profile. A total of eight GFP-positive
cell lines were derived from tumors formed by the POT1a-tetOFF-19 and -26
tetraploid cells. Their chromosome numbers, determined after propagation of
the cells for 7-10 days in culture revealed subtetraploid karyotypes, with the
exception of one line which was hyper-tetraploid (chromosome number ∼120,
Fig. 2.36A, B). Evolution of subtetraploid karyotypes had also occurred in
three of four cell lines derived from soft-agar colonies formed by tetraploid
POT1a-tetOFF-26 cells (Fig. 2.36C). As a control, cell lines established from
a soft-agar colony and a tumor formed by diploid cells had a near-diploid
karyotype (Fig. 2.36B, C). These results indicate that tetraploid cells gener-
ated through telomere dysfunction have a high rate of chromosome loss. In
collaboration with Dr. Anna Jauch (University of Heidelberg) we performed
spectral karyotyping (SKY) analysis of some of the tumor-derived cell lines.
This analysis did not show any specific chromosome or group of chromosomes
to be preferentially lost (Fig. 2.37). In addition, SKY analysis showed occa-
sional translocations (Fig. 2.37), probably due to the low level of telomeric
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fusions occurring in POT1a/b DKO cells.
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Figure 2.36: Evolution of subtetraploid karyotypes. (A, B) Graphs indicat-
ing the number of chromosomes/metaphase in cells derived from tumors formed by
diploid and tetraploid POT1a-tetOFF-19 and -26 cells (as in Fig. 2.35B). Cell lines
were derived from tumors and metaphase spreads were analyzed after 7-10 day. The
distribution of the chromosome number of POT1a-tetOFF diploid and tetraploid
cells before injection and of cell lines derived from the indicated tumors derived
from injected diploid or tetraploid cells is shown. (C) Graph indicating the num-
ber of chromosomes/metaphase in cells derived from soft-agar colonies formed by
POT1a-tetOFF-26 (as in Fig. 2.35A). Statistical analysis (one-way ANOVA, Prism
software) did not shown any preferential loss of a specific chromosome or group of
chromosomes.
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It is interesting to note that subtetraploidy was also observed in in hMEC
cells in telomere crisis. While 48RS-GSE22 p20 (early passage before crisis)
showed a normal near-diploid chromosome number, when the same cells were
analyzed during their progression through crisis (p26) we noticed an increase in
the cells containing a near-tetraploid chromosome number, in agreement with
FACS analysis (Fig. 2.38A and Fig. 2.19). Analysis of the chromosome number
of 48RS-GSE22 cells progressing toward the plateau phase of crisis showed a
decrease in the average number of chromosomes per cell, with most of the cells
displaying a subtetraploid karyotype. Furthermore, we FACS sorted diploid
and tetraploid cells by Hoechst staining from 48RS-GSE22 p25 and followed
their growth in culture (Fig. 2.38B). Interestingly, while the growth curve of
diploid cells plateaued 5-7 passages after the sorting, the tetraploid cell popu-
lation was able to grow for about 10 additional passages before entering in the
plateau phase (Fig. 2.38B). This result suggests that tetraploid cells can bet-
ter sustain the genome instability deriving from telomere crisis, in agreement
with the hypothesis of higher mutational robustness of polyploids compared
to diploids. These data also suggest that clones potentially emerging from
post crisis cells after hTERT activation or different mechanisms of telomere
maintenance will be likely to display a subtetraploid karyotype.
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Figure 2.37: SKY analysis of subtetraploid tumor-derived and colony-
derived cell lines. (A) Example of SKY analysis of POT1a-tetOFF-26-tetra
tumor-1 cell line. (B) Cell lines derived from POT1atetOFF 26 tetra tumor 1, 2 and
3 were analyzed using SKY. The copy number for each chromosome was scored in
each metaphase and is shown (grey spots). In red is the average value with standard
deviation. (C) Cell lines derived from POT1atetOFF 26 tetra colonies 1, 2 and 4
were analyzed and plotted as in B.
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Figure 2.38: Analysis of tetraploidy in hMECs in telomere crisis. (A)
hMECs 48RS GSE22 at the indicated passage were analyzed for chromosome num-
ber. (B) Diploid and tetraploid cells were FACS sorted from hMECs 48RS-GSE22
p26 and analyzed for proliferation. The growth curve is shown.
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2.4 Evidence for telomere crisis in cancer cell
lines with high chromosome number
If telomere dysfunction is the source of tetraploidy and subtetraploidy dur-
ing tumorigenesis, it is expected that tumors with high chromosome numbers
show features of prior telomere crisis. In order to test this hypothesis, we
adapted a recently described method to amplify telomeric fusions (Capper et
al., 2007; Letsolo et al., 2010; Lin et al., 2010). This method, called fusion
PCR, is a PCR-based method to amplify products derived from end-to-end
fusion of human chromosomes. The PCR is mediated by primers specific to
the subtelomeres, DNA sequences immediately adjacent to terminal TTAGGG
repeats in human chromosomes (Riethman et al., 2003). The PCR utilizes at
least two subtelomere-specific primers, 5’-3’oriented toward the chromosome
terminus, so that if an end-to-end fusion is present between the two chromo-
somes, a fusion product will be amplified, spanning from one subtelomere to
the other, with the two head-to-head fused telomeres in between. The ampli-
fied telomeric fusions are then detected by Southern blotting with a subtelom-
eric specific probe (Fig. 2.39A). In human cells with a normal karyotype, no
product amplification is expected, while in cells in telomere crisis, telomeric fu-
sions should be amplified. The conditions for the PCR reaction are optimized
for the amplification of long amplicons, however the amplification of smaller
products containing a shorter tract of telomeric DNA will be anyway favored
in the PCR reaction. The first described version of the fusion PCR made use
of primers specific for the subtelomeres XpYp and 17p (Fig. 2.39A, (Capper
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et al., 2007). The assay was proved to efficiently amplify fusion products in
human cells in crisis, however it was limited to the detection of one type of
telomeric fusion, occurring between two human chromosome arms. Ideally,
a fusion PCR assay designed to estimate the frequency of telomeric fusions,
should amplify all the possible fusions between human chromosomes. How-
ever, this is practically impossible since increasing the number of subtelomeric
primers would also enormously increase the nonspecific products. A recently
described modified version of the fusion PCR assay was designed to simulta-
neously detect multiple types of fusions by taking advantage of the fact that
groups of human subtelomeres share the same or similar sequence (Riethman
et al., 2003, Letsolo et al., 2010). Specifically, there are two families of sub-
telomeres sharing similar low-copy repetitive regions, called Tel Bam11 and
Tel Bam 3.4 (Riethman et al., 2003).
Due to the presence of nonspecific bands and to the absence of an inter-
nal control in this assay, we set out to optimize the assay. We included the
two well characterized primers specific for XpYp and 17p subtelomeres. We
designed an internal control, represented by a 0.5 kb region amplified on the
XpYp subtelomere by the XpYpM (primer also used to amplify fusions) and
an additional reverse primer (XpYp-ctr2, Fig. 2.39B). Then we designed new
primers and probes specific to the Tel Bam11 family of subtelomeres (called
21q family, which includes 21q, 5q, 10q, 17q and 22q) and the Tel Bam 3.4
family (called 16p family, which includes 16p, 9p, 15q and XqYq) (Fig. 2.39B).
We tested these primers by using DNA extracted from hMECs 184B-GSE22
p20 in telomere crisis and the same cells immortalized at passage 9 by over-
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Figure 2.39: Fusion PCR to detect telomeric fusions. (A) Simplest version of
the fusion PCR assay where two subtelomere specific primers, one specific for XpYp
and the other specific for 17p are used together to detect potential fusions between
these two chromosomes. The box in dark grey represents the XpYp specific probe.
(B) Optimized fusion PCR assay. Primers for Tel Bam11 (21q) and Tel Bam3.4
(16p) subtelomere families are shown in black. Primers in grey are the primers used
in the nested fusion PCR. Boxes in dark represents the probes used in the assay
(for primers see Exp. Procedures). Distance of the primers from the start of the
telomeric repeats is shown. The only EcoRI site in these subtelomeric regions is
shown.
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expression of telomerase (184B-GSE22 hTERT), which as expected resulted
in telomere elongation. The primers were evaluated based on their ability to
amplify telomeric fusions in crisis cells in the absence of nonspecific products
in hTERT immortalized cells. As shown in Fig. 2.40A-B, the fusion PCR can
amplify fusion products in 184B-GSE22 p20 in crisis, while no products are
amplified by using DNA from 184B-GSE22 hTERT. In addition, progressively
higher frequency of fusions are detected in 48RS-GSE22 hMECs progressing
through crisis Fig. 2.40C. The internal control product on the XpYp arm shows
that the efficiency of the PCR was similar in the different reactions.
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Figure 2.40: Increased telomere fusions in hMECs progressing through
crisis. (A) Fusions PCR assay using XpYp, 17p, 21q, 16p and XpYp-ctr primers in
the indicated hMEC cell lines, expressing hTERT or in crisis (multiple repeats were
performed in each case). 21q probe and XpYp probe (for the control) were used as
shown. In the first two lanes of 184B GSE hTERT and 184B GSE p20, the PCR
was performed without the control primer XpYp-ctr2. (B) Telomere blot for hMECs
184B GSE22 p9 before or after hTERT over-expression showing telomere elongation
after hTERT expression. (C) Fusion PCR assay as in (A) in the indicated hMECs
progressing through crisis.
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Finally, to further verify the specificity of these products for subtelomeric
and telomeric regions, we used nested PCR amplification of the fusion PCR
product (Fig. 2.41). For each subtelomere family, nested primers were designed
in the region adjacent to the primary primers 5’-3’ oriented toward the telomere
end (Fig. 2.41). Nested PCR was performed on the diluted PCR product of
the primary PCR reaction. Also in this case, 184B GSE p20 or 184B GSE
hTERT cells were used in parallel to test the specificity of the designed fusion
PCR primers (Fig. 2.41). In some cases, the products of the nested PCR were
sequenced in order to verify that they contained subtelomeric and telomeric
regions. It is important to note that, even if we can readily amplify fusions
from crisis cells, the efficiency of the method in detecting potential fusions is
still low. In fact, the number of all possible fusions in a diploid human cell
is 4560 (two by two combinations of the 92 telomeres), while the fusion PCR
assay (using XpYp, 17p, 21q and 16p primers and 21q probe) theoretically
detects only 165 potential fusions (1 in 28).
In order to apply the optimized fusion PCR to cancer-derived cell lines, we
selected breast cancer cell lines with near-diploid or high chromosome numbers
(Fig. 2.42). The near-diploid lines had an average chromosome number of
43-48, while the high chromosome number lines had an average chromosome
number of 64 to 90 (one exception with 60 chromosomes). All the cell lines
are derived from carcinoma of the breast, either from the primary site (breast)
or from a metastatic site (pleural effusion). The cases known to be hereditary
were excluded as well as cases where the patient was previously subjected to
chemotherapy or radiation therapy.
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Figure 2.41: Nested PCR to validate fusion PCR. Fusion PCR was performed
using only one of the 21q primers (recognizing telomeres in the Tel Bam11 family)
represented in (A). A nested PCR was performed on of the product from the primary
PCR using the 21q3 as a nested primer. The indicated cell lines were used, 184B
GSE p20 in crisis and 184B GSE hTERT as negative control. The 5 primers used in
the primary PCR were evaluated based on the presence of fusion products in crisis
cells (p20) and absence of nonspecific products in the PCR performed on 184B
GSE22 hTERT cells. PCR using 21q1 and 21q2 primers does not show products
in cells in crisis (lines a, b, f, g) while primer 21q4b shows a product in the crisis
cells but also some non specific products in hTERT expressing cells (lines d and i).
The primer 21q4 is able to amplify a specific band from crisis cells in the absence
of specific products in hTERT expressing cells (lines e and j) and is therefore the
most specific.
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Figure 2.42: Breast cancer cel lines near diploid and with high chromo-
some numbers. List of the breast cancer cell lines near diploid (blue) and with
high chromosome number (red) and the corresponding chromosome number, type
of cancer, site of origin and age. IDC: invasive ductal carcinoma; DC: ductal carci-
noma not specified; AC: adenocarcinoma; Carc: carcinoma. IIB refers to the stage
of the disease
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Fusion PCR reactions were performed using the validated primers (Fig. 2.43
and Fig. 2.44). In order to quantify the number of telomeric fusions present in
each cell line, we scored the number of bands appearing in each PCR reaction
(performed in multiple repeats) and calculate the average number of fusions
Fig. 2.45. Fusion PCR on these cell lines using different primer combinations
showed a higher number of telomeric fusions in the cell lines with high chromo-
some numbers as compared to the near-diploid lines (Fig. 2.43 and Fig. 2.44).
Quantification of the fusions products indicates that this difference is signif-
icant (Fig. 2.45).There was no correlation between the frequency of fusions
and the stage or the origin of the cell line, being the primary tumor site or the
metastatic one.
It is important to note that in many cases multiple repeats of the same
PCR reaction did not result in the amplification of the same pattern of bands.
This is probably due to the low efficiency of fusion detection by this assay and
to the heterogeneity of the cancer cell population, which most likely contains
multiple clonal cell populations, each with a different frequency of telomere
fusions. When we estimated the ’real’ number of fusions, considering the
efficiency of the assay (detection of one fusion every 28), the number of fusions
estimated was lower than 1 fusion per cell, even in the cell line with the
highest number of fusions, BT 549 (1 estimated fusion every 80 cells). This
result suggests that, if our estimate is correct, even in the cell lines that most
likely have undergone crisis, only a small fraction of cells still contain telomeric
fusions.
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Figure 2.43: First fusion PCR on breast cancer cell lines. Fusion PCR was
performed on breast cancer cell lines using primers specific for XpYp, 17p, 21q and
XpYp-ctr. The indicated probes were used.
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Figure 2.44: Second fusion PCR on breast cancer cell lines. Fusion PCR
was performed on breast cancer cell lines using primers specific for XpYp, 17p, 21q,
16p and XpYp-ctr. The indicated probes were used.
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Figure 2.45: Quantification of telomere fusions in breast cancer cell lines.
(A) Example of quantification of the number of telomeric fusions in two cancer cell
lines. The quantification of the number of fusions is shown for each lane below the
blot (each lane represents a repeat of the same fusion PCR reaction). The signal
intensity of each band was quantified (ImageJ) and a minimum threshold of signal
was applied (in each Southern blot) in order to decide whether to consider or not a
band as a fusion or discard as background or nonspecific signal. (B) Quantification
and statistical analysis of telomere fusions in breast cancer cell lines. Experiments
shown in Fig. 2.43 and Fig. 2.44 were quantified as in (A) and the average number of
fusions (per tera base-pair) was calculated for each cell line. T-test (Mann-Withney
test) was applied (p=0.010).
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Figure 2.46: Analysis of telomere fusions analysis in breast cancer cell
lines. For each cell line the average number of telomeric fusions was calculated as in
Fig. 2.45. In addition, the average number of fusions per cell line was also calculated
considering their ploidy (average number of chromosomes). The estimated number
of fusions per line was calculated by multiplying the calculated number of fusions
by 28, as the efficiency of fusion detection by this assay was calculated to be 1 in
28.
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2.5 Telomere-independent sources of
endoreduplication in cancer
Since endoreduplication seems to originate from the prolonged activation of the
DNA damage signaling pathway independently of its source, we reasoned that
other possible sources of persistent DNA damage might result in tetraploidy.
Two cancer-relevant pathways resulting in DNA damage activation are de-
fects in DNA damage repair factors such as BRCA1 and BRCA2 (required for
homology-directed repair) inactivated in many hereditary breast and ovarian
cancers, and abnormal activation of oncogenes such as Myc or Ras (Negrini et
al., 2010). We set out to determined whether deregulation of these pathways
was sufficient to induce endoreduplication-mediated polyploidy. We made use
of MEFs conditionally deficient for BRCA2 (BRCA2F/- and littermate con-
trols BRCA2F/+), where BRCA2 genes can be conditionally inactivated after
expression of Cre recombinase (Badie et al., 2010). BRCA2F/- and BRCA2F/+
MEFs were immortalized by overexpression of TBX2, a suppressor of p16
and p19 pathways (Jacobs et al., 2000). BRCA2 deletion resulted in progres-
sive increase of polyploidy from 1% to 12% or 18%, 10 or 12 days after Cre,
respectively. Cre treatment had no effect on the level of polyploidy in con-
trol BRCA2F/+, which remained at a basal level of 1-2% (Fig. 2.47A-B). As
expected, treatment of BRCA2F/- cells with Cre resulted in accumulation of
DNA damage lesions as judged by the accumulation of 53BP1 foci (Fig. 2.47C).
FUCCI live cell imaging showed an increase from 2 to 14% of cells undergoing
mitosis-independent geminin degradation, consistent with endoreduplication
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cycles (Fig. 2.47D). No significant increase in mitotic failure was observed
after BRCA2 loss (Fig. 2.47D and Movie 14).
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Figure 2.47: BRCA2 deletion induces endoreduplication and tetraploidy.
(A, B) BRCA2F/+ and BRCA2F/- MEFs overexpressing TBX2 (Badie et al., 2010)
were treated with Cre and analyzed by FACS at the indicated time points. Quan-
tification of three experiments is shown in B. (C) 53BP1 staining and quantification
of the number of DNA damage foci per cell in the indicated cells. (D) Cells were
treated as in (A) and analyzed with FUCCI imaging at day 8. Quantification of
endoreduplication and mitotic cycles is shown.
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We next examined the role of aberrant oncogene activation in inducing
tetraploidization. The mutant form RasG12V (RasV12, Serrano et al., 1997),
a constitutively active form, was overexpressed in human RPE cells. In order
to inactivate p53 and Rb pathways, RPE cells were previously transduced
with SV40-LT or with p21 shRNA and Rb shRNA. Overexpression of RasV12
in RPE cells lead to an accumulation of polyploid cells, whose percentage in
the cell population increased from 2% to 14-17% (Fig. 2.48A-B). This result
was expected since increase in tetraploidy has been described previously after
Ras hyperactivation in human fibroblasts (Chicas et al., 2010). Activation of
the DNA damage singnaling was confirmed by the increase of 53BP1 foci per
cell in RasV12 overexpressing cells as compared to control cells (Fig. 2.48C).
In order to determine the mechanism of polyploidization, RasV12 expressing
cells and control cells were analyzed by live cell imaging. We observed an
increase in endocycles after Ras overexpression, as suggested by the increase
mitosis-independent geminin degradation events, from 4 to 12% (Fig. 2.48D
and Movie15). In addition, we observed an increase in mitotic failure events
from 5 to 10%, resulting in binucleated or multinucleated cells after RasV12
expression (Fig. 2.48D and Movie 15).
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Figure 2.48: Analysis of polyploidy after RasV12 over-expression. (A)
Human RPE cells were first transduced with SV40-LT or p21sh and Rbsh. Then
cells were transduced for RasV12 overexpression and FACS analysis was performed
10 days after. (B) Quantification of polyploidy in three independent experiments is
shown. (C) IF staining for 53BP1 positive DNA damage foci in the indicated cells.
(D) Cells were treated as in (A) and analyzed by FUCCI live cell imaging starting
one week after transduction with RasV12. Quantification of endoreduplication and
mitotic failure is shown.
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Chapter 3
Discussion
3.1 Model of telomere-induced tetraploidy
during tumorigenesis
These data show that persistent telomere dysfunction can lead to tetraploidiza-
tion and suggest a plausible scenario for the generation of aneuploid cancer
cells with a sub-tetraploid chromosome number (Fig. 3.1). During the early
stages of tumorigenesis, aberrant proliferation of precancerous cells leads to
excessive telomere shortening. Very short telomeres will no longer contain suf-
ficient telomeric DNA for their full protection resulting in activation of ATM
and/or ATR mediated DNA damage signal (d’Adda di Fagagna et al., 2003).
Such cells are normally expected to undergo permanent cell cycle arrest, with
accompanying senescence or apoptosis. However, if cells can bypass this ar-
rest, due to inactivation of the p53 and Rb pathways, cells will eventually enter
telomere crisis which can eventually lead to tetraploidization. Tetraploidy dur-
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ing telomere crisis in early tumorigenesis can result from endoreduplication
cycles or failure in mitosis caused due to dicentric chromosomes (Fig. 3.1).
We suggest that reactivation of telomerase (or other mechanisms of telomere
maintenance) will allow the tetraploid clone to expand and evolve into a fully
transformed cancerous state. The chromosome instability due to prior telom-
ere dysfunction and the inherent high rate of chromosome mis-segregation of
tetraploid cells will foster the evolution of a rearranged subtetraploid cancer
karyotype.
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Figure 3.1: Telomere-dependent tetraploidization during tumorigenesis.
The figure illustrates the process of telomere shortening in human somatic cells
and its consequences for the development of an aneuploid tumor. Extensive telom-
ere attrition in the absence of p53/Rb pathways can lead to tetraploidy through
endoreduplication or mitotic failure. Photographs from FUCCI live-cell imaging of
human cells in crisis undergoing endoreduplication or mitotic failure are shown. The
endocycle, due to persistent telomere dysfunction, is characterized by alternating
oscillations of Cdt1 (G1/early S) and geminin (S/G2) and by mitosis-independent
geminin degradation. Mitotic failure, due to the presence of dicentric chromosomes,
involves normal entry into mitosis and geminin degradation during anaphase, but
cytokinesis is not completed resulting in a binucleated cell. In cancer, telomerase
reactivation may allow proliferation of the tetraploid cells by reestablishing telomere
protection. (PD, population doubling).
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3.2 Endoreduplication cycles after POT1a/b
deletion or prolonged genome-wide
DNA damage
Normally when a cell experiences a DNA damage insult, the cell cycle is tem-
porarily paused and DNA damage repair occurs. Once the DNA damage is
repaired, the cell cycle resumes, a process called checkpoint recovery. This
phenomenon is usually observed when cells are treated for a short period of
time with a DNA damage-inducing agent or with sub-lethal doses of ionizing
radiation (IR; van Vugt et al., 2004; Macurek et al., 2008; Geng et al., 2007).
When DNA damage persists, a prolonged p53 and/or Rb mediated arrest oc-
curs, resulting in senescence or apoptosis. Our data show that, if the DNA
damage signal persists in the absence of functional p53 and Rb pathways,
whole genome duplication can occur. Polyploidization is independent on the
source of the damage, whether it is telomere-specific after POT1a/b loss or
genome-wide induced by zeocin or other DNA damage inducing agents. In ad-
dition to being persistent, our data indicate that the DNA damage level must
reach a threshold that we estimated to be around 15-20 lesions per cell. Several
reports in literature are consistent with our findings, showing polyploidy after
persistent exposure to DNA damage inducing agents (Bulavin et al., 1999;
Illidge et al., 2000; Ivanov et al., 2003; Cortes and Pastor, 2003; Cantero et
al., 2006; Puig et al., 2008; Cosimi et al., 2009; Nakayama et al., 2009). Our
data are also in agreement with early observations on the uncoupling of S and
M phase in IR-treated p21-deficient cells (Waldman et al., 1996; Lanni and
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Jacks, 1998).
One point that is not completely clear and would require further investiga-
tion is why tetraploidy is more evident after POT1a/b deletion as compared
to other genetic backgrounds where prolonged telomere dysfunction is induced
such as after TRF2 deletion in Lig4-/- cells or after TRF1 inactivation (Sfeir et
al., 2009). Upon POT1a/b depletion, ATR is activated resulting in both Chk1
and Chk2 activation. In the case of TRF2 deletion in Lig4-/- cells, the DNA
damage signal depends only on ATM (not ATR), which activates Chk2, but
not Chk1 (Denchi and de Lange, 2007). It is possible that the lack of ATR
and Chk1 activation accounts for the lower level of tetraploidy after TRF2
deletion. On the other hand, TRF1 deletion does result in ATR and Chk1
activation due to replication fork stalling at telomeres (Sfeir et al., 2009). In
this case, there are two possible reasons why tetraploidy is not induced. First,
it is not completely clear whether the level of DNA damage signal persists dur-
ing the cell cycle or, instead, the number of telomeres rendered dysfunctional
by replication problems is higher during S-phase and decreases at the end of
S-phase and in G1/G2. Second, the replication-induced DNA damage signal,
which in the case of TRF1 depletion does not induce Chk2 activation, might be
quantitatively different from the case of POT1a/b deletion and not sufficient
to block of mitosis. Overall we can argue that the activation of both Chk1 and
Chk2 and the persistence of the DNA damage through the cell cycle are nec-
essary for the induction of endoreduplication, but further investigations would
be necessary to fully understand the precise requirements of endoreduplication
after DNA damage.
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Our data shed light on the mechanism of tetraploidization induced after
persistent activation of the DNA damage response. The endoreduplication
cycle depends on the activation of ATM/ATR and downstream effector ki-
nases Chk1 and Chk2. Chk1/Chk2 inhibit the phosphatase Cdc25C, nor-
mally required to remove the inhibitory phosphorylation on the mitotic kinase
Cdk1/CyclinB. As a result, cells cannot enter mitosis and are blocked in G2.
After a prolonged G2 phase, cells eventually switch to a state that is more simi-
lar to G1. Importantly, the DNA replication inhibitor geminin, which prevents
re-replication in G2, is degraded despite the absence of mitosis. As a result of
this altered state, cells re-enter S phase, despite the lack of progression through
mitosis. Our findings are consistent with work in fission yeast and in human
cells showing re-replication upon inhibition of the mitotic kinase Cdk/cyclin
(Hayles et al., 1994; Kiang et al., 2009; Itzhaki et al., 1997). In addition, re-
licensing of replication origins in late G1 normally depends on low Cdk activity
(Diffley, 2004). Thus, in our setting, a persistent state of low Cdk1/CyclinB
activity can allow re-replication. We also find that Cdh1 is important for en-
doreduplication, most likely because it mediates the degradation of geminin.
An unsolved question is how APC/Cdh1 is activated in this setting. Previ-
ous work indicates that APC/Cdh1 can be activated by the DNA damage
response through a mechanism involving Cdc14B phosphatase (Bassermann
et al., 2008). In the context of telomere damage, however, the degradation of
geminin may simply be due to a gradual rise in APC/Cdh1 activity during the
prolonged post-replication period without Cdk1/CyclinB. Normally, during
mitosis Cdk1/CyclinB dependent phosphorylation promotes APC/Cdc20 ac-
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tivation (Lukas et al., 1999; Kraft et al., 2003) but strongly inhibits APC/Cdh1
(Zachariae et al., 1998), allowing their sequential activation in the cell cycle. In
fact, at the beginning of mitosis, the high activity of Cdk1/CyclinB promotes
the activation of APC/Cdc20 complex while it inhibits APC/Cdh1 activation.
APC/Cdc20-mediated degradation of CyclinB at the metaphase-to-anaphase
transition leads to the inhibition of Cdk1/CyclinB, allowing the activation of
APC/Cdh1 complex at the end of mitosis and in early G1. Therefore, our con-
text, where Cdk1 activity is continuously low, is expected to be permissive for
APC/Cdh1 activation, while APC/Cdc20 activation is prevented. The regula-
tion of the kinetics of APC/Cdh1 activation and geminin degradation during
the DNA damage-induced endoreduplication cycle remain to be determined.
Many similarities appear between the developmentally planned endocycles
in placental trophoblasts and the endocycle induced after telomere dysfunction
(Ullah et al., 2009). First, in both cases, the transition to endocycle is initiated
by inhibition of the mitotic kinase Cdk1/CyclinB, mediated by the increased
levels of the inhibitor p57 in trophoblasts (Ullah et al., 2008) and by the DNA
damage checkpoint after telomere dysfunction. Second, APC/Cdh1 activity
plays a significant role in both kinds of endocycles allowing degradation of
the replication inhibitor geminin and re-entry in the absence of mitosis. Im-
portantly, Cdh1 is required for the endocycle of placental trophoblasts and in
the Drosophila salivary gland (Garcia-Higuera et al., 2008; Narbonne-Reveau
et al., 2008; Zielke et al., 2008; Li et al., 2008). Finally, activity of the S-
phase complex Cdk2/CyclinE is important for endoreduplication to mediate
periodic DNA re-replication (Geng et al., 2003; Ullah et al., 2008). Based on
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these similarities, we can argue that a developmentally planned variation of
the cell cycle, might be aberrantly triggered by persistent DNA damage in
somatic cells, if p53 and Rb are inactive.
3.3 Mechanism of tetraploidization after
natural telomere shortening
Our data indicate that tetraploidization is not restricted to telomere depro-
tection after inactivation of POT1a/b (or TRF2), but can occur in the cancer
relevant context of telomere crisis. Not only fibroblasts, but also epithelial
cells, which are more likely to represent the cell of origin of solid tumors, can
undergo polyploidization after telomere erosion. In agreement with our find-
ings, polyploidy occurs in human cancer cells after impairment of telomerase
(Pantic et al., 2006), although here the mechanism is not known. Similarly,
an increase in polyploidy has been reported in human cells after extensived
telomere shortening (Shay and Wright, 1989; der-Sarkissian et al., 2004; Shay
et al., 1993). Consistent with a role of p53 and Rb in blocking tetraploidiza-
tion, polyploidy is rare in senescence, where most of the cells arrest in a G1-like
state (Saksela and Moorhead, 1963; Benn, 1976).
There are a number of differences between crisis cells and POT1a/b DKO
cells. For instance, removal of POT1a from mouse telomeres exposes the single-
stranded DNA and permanently activates the ATR kinase pathway whereas
critically shortened telomeres may be expected to lose several (or all) shelterin
proteins rather than POT1 alone and are known to activate both ATM and
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ATR signaling (d’Adda di Fagagna et al., 2003). It is also unlikely that all
telomeres in crisis become dysfunctional at the same time so that the overall
level of the DNA damage signal elicited by telomere crisis might be less than in
the POT1a knockout cells. Furthermore, rather than the irreparable damage
at all telomeres generated by POT1a deletion, critically shortened telomeres
are likely to be repaired by end-to-end fusion and the resulting damage sig-
nal at each telomere is therefore expected to be transient. These differences
can explain the mechanism of tetraploidization of crisis cells, compared to
POT1a/b DKO cells. Human cells in crisis undergo tetraploidization not only
through endoreduplication, but also through mitotic failure. Epithelial cells
are more prone to mitotic failure than endoreduplication, while the opposite
is true for fibroblasts.
Which are the factors determining the frequency of endoreduplication ver-
sus mitotic failure? First, the DNA damage threshold necessary for a Chk1/Chk2-
mediated block of Cdk1/CyclinB and entry into mitosis will important in de-
termining whether a cell in crisis will bypass mitosis and enter endocycle or
will enter mitosis. Compared to the p53/Rb mediated G1/S arrest in senes-
cence, a higher number of dysfunctional telomeres is probably necessary for
the Chk1/Chk2-mediated arrest in G2 (Jeyapalan et al., 2007; Deckbar et
al., 2007). In fibroblasts we estimate a threshold for endocycle, and thus for
prolonged arrest in G2 and block of mitosis, of 15-20 DNA damage foci per
cell. This threshold seems to be reached in a fraction of the fibroblasts in
crisis, most likely undergoing endoreduplication. This DNA damage threshold
is likely to be cell type specific and our data suggest that it might be higher
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in epithelial cells, which are less prone to undergo endoreduplication than fi-
broblasts after zeocin treatment or in telomere crisis. If this threshold is not
reached, it is possible that the cells will continue
Second, the occurrence of mitotic failure versus endoreduplication in cri-
sis will depend on the occurrence of telomeric fusions. The accumulation of
critically short unprotected telomeres will promote prolonged activation of the
DNA damage response signal and endocycle entry. Conversely, chromosome
fusion would silence the DNA damage signal, promote entry into mitosis and
mitotic failure. The two scenarios are outlined by TRF2 versus POT1a/b
deletion. In TRF2 deficient cells, the unprotected telomeres are aberrantly
repaired by NHEJ-mediated fusion and polyploidization is mostly due to fail-
ure in mitosis, as evident by frequent anaphase bridges in mitotic cells (van
Steensel et al., 1998; Celli and de Lange, 2005; Lazzerini Denchi et al., 2006).
This NHEJ reaction quickly silence the telomeric DNA damage signal in TRF2
deficient cells. Instead, the DNA damage created by POT1a/b loss at telom-
eres can not be repaired since the presence of TRF2 continues to block NHEJ,
thus the signal persists. The mechanism of fusions of very short telomeres
is unclear both in human and mouse cells (in late generation Terc-/- mice),
where it does not depend on the classical NHEJ pathway (Maser et al., 2007).
Third, an important point relates to the consequences of dicentric chro-
mosomes in mitosis. If the dicentric breaks before or during mitosis, the cell
will complete mitosis and undergo a BFB cycle, while if the dicentric remains
intact, it can impede mitotic furrow completion, resulting in tetraploidy. In
S. cerevisiae, an elegant analysis of the fate of a single dicentric chromosome
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suggest that dicentrics have the tendency to break, and preferentially do so
at the telomere fusion point. This pathway would allow fused chromosomes
to be segregated normally, avoiding chromosome imbalances in the daughter
cells (Pobiega and Marcand, 2010). No failure in mitosis was described in this
study and the mechanism and the cell cycle stage where the break is induced
is not known. In mammals, tracing a dicentric is impossible due to the lack
of appropriate genetic systems. The only possible approach that was followed
involved the integration of a plasmid containing a negative selection marker
close to the telomere of one chromosome in a cancer cell line. Analysis of
clones that had lost the selection marker (due to telomere loss) allowed study-
ing the fate of a single dysfunctional telomere (Fouladi et al., 2000; Lo et al.,
2002). A similar approach was used in mouse ES cells, where a break could be
induced close to the telomere ends of two chromosomes (Lo et al., 2002). The
most frequent outcome of the induction of one or two dysfunctional telomeres
was the formation of dicentric chromosomes most likely due sister-chromatid
fusions. Non reciprocal translocations and fusions to different chromosomes
was also observed, albeit with less frequency. In these studies, polyploidy was
not evident, suggesting that one (or possibly two in mouse cells) is probably
insufficient to induce failure in mitosis. However, a more detailed analysis of
the consequences of one or more dicentric chromosomes in mitosis during one
or two cell cycles (for example by time lapse imaging) is necessary to derive
any conclusion.
In our imaging experiments, we noticed that in some cases after mitosis, the
two daughter cells remained linked by a sort of bridge, presumably formed by
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a dicentric, until the following G1 phase. Interestingly, sometimes this bridge
disappeared in the following G1 or S phase and the daughter cells separated,
while in other cases the cells were pulled together to form a binucleated cell.
We can speculate that dicentrics can break in G1 or S phase and this would de-
termine whether two diploid cells or a single binucleated tetraploid cell would
form. Finally, an unsolved question is how the mechanism of tetraploidy (en-
docycle or mitotic failure) can influence the viability and proliferation of the
cell progeny. This could be investigated by live-cell imaging, even though it
would require very long imaging time, which can be technically challenging.
3.4 Transformation potential of tetraploid cells
Tetraploidization was initially shown to promote transformation in mouse ep-
ithelial cells with inactive p53 (Fujiwara et al., 2005). In that study, tetraploidy
was induced by failure in cytokinesis after treatment with an actin inhibitor.
Subsequently, tetraploidy was shown to promote transformation in a variety of
different contexts and model systems. For example, polyploidy induced after
overexpression of the oncogenic kinase Pim1 was shown to promote tumori-
genesis in human prostate and mammary epithelial cells (Roh et al., 2008).
Inactivation of the APC inhibitor Emi1 in zebrafish induces endoreduplica-
tion and cooperates with p53 in tumor development (Rhodes et al., 2009).
Similarly, a mutant form of separase in the same model organism induces
polyploidy and increases susceptibility to epithelial carcinogenesis with near-
tetraploid karyotypes (Shepard et al., 2007). Our data show that also in the
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case of telomere-driven tetraploidy, once telomere protection is re-established,
the tetraploid cells can proliferate and have a higher transformation potential
compared to diploid cells. Interestingly, the karyotype of the tumor-derived
cell lines displayed subtetraploid chromosome number, resembling human tu-
mors with high chromosome numbers. Additionally, in human hMECs during
telomere crisis we found frequent metaphases containing subtetraploid chro-
mosome numbers. Subtetraploid karyotypes (75-85 chromosomes) in hMECs
in crisis are likely to derive from transient tetraploidization followed by chro-
mosome loss and not from accumulation of chromosome gains in diploid cells
as tetraploidization precedes the occurrence of subtetraploidy during crisis and
intermediate chromosome numbers between diploid and subtetraploid values
are rare.
One question that remains is why tetraploid cells have a greater transfor-
mation potential than diploid ones and how they evolve toward aneuploidy.
Chromosomal instability (CIN) in tetraploid cells has been proposed as an
important factor in promoting transformation and tumorigenesis ((Boveri, T.,
1914, Shackney et al., 1989, Fujiwara et al., 2005). In the context of telomere
crisis, tetraploidy is coupled with other kinds of telomere dysfunction-related
genome instability so it is difficult to distinguish between these two interre-
lated phenomena (Artandi et al., 2000; Maser and DePinho, 2002). In our case
of transient POT1a depletion, tetraploidization occurs through endocycle and
telomere fusions are rare in this setting (Hockemeyer et al., 2006). However,
we cannot formally rule out the possibility that telomere fusions contribute to
transformation in this setting as occasional fusion events are observed by SKY
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in the tumor-derived subtetraploid cell lines.
The increased number of centrosomes deriving from tetraploidy has been
proposed as a source of CIN since Theodore Boveris idea nearly 100 years
ago (Boveri, T., 1914). In recent years, a molecular mechanism for the oc-
currence of chromosomal instability in tetraploid cells has been demonstrated
(Ganem et al., 2009; Silkworth et al., 2009). In most tetraploid cells analyzed,
multiple centrosomes form a transient multipolar spindle before clustering at
the opposite poles of a bipolar spindle. This temporary multipolar spindle
results in increased rate of merotelic kinetochore-microtubule attachments,
lagging chromosomes and unequal chromosome segregation in tetraploid cells
with multiple centrosomes compared to genetically matched tetraploids with
a normal centrosome number. In addition, the mere induction of centrosome
reduplication in otherwise normal diploid cells leads to multipolar spindles and
missegregation. It is likely that this type of chromosomal instability promotes
tumorigenic transformation of tetraploid cells. However, it has not been for-
mally proven that chromosomally stable tetraploid cells (with a normal centro-
some number) have a lower transformation potential than genetically matched
tetraploid cells with multiple centrosomes. It is important to note that, in a
p53-deficient background (required for efficient proliferation), even a transient
state of supernumerary centrosomes can potentially result in a prolonged state
of chromosome instability. In fact, in a recent study, it has been shown that in
the absence of p53, a transient period of chromosome missegregation can orig-
inate a permanent state of chromosome instability (Thompson and Compton,
2010). In that study, transient treatment with a kinesin inhibitor generates
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viable aneuploidy cells only when p53 is not functional. Interestingly, clones
derived many generation after release from the drug treatment are still chro-
mosomally unstable. The molecular mechanism of this phenomenon is not
known, but if this finding is generally true for different cell types, a transient
state of supernumerary centrosomes might generate an aneuploid state that is
chromosomally unstable in the absence of p53. Therefore, a careful study of
not only centrosome number but also progressive chromosome number changes
is necessary to formally prove that chromosomal instability is required for tu-
morigenesis of tetraploid cells.
In addition to chromosome missegregation and instability, an important
factor in the transformation potential of tetraploid cells relates to the occur-
rence of endogenous DNA damage, the ability of the cells to repair the lesions
and the consequence of genotoxic stress for cellular viability. The aberrant
regulation of these three pathways can contribute to a mutator phenotype in
tetraploids. One source of endogenous chromosome breaks that has been re-
cently recognized is again related to chromosome missegregation (Crasta et
al, 2012). Lagging chromosomes in mitosis can give rise to micronuclei in
the daughter cells. These micronuclei are characterized by higher endogenous
damage and can lead to massive chromosome fragmentation. Since this phe-
nomenon is dependent on chromosome missegregation, it is predicted to occur
in tetraploids with supernumerary centrosomes.
Different question is whether higher endogenous damage might be the con-
sequence of the sole state of having a duplicated genome. Tetraploid yeasts,
with an unaltered centrosome number, are much more sensitive to the inhi-
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bition of homology-directed DNA repair pathway and show increased endoge-
nous DNA damage lesions in mitosis (Storchova et al., 2006). The increased
persistence of unrepaired damage might reflect a higher frequency of DNA
damage lesions during the replication of the double-sized genome and/or to
defects in the DNA damage repair pathways. Whether a similar phenomenon
occurs in mammalian cells in not known. In human cells, studies of the re-
sponse of tetraploid cells to genotoxic agents suggest a different scenario. As
compared to control diploid cells, tetraploids were more resistant to apoptosis
induced by treatment with genotoxic agents such as camptothecin, etopoxide,
IR and UV irradiation (Castedo et al., 2006). For other drugs such as dox-
orubicin or hydroxyurea, no difference was noticed between tetraploids and
diploids (Castedo et al., 2006). The molecular mechanism of this phenomenon
and whether it depends on the integrity of the p53 pathway (as it has been
suggested) are not clear. In agreement, we found that tetraploid cells have a
longer lifespan than diploid cells after telomere crisis, where the mutational
load is determined by the endogenous telomere-dependent genome instability.
Overall these data are in agreement with increased mutational robustness after
polyploidization in mammalian cells.
It is likely that in steady-state conditions, polyploid cells have lower fit-
ness than diploid cells, as suggested by the slightly lower proliferation rate in
culture dish, as indicated by our and previous data (our data, Fujiwara et al.,
2005). However, in the presence of a selective pressure or mutator phenotype,
as for example in the transformation assay after injection into nude mice or
as it might be during telomere crisis, polyploidy confers an evolutionary ad-
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vantage. In our case of telomere-derived tetraploidy after transient depletion
of POT1a/b, the low level of chromosome fusions might also contribute to the
higher transformation potential of tetraploids.
3.5 Telomere dysfunction as a widespread source
of tetraploidy in cancer
Different sources of polyploidy have been proposed in cancer, such as virus-
mediated cell fusion or failure in mitosis or cytokinesis due to deregulation of
mitotic factors such as APC, Mad2 or Emi1 (Caldwell et al., 2007; Sotillo et
al., 2007; Dikovskaya et al., 2007). Telomere-derived tetraploidy is relevant be-
cause telomere dysfunction represents a widespread phenomenon in the early
stages of human tumorigenesis. Telomere dysfunction depends on overprolifer-
ation of preneoplastic cells and, as genetic alterations, it requires only Rb loss,
which is a frequent event in solid tumors, in addition to p53 loss. Interestingly,
there is a strong correlation between the occurrence of near-tetraploid kary-
otypes and the frequency of inactivation of the Rb pathway in different types
of human solid tumors (Fig. 3.2), suggesting an important role for Rb loss
in tetraploidization during tumorigenesis (see next section for the timing of
p53 and Rb loss and tetraploidy). Moreover, among the potentially pervasive
sources of genome instability in cancer, an episode of telomere dysfunction
stands out due its potential aggregate effect. In p53-deficient cells, BFB cy-
cles can promote the main genomic alterations observed in cancer: loss of
heterozygosity, gene amplication, and non-reciprocal translocations (Artandi
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et al., 2000; Maser and DePinho, 2002; de Lange, 1995). The telomere-driven
tetraploidization is likely to provide a considerable advantage to precancer-
ous cells experiencing this type of genome instability since it diminishes the
chance that an essential gene function is lost. Furthermore, the DNA damage
signal that induces tetraploidization is a temporary phenomenon, dissipating
when telomere protection is restored by activation of telomerase or alternative
mechanism of telomere maintenance.
Even if the role of of telomere dysfunction in polyploidy during tumorigen-
esis seems to be important, experimental evidence of its significance in human
tumors is still lacking. First of all it would be important to assess whether
tetraploidy actually occurs in early cancer lesions and it correlates with the
evidence of DNA damage activation. Activation of the DNA damage response
is frequently observed in hyperproliferative preneoplastic lesions which usu-
ally show high levels of γ-H2AX, P-Chk2 P-ATM and also of the inhibitory
phosphorylation of Cdk1 (Gorgoulis et al., 2005; Bartkova et al., 2005). Si-
multaneous analysis of DNA damage response and tetraploidy may be useful,
but the transient nature of the presumed tetraploidy most likely would render
this task difficult. Nevertheless, our preliminary analysis of telomeric fusions
in breast cancer cell lines showed a higher frequency of fusions in cell lines with
high chromosome numbers, compared to near-diploid cell lines, in agreement
with our hypothesis. It will be important to extend our analysis to primary
human tumors. Analysis of telomere fusions has been successful in primary
samples from chronic lymphocytic leukemia, demonstrating telomere crisis in
the later stages of the disease and opening the way to a similar analysis in
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human solid tumors (Lin et al., 2010).
Finally, the hypothesis of telomere-derived tetraploidy in tumorigenesis
could be tested in an experimental system using human cell lines experiencing
telomere crisis. Overexpression of telomerase in hMECs as the cells enter cri-
sis might allow isolating post-crisis cells, immortalized after they experienced
telomere crisis. These post-crisis cell lines can be analyzed for the evolution of
their karyotype and for their transformation potential. This approach would
also allow creation of a model system for the study of potential crisis-associated
features and vulnerabilities.
Figure 3.2: Correlation between the frequency of Rb inactivation and
near-tetraploid karyotypes. The graphs shows the correlation between the fre-
quency of inactivation of the Rb pathway and the percentage of karyotypes with
high chromosome number (hypertriploid karyotypes, data from Fig. 1.7) for the in-
dicated cancers. Analysis of linear regression shows significant correlation (slope and
p-value are reported, from F-test using Prism-5 software). TCC: transitional cell
carcinoma; SCC: squamous cell carcinoma; ac: adenocarcinoma; carc: carcinoma
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3.6 Timing of tetraploidization during
tumorigenesis and order of the events
The outgrowth of all tetraploid clones is blocked by the p53 pathway (An-
dreassen et al., 2001; Meraldi et al., 2002; Fujiwara et al., 2005) and, in the
case of telomere-derived tetraploidization, also by the p16/Rb pathway. There-
fore, tetraploidization is more likely to contribute to those cancers in which
the relevant tumor suppressor pathways are frequently inactivated at an early
stage, before the emergence of the tetraploidization stimulus. Although much
of the relevant information is missing, I will consider here, for each possible
mechanism of tetraploidization, the potential order of the relevant events in
cancer types in which tetraploidization is observed (Fig. 3.3).
In the case of virally-induced cell fusion, the presumed causative agent is
elusive. The exception is HPV-induced cervical cancer in which viral infection
could both induce fusion and, through the action of HPV E6, inactivate p53
(Moody and Laimins, 2010), creating a permissive setting for the prolifera-
tion of tetraploid cells (Fig. 3.3). Tetraploidization induced by the failure in
progression through mitosis represents a more complex scenario since mitotic
failure can be induced in a variety of ways (Fig. 1.4). In the case of APC
mutations in colon carcinoma, p53 loss is a later event (Fodde et al., 2001),
suggesting that mitotic failure might take place early on but will only result in
viable tetraploid clones at a later stage. Similarly, for Mad2 and Emi1, overex-
pression due to inactivation of the Rb pathway, the mitotic problems induced
by Mad2 or Emi1 are unlikely to give rise to tetraploid clones unless p53 is inac-
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tivated. For instance, in lung adenocarcinoma, inactivation of Rb precedes the
loss of p53, which occurs at the time that invasive cancer develops (Noguchi,
2010; Fig. 3.3). Therefore, the development of tetraploid clones induced by
overexpression of Mad2 or Emi1 are most likely to arise at the transition to in-
vasive cancer (Garber et al., 2001; Lehman et al., 2007). In a fraction of breast
cancer both the p53 and the Rb pathway are inactivated early, allowing Mad2-
or Emi1-driven tetraploidization events to contribute to tumor progression at
a pre-invasive stage (Shackney and Silverman, 2003; van ’t Veer et al., 2002;
Lehman et al., 2007; Fig. 3.3). Other sources of cytokinesis failure such as inhi-
bition of LATS1 or AuroraA overexpression are more difficult to evaluate since
the timing of these changes are not known. An exceptional case is liver adeno-
carcinoma. Since hepatocytes are prone to undergo tetraploidization despite a
functional p53 pathway (Fig. 1.2), Mad2/Emi1-induced tetraploidization may
well occur at an early stage when Rb is inactivated but p53 is not (Martin and
Dufour, 2008; Teramoto et al., 1994; Hui et al., 1998; Fig. 3.3).
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Figure 3.3: Timing of loss of p53/Rb, activation of telomerase, and
tetraploidization in select human cancers. For a subset of cancers with evi-
dence for tetraploidization, the potential causes of tetraploidy (OE: overexpression),
the incidence of karyotypes with high chromosome numbers (hypertriploid kary-
otypes, from Fig. 1.7), the timing of loss of p53 and Rb pathways (% from Fig. 1.7),
activation of telomerase, and tetraploidization are indicated. Four stages of neo-
plastic progression are considered: dysplasia, in situ cancer lesion, invasive cancer,
and advanced/metastatic cancer. Evidence for tetraploidization includes data on
chromosome number in metaphase spreads, FACS analysis of the DNA content, and
supernumerary centrosomes.
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The third potential cause of tetraploidization, endoreduplication or mi-
totic failure due to dysfunctional telomeres, requires the correct order of three
events. First, the p53 and p16/Rb pathways need to be disabled to allow cell
to proliferate to the point of telomere crisis; second, tetraploidization needs to
occur; and third, telomerase has to be activated to restore telomere function
and avoid further telomere shortening. Telomere shortening is notable in the
pre-invasive stages of most epithelial cancers (Meeker et al., 2002; van Heek et
al., 2002; Meeker et al., 2004; Meeker and Argani, 2004), which also represents
the approximate timing of inactivation of the p53 and Rb pathways in many
tumors (Fig. 3.3). For instance, in esophageal carcinoma, Rb inactivation is
an early event that is followed by p53 dysfunction and telomerase activation at
the pre-invasive stage when tetraploidy arises (Maley, 2007; Reid et al., 1996).
In breast cancer, tetraploidization occurs at the DCIS stage when the p53 and
Rb pathways are inactivated and telomerase is increasingly detectable (Shack-
ney and Silverman, 2003; Shay and Bacchetti, 1997; Herbert et al., 2001).
In addition, there is good evidence for telomere crisis in DCIS followed by
stabilization of the genome due to telomerase-mediated telomere restoration
(Chin et al., 2004). In pancreatic adenocarcinoma, frequent inactivation of
Rb and p53 pathways also takes place before the activation of telomerase at
an early stage (usually in intra-epithelial/in situ neoplasia) when tetraploidy
is observed (Maitra and Hruban, 2008; van Heek et al., 2002; Suehara et al.,
1997; Tanaka et al., 1984; Sato et al., 1999). In bladder, ovarian and prostate
cancer, inactivation of Rb/p53 pathways and telomerase reactivation occur ap-
proximately at the same time, at the transition from in situ to invasive cancer,
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where there is evidence of tetraploidy (Mitra and Cote, 2009; Lin et al., 1996;
Shackney et al., 1995; Bast et al., 2009; Murakami et al., 1997; Kallioniemi et
al., 1988; Braly and Klevecz, 1993; Abate-Shen and Shen, 2000; Koeneman et
al., 1998; Montgomery et al., 1990). In summary, in a number of tumor types
with evidence for tetraploidization (Fig. 3.3), the order of p53/Rb inactiva-
tion, occurrence of tetraploidy, and telomerase upregulation is in agreement
with telomere dysfunction as the stimulus for tetraploidization. This contrasts
with other cancers in which the correct order of events is unlikely to occur.
For instance, in kidney carcinoma, inactivation of p53 and Rb pathways is
rare and occurs late, often in advanced or metastatic tumors (Ibrahim and
Haluska, 2009). Indeed, the near-diploid karyotype of most kidney carcinomas
argue against tetraploidization in the formation of this cancer type. Similarly,
tetraploidization is rare in human tumors arising from telomerase competent
cells in which telomerase activation presumably precedes other events. Near-
diploid karyotypes are present in most human leukemias and some lymphomas,
which originate from telomerase competent cells (Hilgenfeld et al., 1999; Broc-
coli et al., 1995).
3.7 Telomere-independent origin of tetraploidy
in cancer
Our data indicate that at least two telomere-independent sources of prolonged
DNA damage signaling relevant for cancer can lead to tetraploidization in
p53 and Rb deficient cells. The first source of DNA damage is represented
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by defects in homology-directed repair (HDR) due to BRCA2 inactivation.
When HDR is diminished, unresolved S phase problems can elicit a persis-
tent DNA damage signal in G2 and induce tetraploidization. In agreement,
XRCC3-deficient cells, which have impaired HDR, show a low frequency of
endoreduplication (Yoshihara et al., 2004). Furthermore, overexpression of
RPA, or deletion of Nbs1 and Rad17 results in polyploidy, most likely because
of persistent unrepaired DNA damage (Reina-San-Martin et al., 2005; Wang
et al., 2003). The relevance of these observations to tetraploidization in human
cancer remains to be determined but it is noteworthy that p53-deficient breast
cancers lacking the HDR protein BRCA2 are often polyploid (Gretarsdottir et
al., 1998). The second possible cause of DNA damage-induced tetraploidiza-
tion is replication stress induced by aberrant oncogene activation. Activation
of the DNA damage response, presumably due to unscheduled DNA replica-
tion, is frequently observed in hyperproliferative preneoplastic lesions and a
DNA damage response is induced upon oncogene expression in cultured cells
(Gorgoulis et al., 2005; Bartkova et al., 2005; Bartkova et al., 2006; Di Micco
et al., 2006). We found that overexpression of the constitutively active RasV12
mutant can lead to tetraploidy both through endoreduplication or mitotic fail-
ure in human epithelial cells. Mitotic failure in this setting might be due to
the formation of dicentrics or other chromosomal structural abnormalities due
to aberrant repair of the DSBs induced in S -phase. In agreement with our
data, previous reports also showed polyploidy after oncogene overeexpression
in U2OS osteosarcoma (CyclinE) cells and IMR90 fibroblasts (Ras; Bartkova
et al., 2006; Chicas et al., 2010).
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While telomere dysfunction is a transient state buffered later in tumorige-
nesis by telomerase reactivation, oncogene activation is usually a permanent
genetic lesions occurring relatively early in tumorigenesis and persisting dur-
ing tumor development. In this context, the switch from the endocycle to
the mitotic cycle might be mediated by inactivation of the ATM/ATR and
Chk1/Chk2 pathways. Interestingly, in bladder cancer, high Chk2 phospho-
rylation in early lesions with low genomic instability is decreased in more ad-
vanced lesions with higher genome instability, suggesting that the Chk1/Chk2
checkpoint activation is transient and precedes aneuploidy (Bartkova et al.,
2006). Moreover, mutations in ATM or Chk2 correlate with the transition
from early genomically stable tumors to later more unstable ones. In some
cases of advanced stage melanomas and lung cancers, absence of active down-
stream effector P-Chk2 was observed in the presence of active upstream DNA
damage factor γ-H2AX (Gorgoulis et al., 2005), reflecting the presence of on-
going DNA damage but inactive downstream checkpoint.
Besides oncogene-induced senescence and replicative senescence, other mech-
anisms have been implicated as sources of DNA damage signal in early can-
cerous lesions, such as hypoxia, reactive oxygen species and inflammatory cy-
tokines (d’Adda di Fagagna, 2008). In addition to cancer-causing sources,
induction of DNA damage is relevant to the context of commonly used cancer
therapies, such as chemotherapy or radiation therapy (Helleday et al., 2008).
Our data would suggest that, if the DNA damage signal is sufficiently intense
and prolonged, chemotherapic treatment might result in polyploidy in p53
and Rb deficient tumor cells. During or after treatment, most of tumor cells,
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including polyploid cells, are expected to undergo apoptosis or mitotic catas-
trophe due to high levels of chromosomal aberrations. However, if a polyploid
cancer clone can survive this stage, it might be able to more rapidly acquire
resistance or ability to colonize new niches. It would be interesting to moni-
tor changes in ploidy during cancer treatment, tumor relapse, therapy-related
secondary tumors and metastasis formation in the (mouse) clinic.
3.8 Future directions
A better insight into the pervasive pathway of tetraploidization toward ane-
uploidy can better illuminate the nature of genome instability in cancer and
may reveal cancer-specific vulnerabilities that can be exploited in the clinic.
It is likely that progression through a tetraploid intermediate requires adap-
tations that may become permanent in the developing cancer lineage. An
example of polyploidy-specific adaptation of tumor cells is centrosome cluster-
ing to allow bipolar spindle formation (Kwon et al., 2008). Other adaptations
are likely to be specific for the mechanism of polyploidization and in this re-
gard, it will be important to identify the mechanisms/instigators of the whole
genome duplication for each cancer type. For example, progression through
telomere crisis by precancerous cells might be associated with specific genetic
or epigenetic features allowing cells to progress through crisis before evolution
of a tumorigenic clone. Furthermore, a deeper knowledge of the causes and
consequences of tetraploidization in cancer could deliver diagnostic tools to
parse subsets of cancers based on their route to aneuploidy. As a first step in
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this direction, PCR-mediated analysis of telomeric fusions in tumor samples
represents a method to distinguish between tumors that did or did not undergo
telomere crisis in their natural history. This and similar approaches may be
useful to optimize cancer diagnosis and treatment based on the mechanism of
past polyploidization.
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Chapter 4
Experimental Procedures
4.1 Constructs
Cre-recombinased was transduced into the cells by retroviral vectors using
pWZL-hygro-Cre and pWZL empty vector as negative control. Alternatively,
pMMP Hit&Run Cre (Silver and Livingston, 2001) was used and mock infec-
tion as negative control in this case. For pLPC-CyclinE-eGFP, the C-terminus
of full length hCyclinE (provided by Dr. J. Pines) was fused in frame to the
eGFP in pLPC retroviral vector, using the Gateway cloning system (Invitro-
gen). The following primers were used: CycE-fw: 5’-CACCGCCACCATGGA
GGAGGACGGCGGC-3’; CycE-rv: 5’-CTCGAGCGCCATTTCCGGCCCGC
TGCT-3’; eGFP-fw: 5’-CTCGAGGTGAGCAAGGGCGAGCTG-3’; eGFP-
rv: 5’-CTCGAGTCACTTGTACAGCTCGTCCATGCC-3’. pBabe-Puro-Myc
was gently provided by Dr. Pier Giuseppe Pelicci. Full-length hTERT was
cloned into the bicistronic lentiviral vector pLVX-IRES-Hygro (Clonetech,
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632182). pWZL-Hygro-RasV12 and pLM2P-shRB.698-p21.890 (for the simul-
taneous knock-down of p21 and Rb) were kindly provided by Dr. Scott Lowe
(Chicas et al., 2010). TopBP1-ER was provided by Dr. Oscar Fernandez-
Capetillo (Toledo et al., 2008). For the POT1atetOFF system, full-length
mouse POT1a was cloned into P-TRE-Tight (Clonetech, 631059) using BamH1
and EcoR1 restriction sites and the following primers: POT1a-fw: 5’-ATGCGG
ATCCACCATGTCTTTGGTTTCAACA-3’and POT1a-rv: 5’-ATGCGAATT
CCTAGACAACATTTTCTGC
AACTGT-3’. P-TRE-TIGHT was used in combination with P-Tet-Off-Advanced
(Clonetech, 630934) to develop the inducible system in POT1a/b DKO MEFs.
FUCCI lentiviral vectors were generously provided by Atsushi Miyawaki (Sakaue-
Sawano et al., 2008). The FUCCI system is made of two lentiviral vectors
expressing the two fluorescently-tagged cell cycle markers: CSII-EF-MCS-
mKO2-hCdt1(30-120) and CSII-EF-MCS-mAG-hgeminin(1-100). For overex-
pression of SV40-LT, pBabe-neo-SV40LT or pLPC SV40LT retroviral vectors
were used. Sh-RNA mediated knock-down of the following endogenous pro-
teins was performed by using lentiviral vectors purchased from Openbiosys-
tem: empty vector as control (pLK0.1), vectors for Chk1 shRNA (RMM3981-
9580337 (set1) and RMM3981-9580340 (set2)), vectors for Chk2 shRNA (RMM
3981-9580345 (set1) and RMM3981-9580346 (set2)), vector for Cdh1 shRNA
(RMM3981-9593724) and vector for APC1 shRNA (RMM3981-97076474). The
ATR shRNA retroviral vector was as described (Denchi and de Lange, 2007).
pBabe-neo-p53175H and pSuper-retro-hygro-p53sh were previously described
in Jacobs and de Lange, 2004.
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4.2 Isolation of MEFs
POT1a/b DKO MEFs lacking ATM were generated by intercrosses of POT1aF/-
POT1b F/F (Hockemeyer et al., 2006) and ATM+/- (Barlow et al., 1996)
mice. MEFs were isolated, from E13.5 embryos of timed pregnancies using
standard techniques and were grown in DMEM containing 15% Fetal Bovine
Serum (Gibco), supplemented with 100 U/ml penicillin (Sigma), 0.1 µg/ml of
streptomycin (Sigma), 2 mM L-glutamine (Invitrogen), 0.1 mM non-essential
amino acids (Invitrogen), 1 mM sodium pyruvate (Sigma), and 50 mM b-
mercaptoethanol (Chemicon). Primary MEFs were immortalized by overex-
pression of SV40-LT at passage 2. BRCA2F/+ and BRCA2F/- MEFs overex-
pressing TBX2 (Badie et al. 2010) were a gift from Dr. J. Jonkers.
4.3 Cell culture procedures
SV40-LT immortalized MEFs, IMR90 lung fibroblasts (ATCC), were grown in
DMEM supplemented with 100 U/ml penicillin (Sigma), 0.1 µg/ml of strepto-
mycin (Sigma), 2 mM L-glutamine (Invitrogen), 0.1 mM non-essential amino
acids (Invitrogen), and 10% Fetal Bovine Serum (Gibco). BJ fibroblasts
(ATCC) and retinal epithelial cells (RPE, ATCC) were grown in the same
culture medium described above except that the base medium was composed
of 80% DMEM and 20% Medium199 for BJ cells and DMEM/F12 medium
for RPE cells. Pheonix ecotropic or amphotropic packaging cell line (ATCC)
and 293T cells (ATCC) were grown in DMEM supplemented as above except
for the serum which was replaced with 10% Bovine Calf Serum (HyClone).
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Human mammary epithelial cell lines 184B and 48RS (Romanov et al., 2001),
expressing or not the GSE22 peptide (GSE), acting as a p53 dominant neg-
ative (Garbe et al., 2007) were kindly provided by Dr. Martha Stampfer.
hMEC cells were grown in MEMG (Lonza, CC-3051A) supplemented with
bovine pituitary extract (BPE, Lonza, CC-4009), 10µM isoproterenol (Sigma,
I-5627) and 5µg/ml of transferrin (Sigma, T-2252). hMECs were cultured
according to the procedures described by Martha Stampfer on this website:
http : //hmec.lbl.gov/mindex.html. All cells were grown at 3737◦C in the
presence of 5% CO2 and 95% humidity. Breast cancer cell lines were pur-
chased from ATCC (30-4500K) and each of the lines was cultured using to
the recommended medium and culture conditions. A list of all the cell lines is
provided in the Appendix C.
4.4 Viral gene delivery
For retroviral and lentiviral infections, phoenix cells (retro) or 293T (lenti)
cells were transfected with 10-20 µg of the transgene-expressing plasmid (in
addition to lentiviral packaging vectors in the case of 293T). Starting 36 hours
after transfection, supernatants from transfected packaging cells were filtered
(45µm filter unit) added with polybrene (2-4 µg/ml final concentration) and
used to infect targeting cells. Medium was replaced on the transfected cells
and the supernatant was used again for subsequent infections, performed in
the same way. A total of 3-4 consecutive infections delivered at 6-12h inter-
vals for each experimental condition. In some cases, filtered viral supernatant
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were frozen using liquid nitrogen and stored at -80◦C. 24-48 hours after the
last infection, cells were split into fresh media, which contained antibiotics for
selection if a selection marker was present in the vectors used (puromycin 2
µg/ml, hygromycin 90 µg/ml). Selection was maintained for 3-6 days, until
uninfected control cells had died. Cre recombinase was introduced through
retroviral infection. MEFs were infected 3 times at 12 h intervals with retro-
virus vector pWzl-hygro-Cre or empty vector, as a negative control, followed
by hygromycin selection. Alternatively, pMMP Hit&Run Cre retroviral vec-
tor (Silver and Livingston, 2001) was used and no selection was applied. The
experimental time-points were counted as h or days after the last retroviral
infection. For the two lentiviral vectors of the FUCCI system, 2 infections or
4-5 hours each were performed with each vector during two consecutive days.
No selection marker is contained in these vectors, so no selection was applied.
In some cases the cells were FACS-sorted for expression of both transgenes
(mKO2 and mAG double-positive cells).
4.5 G1/S synchronization by double
thymidine block
MEFs at 25-30% confluence were incubated with culture medium containing
2mM thymidine for 16-18h (first block). The next day, thymidine was removed
by washing three times with PBS and fresh culture medium was added to allow
the cells to progress through the cell cycle. After 8-10h, 2mM thymidine was
added to the medium and incubated for other 16-18h (second block). Finally,
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after the second block, cells were released into the cell cycle by removing
the thymidine containing medium and washing 3 times with PBS. After the
double-thymidine block cells are synchronized in G1/S and after release they
progress through S-phase (lasting around 4 hours in SV40 MEFs), G2 (lasting
around 2 hours), mitosis and subsequent G1 phase.
4.6 Treatment with drugs and with UV
Zeocin (Invitrogen, R250-01, stock solution) was used at a concentration vary-
ing from 2 to 100 ug/ml as indicated. Doxorubicin (Sigma, D1515) was dis-
solved in water and used at 1 µM. Bleomycin (Sigma, B5507) was dissolved in
water and used at the concentration of 50 µg/ml. These three DNA damage
inducing agents were used to treat the cells continuously for 72h or 96h by
adding the drug every 24-48 h. Doxycycline (Sigma, D9891) was dissolved in
water and used at 2 ug/ml. 4-hydroxytamoxifen (OHT, Sigma, H7904) was
dissolved in ethanol and used to treat the cells at a final concentration of 0.5
µM. For UV treatment, MEFs were first washed with PBS and treated with
20J/m2 UV every 2 hours for two periods of 12 h with 12 h in between.
4.7 FACS analysis and FACS sorting
For FACS analysis of the cell cycle with BrdU and propidium iodide (PI)
staining, cells were grown at 50-70% confluence and treated with 10 µM
BrdU (Sigma, 5002) for 1 hour prior to harvesting. Cells were harvested by
trypsinization, counted and fixed by adding -20◦C cold ethanol while vortex-
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ing. Cells were stored overnight at -20◦C and then at 4◦C. For FACS analysis,
2-5 105 cells were used for each sample. Cells were first incubated with 2N
HCl/Triton-X-100 0.5% (added while vortexing) for 30 min at R.T. to de-
nature the DNA. Cells were then re-suspended in 0.1M Na2B4O7X10H2O
pH 8.5. Next cells were resuspended in blocking buffer (PBS containing
0.5%Tween20/0.5%BSA). Staining with FITC-conjugated anti-BrdU (BD, Bio-
sciences, 347583) was performed by incubating the cells in the blocking buffer
containing anti-BrdU antibody (diluted 1:10) for 30 min in the dark. Cells
were finally washed 3 times in the blocking buffer and resuspended in PBS
containing 0.5% BSA, 5µg/ml PI and 200 µg/ml RNA-ase. Flow cytometry
was performed using the FACSCalibur (Becton Dickinson) and data was ana-
lyzed using FlowJo 8.7.1 software. To calculate the % of polyploid cells (DNA
content >4N), cell doublets and sub-G1 apoptotic cells were first excluded,
then a gate was draw to include the cells with a DNA content >4N (based on
the PI profile). FACS sorting of diploid can tetraploid cells was performed at
the FCRC Facility of the Rockefeller University. Before sorting, the cells were
incubated with 10-12 µM of Hoechst 33342 (AnaSpec Inc., 83218) for 30 min.
Cells were then harvested by trypsinization, counted, washed with PBS and
resuspended in cold PBS for FACS sorting. Sorted G1 diploid cells and G2
teraploid cells were then washed in PBS twice and plated in the appropriate
medium. Usually a sample of 2-3 105 cells was fixed in ethanol and used for
PI-mediated cell cycle analysis. Other FACS sorting, for example for FUCCI
infected cells or for cell populations isolated from tumors, were performed us-
ing standard procedures by preparing single cell suspension of the sample to
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be sorted in PBS.
4.8 Cell lysate and immunoblotting
Cells were lysed in 2X Laemmli buffer (100 mM Tris-HCl, pH 6.8, 200 mM
DTT, 3% SDS, 20% glycerol, 0.05% bromophenol blue) at 106 cells per 100
µl, denatured for 7 min at 100◦C, and sheared with a 28 gauge insulin needle.
Lysate deriving from before loading the equivalent of 2-3 105 cells per lane.
Protein samples were separated by SDS-PAGE and blotted onto nitrocellulose
membranes. Membranes were blocked in 5% milk in TBST (0.5% Tween-20
in 50mM Tris, 150mM NaCl, pH 7.6) for 30 min at RT and incubated with
primary antibodies in 1 or 5% milk containing TBST overnight at 4◦C or for
2 hours at RT. Membranes were washed 3 times in TBST, 5 min each and
incubated with secondary antibody in TBST for 30-45 min at RT, and washed
3 times with PBST at RT. Blots were developed with enhanced chemilumi-
nescence system (Amersham).
4.9 Immunofluorescence (IF)
Cells were grown on coverslips. Cells were rinsed with PBS, fixed with 2%
paraformaldehyde in PBS for 10 min at RT and washed three times with PBS
for 5 min each. Alternatively, cells were fixed in -20◦C cold methanol (Sigma,
154903) for 10 minutes and washed with PBS. Cells were either stored in
PBS with the addition of 10 mM sodium azide or processed immediately.
Cells were blocked with PBG (0.2% (w/v) cold water fish gelatin (Sigma),
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0.5% (w/v) BSA (Sigma) in PBS) for 1 h at RT. Cells were incubated with
primary antibody diluted in PBG for 2 h at RT or overnight at 4◦C, washed
3 times with PBG at RT, incubated with secondary antibody diluted 1:250
in PBG for 1 h at RT, and washed 3 times with PBS. To the second PBS
wash 0.1 µg/ml 4,6-diamidino-2-phenylindole (DAPI) was added. Coverslips
were sealed onto glass sides with embedding media (ProLong Gold Antifade
Reagent, Invitrogen). Digital images were captured with a Zeiss Axioplan II
microscope with a Hamamatsu C4742-95 camera using Improvision OpenLab
software.
4.10 Fluorescence In situ Hybridization-
Immunofluorescence (FISH-IF)
Cells were grown on coverslips and fixed for 10 min in 2% paraformaldehyde at
room temperature followed by PBS washes. Coverslips were blocked for 30 min
in blocking solution (1 mg/ml BSA, 3% goat serum, 0.1% Triton X-100, 1 mM
EDTA in PBS). Next, the cells were incubated with primary antibodies diluted
in blocking solution for 1 h at room temperature. After PBS washes, cover-
slips were incubated with Alexa 488- or Rhodamine-Red-X-labelled secondary
antibody raised against mouse or rabbit (Jackson) for 30 min and washed in
PBS. At this point, coverslips were dehydrated consecutively in 70%, 95% and
100% ethanol for 5 min each, and allowed to dry completely. Hybridizing so-
lution (70% formamide, 1 mg/ml blocking reagent (Roche), 10 mM Tris-HCl,
pH 7.2, containing PNA probe FITC-OO-(AATCCC)3 (Applied Biosystems)
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was added to each coverslip and the cells were denatured by heating for 10
min at 80◦C on a heat block. After 2 h or overnight incubation at room
temperature in the dark, cells were washed twice with washing solution (70%
formamide, 10 mM Tris-HCl, pH 7.2) and three times in PBS. To the second
PBS wash 0.1 µg/ml DAPI was added. Coverslips were sealed onto glass sides
with embedding media (ProLong Gold Antifade Reagent, Invitrogen). Digital
images were captured with a Zeiss Axioplan II microscope with a Hamamatsu
C4742-95 camera using Improvision OpenLab software.
4.11 Metaphase chromosome spreads
Cells were grown to approximately 70-80% confluence on 10 cm dishes and
incubated for 1-2 h in 0.1 µg/ml colcemide (Sigma) for human cells and 0.2
µg/ml colcemide (Sigma) for mouse cells. For spectral karyotyping(SKY) anal-
ysis, colcemid treatment was performed for 3-5 hours. Cells were harvested
by trypsinization, washed in PBS and resuspended in 10 ml of 0.075M KCl
prewarmed to 37◦C. Cells were incubated at 37◦C for 20-30 min. 200µl of
fixative solution (-20◦C cold 3:1 methanol:glacial acetic acid) was added to
each sample (10 ml) and cells were centrifuged and the supernatant was de-
canted. Cell pellets were loosened by tapping and 1 ml of -20◦C cold d fixative
was added dropwise during gentle vortexing. For SKY analysis cells were
washed five times with cold fixative. Tubes were then filled to 10 ml with
the fixative and stored at 4C overnight. For metaphase spreads, cells were
centrifuged and resuspended in 600-800µl of freshly prepared fixative. 100µl
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were dropped from approximately 20 cm onto glass slides, which had been
soaked in cold water and dried. Slides were washed with fresh fixative twice
and dried at RT overnight. Alternatively, 100 ml of cells resuspended in fixa-
tive were dropped on dry slides in a temperature-controlled chamber (settings
at 20◦C and 50% humidity, Thermotron). To perform chromosome counts in
metaphase spreads, DAPI staining was performed. Slides were rehydrated in
PBS for 5 min, stained with DAPI in PBS for 5 min, washed in PBS for 5
min, and allowed to dry before mounting. For FISH on metaphase spreads,
slides were washed in PBS twice, dehydrated by consecutive 5-min incuba-
tions in 70%, 95% and 100% ethanol. After air-drying, Hybridizing Solution
(70% formamide, 1 mg/ml blocking reagent (Roche), 10 mM Tris-HCl, pH 7.2)
containing FIu-OO-(AATCCC)3 PNA probe (peptide nucleic acid , Applied
Biosystems) was added and spreads were denatured by heating for 10 min at
80◦C on a heat block. Spreads were then allowed to hybridize in the dark for 2
h or overnight at room temperature. Two 15-min washes were performed in a
washing buffer made of 70% formamide, 10 mM Tris-HCl, pH 7.0. Slides were
then washed three times in PBS. To the second PBS wash 0.1 µg/ml DAPI
was added. Coverslips were sealed onto glass sides with embedding media
(ProLong Gold Antifade Reagent, Invitrogen). Digital images were captured
with a Zeiss Axioplan II microscope with a Hamamatsu C4742-95 camera us-
ing Improvision OpenLab software. Dropping of metaphase spreads, staining
and image analysis of metaphase spreads for SKY analysis was performed in
collaboration with the laboratory of Dr. Anna Jauch at the University of
Heidelberg, Germany.
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4.12 Cdk kinase assay
106 cells were plated the day before in a 10cm dish. The next day cells were
washed once with ice-cold PBS and harvested by cell scraping. Cells were
lysed in cold IP lysis buffer (0.3% Triton X-100, 50 mM sodium phosphate
pH 7.2, 2 mM EDTA, 2 mM EGTA, 25 mM NaF, 100 µM NaVO4, 25 mM
2-glycerophosphate, 1 mM PMSF, and a protease inhibitor cocktail (Roche
Diagnostics) and frozen in liquid nitrogen. Thawed extracts were sonicated,
cleared after incubation with Protein G Sepharose (GE Healthcare), and in-
cubated with anti-CyclinB1 (sc-245, Santa Cruz), anti-CyclinE M-20 (sc-481,
Santa Cruz), or control IgG for 2 h. After 45 min with Protein G Sepharose
beads, IPs were collected and washed 3 times in IP lysis buffer. Kinase ac-
tivities were determined by incubating beads with histone H1 (5 µg, Roche)
in kinase reaction buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 50 mM 2-
glycerophosphate, 0.1% Triton X-100, 1 mM DTT) with 150 γ −32 P − ATP
(10 µCi/µl) for 10 min at 30◦C. Laemmli buffer was added and samples were
fractionated on SDS-PAGE. H1-P was detected using a Storm PhosphorIm-
ager (Amersham). Kinase activity was quantified using ImageQuant software
and normalized to the amounts of H1 and Cdk1 or Cdk2 in the IPs (ImageJ
software).
4.13 Growth analysis
For growth curves of human fibroblasts BJ-SV40, IMR90-SV40, BJ-E6E7, BJ-
p53dn and hMECs cells were plated at a density of 0.5 105 cells per 10 cm
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dish and after 72 or 96h the cells were harvested, counted, and replated at
the same density. This process was repeated until the cell population under-
went telomere crisis. Growth curve was presented as cumulative population
doublings (PD) plotted against time. PDs were determined by the following
formula, where N is the number of cells at the indicated PD and n is the pas-
sage number: PDn = PDn−1+log2(NPDn/NPDn−1). For hMECs cell lines, the
the initial passage number was known but not the initial PD, which was set
arbitrarily to 0, in order to count the PD from the beginning of the experi-
ment. hMECs were split every 4 days (one split corresponds to one passage)
and in this case growth curves were presented as cumulative number of PDs
plotted against the number of passages.
4.14 Live-cell imaging
For FUCCI live cell imaging, the cells were previously transduced with FUCCI
vectors (Sakaue-Sawano et al., 2008) and in some cases sorted for expression
of both the cell cycle fluorescent markers. For CyclinE-eGFP and H2B-GFP
live cell imaging, MEFs were previously transduced with the corresponding
retroviral constructs. For the analysis of POT1a/b deletion, MEFs of the
indicated genotype were infected with Cre and/or shRNA expressing vector
2-4 days before the beginning of the imaging session. Live-cell imaging was
started at day 3 after Cre and/or 2 days after treatment with Cdh1 shrine.
For BRCA2F/+ and BRCA2F/F MEFs and RPE over expressing RasV12, cells
were analyzed by FUCCI imaging starting at day 8 after Cre or after expres-
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sion of RasV12, respectively. Cells were plated 24h before the imaging session
at 40-50% confluence in 4-chambered coverglass (LabTek) or in glass bottom
plates (MatTek). Regular medium was replaced 1 h before the imaging ses-
sion by phenol red-free Liebovitzs L-15 medium (GIBCO) containing 10-15%
FBS100 U/ml penicillin (Sigma), and 0.1 µg/ml of streptomycin (Sigma) 2
mM L-glutamine (Invitrogen). In the cases of continuous zeocin treatment,
zeocin was also added one hour before the imaging session and maintained in
the medium. Time-lapse live-cell imaging was performed using an Olympus
IX71 inverted microscope (Olympus) or by LCV110 ”VivaView” Incubator
Microscope (Olympus) for 72 or 96 hours at the Bioimaging Facility of the
Rockefeller University. Phase contrast and fluorescent (GFP and RFP filters)
images were acquired every 15-20 min with a 10X objective. MetaMorph soft-
ware (Universal Imaging, Media, PA) and ImageJ software were used for data
analysis. For CyclinE-eGFP live cell imagine, a 20X objective was used. Nu-
clear size was calculated from digital images using the Openlab (Improvision)
measure module and statistical analysis was performed using a non-parametric
Krustal-Wallis test (Prism software). After adjustment of the contrast in all
the channels, all the images corresponding to one imaged field were assem-
bled into a movie. In order to score the fraction of cells undergoing failure to
complete mitosis or mitosis-independent geminin degradation (as an indicator
of endoreduplication) in each movie, I used the following method. First the
cells at the beginning, middle and end of the movie were scored: the average
of these three numbers was considered as the total number of cells. Alterna-
tively, the total number of cells was considered as the sum of the green-positive
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(expressing geminin) cells every 8 hours. The number obtained with the two
methods is similar. Next, I scored the number of cells showing mitotic failure
through out the movie and the cells undergoing mitosis-independent geminin
degradation and reversion to a G1-like state (expression of Cdt1). The cases
in which binucleated or multinucleated cells underwent mitosis-independent
geminin degradation were scored as endocycle events.
4.15 In vitro soft agar transformation assay
Soft agar colony-forming assay was performed in 6-well dishes. SeaPlaque
agarose (Lonza) was dissolved in water at a concentration of 4.5%. Each well
contained a bottom layer (2ml, 0.9% agarose) and a top layer (2ml, 0.45%
agarose). First the bottom layer was prepared by preparing culture medium
containing 0.9% agarose (2ml per well) and allowed it to solidify. MEFs were
harvested by trypsinization, counted (twice, before and after dilution) and
diluted to 105 cells per ml. 104 cells were seeded in each well in the upper
layer by quickly mixing the diluted cell suspension in agar containing medium
pre-warmed at 37◦C. After seeding the cells, the upper layer was allowed to
solidify at 4◦C for 30 min. For each sample, 3 or 6 replicates (each well
correspond to one replicate) were plated and analyzed. Cells were incubated
at 37◦Cand 300-500 µl of complete medium was added to each well once a
week. When desired, 4-hydroxytamoxifen was added to the top soft-agar top
layer and to the culture medium. After 4-6 weeks, colonies were stained with
nitro-blue tetrazolium and the number of colonies was scored. In order to
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derive cell lines from soft-agar colonies, the colonies were not stained and the
biggest colonies were picked, trypsinized for 5-10 minutes at 37◦C and plated
in 48-well dishes.
4.16 In vivo transformation assay
In vivo tumorigenic assay was performed by subcutaneous injection in nude
mice with the expert help of Devon White. MEFs were harvested by trypsiniza-
tion, counted and resuspended in PBS. 5 105 diploid or tetraploid cells were
resuspended in 150 ul of PBS and injected into the contra-lateral sides of
NCR-Foxn1nu/nu female mice (Taconic). In some cases, two spots per side
were injected. Injections were performed by Devon White or by me with
Devons assistance after transiently anhestetizing the animals with isoflurane.
The recipient mice were checked once or twice a week for tumor formation
and euthanized when tumors reached 1 cm of diameter, in accordance with
institutional procedures. Latency of the tumor was considered as the number
of weeks prior to the development of a tumor of approximately 1 cm in di-
ameter. When cell lines were derived from the tumors, the tumor mass was
excised and dissociated in culture into single cells by treatment with colla-
genase A (Roche) at 250 units/ml in DMEM for 3 hours at 37◦C or with
collagenaseD/dispase neural protease (4mg/ml of each in DMEM, Boeringher
Mannheim cat 1088858 and 165859) for 1 hour. Cells were then plated in
complete medium for MEFs in 6-well dishes and expanded. All experiments
involving mice were performed in accordance with the institutional regulations
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and ethical guidelines, and have been authorized by the Institutional Animal
Care and Use Committee (IACUC) at Rockefeller University.
4.17 Telomere length analysis
For genomic blotting, cells were harvested at the indicated PD, DNA was iso-
lated by phenol-chloroform extraction using standard technique and digested
with AluI and MboI restriction enzymes (New Engnd BioLabs). After mea-
surement of the DNA concentration by fluorometer (Hoechst staining), 4 ug
of DNA were size-fractionated on a 0.7% agarose gel and transferred to a
Hybond membrane for hyridization using an 800-bp telomeric DNA probe
from pSP73Sty11 labeled with [CCCTAA]3-primed Klenow polymerase and
α−32 P − dCTP . Blots were exposed to a phosphor-imaging screen and ana-
lyzed using ImageQuant software.
4.18 Fusion PCR Assay
DNA from 107 cells was first isolated by phenol-chloroform extraction (stan-
dard method), digested with EcoRI or XhoI restriction enzymes overnight at
37◦C and analyzed for DNA concentration with fluorometer using Hoechst.
Fusion PCR was performed using the following primer concentrations (primer
sequence is given in the Appendix B): 1uM 21q1, 0.5uM 16p9, 0.25uM XpYpM,
0.25uM 17p6 and 0.05uM XpYp-ctr2 (in some cases the primer 16p9 was omit-
ted). Each reaction was performed in a final volume of 20µl, containing 20-
100ng of DNA, 2X Failsafe Buffer H (Epicenter, FSP995H) and 0.8µl of Failsafe
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Enzyme Mix (Epicenter, FS99100). PCR cycles were as follow: 25 cycles of
94◦C for 20 sec, 59◦C for 20 sec and 68◦C for 10 min, with a final extension
time of 10 min at 68◦C. Products of PCR reactions were resolved by 0.7%
TAE (40 mM Tris acetate 1 mM EDTA pH 8) agarose gel electrophoresis and
detection by Southern hybridization with random-primed probe labeled with
α−32P−dCTP . 21q specific probe (21q probe) was made using 21q4 and 21q-
seq-rev primers (Appendix B). The 0.5 kb product amplified by XpYpM and
XpYp-ctr-2 was used as internal control and detected using a probe generated
by XpYpO and XpYpB2 primers (XpYp probe). Nested PCR reactions for
21q primers were performed using 1 ul of 1:20 diluted primary PCR product
and 21q3 primer as nested primer on the 21q subtelomere. Nested PCR was
performed using the same PCR buffer/enzyme and the same thermal-cycling
conditions described for the primary fusion PCR except that 35 cycles were
performed. Blots were exposed to a phosphor-imaging screen and analyzed
using ImageQuant software. For quantification of the fusion bands, ImageJ
software was used to quantify the intensity of each band. An arbitrary thresh-
old was decided for each Southern blot, in order to decide in each case whether
to consider the band as a telomeric product or background or nonspecific prod-
uct.
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4.19 Tet-Off inducible system for POT1a
expression
POT1a cloned into P-TRE-Tight and P-Tet-Off-Advanced (Clonetech) were
transduced into POT1aF/-POT1bF/F MEFs. After treatment with Cre, clones
were isolated with cloning cylinders and analyzed by PCR for the deletion of
the endogenous POT1a. Clones were tested for doxycycline (2µg/ml) inducible
depletion of POT1a and tetraploidy. Two clones were selected for further anal-
ysis, clones 19 and 26.
4.20 List of antibodies
POT1a (1221) and POT1b (1223) (Hockemeyer et al., 2006); ATR N-19 (sc-
1887, Santa Cruz); Chk1 (sc-8408, Santa Cruz); Chk1 pS345 (2348, Cell Signal-
ing Technology); Chk2 (611570, BD Biosciences); CyclinE M-20 (sc-481, Santa
Cruz); CyclinA (sc-596, Santa Cruz), CyclinB1 (sc-245, Santa Cruz); Auro-
raA (ab13824, Abcam); AuroraB (ab2254, Abcam); Plk1 (06-813, Upstate);
securin (K0090-3, MBL); Cdc20 (ab64877, Abcam); Cdh1 (ab5483, Abcam);
geminin (sc-13015, Santa Cruz); β-actin (I-19) (sc-1616, Santa Cruz); Cdk1
(cc16, Calbiochem); Cdk2 (M2) (sc-163, Santa Cruz); APC1 (NB 100-86985,
Novus Biologicals); Cdt1 (P26A6, a gift from A. Ballabeni (Ballabeni et al.,
2004); Cdk1 P-Tyr14/15 (9111, Cell Signaling); pericentrin (ab4448 Abcam);
Scc1 (K0202-3, MBL) ; p16 (C-20) (Santa Cruz). IF for 53BP1 was performed
with Ab 100-304A (Novus Biologicals).
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Appendix A
List of Movies
Movie 1
Chapter 1. Phase contrast imaging of control cells
POT1aF/-POT1bF/F MEFs were infected with vector control an imaged (phase
contrast, objective 10X) every 15 min for 48 h. Arrows highlight one dividing
cell and its daughters. Selected frames from this movie are shown in Fig. 2.7A.
Chapter 2. Phase contrast imaging of POT1a/b DKO cells
POT1aF/-POT1bF/F MEFs were treated with Cre and were imaged as in Chap-
ter 1 (imaging started 72 h after introduction of Cre). Arrows highlight 3
representative cells that do not perform mitosis during the imaging session.
Selected frames from this movie are shown in Fig. 2.7A.
Chapter 3. Phase contrast imaging of zeocin-treated cells
POT1aF/-POT1bF/F MEFs were imaged as in Chapter 1 in the presence of
zeocin (added two hours before starting imaging session and maintained in
culture medium during the imaging session). Arrows highlight 3 representa-
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tive cells not dividing during the session. Selected frames from this movie are
shown in Fig. 2.7A.
Movie 2
Chapter 1. Imaging of control cells expressing CyclinE-eGFP
POT1aF/-POT1bF/F MEFs were transduced with CyclinE-eGFP expressing
vector and then treated with vector control. Cells were imaged (phase contrast
and GFP channel, 20X objective) every 15 min. Arrows highlight representa-
tive cells showing raise in CyclinE-eGFP followed by mitosis.
Chapter 2. Imaging of POT1a/b DKO cells expressing CyclinE-
eGFP
POT1aF/-POT1bF/F MEFs were transduced with CyclinE-eGFP expressing
vectors and then treated with Cre. After 72 h, cells were imaged as in Chap-
ter 1. Arrows highlight representative cells showing CyclinE rising multiple
times without an intervening mitosis.
Movie 3
Chapter 1. FUCCI imaging of control cells
POT1aF/-POT1bF/F MEFs transduced with FUCCI vectors were treated with
vector control and imaged (phase contrast, GFP and rhodamine channels) ev-
ery 15 min for 72 h (10X objective). Arrows highlight a representative cell.
Selected frames from this movie are shown in Fig. 2.8.
Chapter 2. FUCCI imaging of POT1a/b DKO cells
POT1aF/-POT1bF/F MEFs transduced with FUCCI vectors were treated with
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Cre and imaged as in Chapter 1 (imaging started 72 h after introduction of
Cre). Arrows highlight representative cells showing geminin and Cdt1 oscil-
lation in the absence of mitotic events. Selected frames from this movie are
shown in Fig. 2.8.
Chapter 3. FUCCI imaging of zeocin-treated cells
POT1aF/-POT1bF/F MEFs transduced with FUCCI vectors were imaged as in
Chapter 1 in the presence of zeocin (added before the beginning of the session
and maintained on the cells). Arrows highlight representative cells showing
geminin and Cdt1 oscillation in the absence of mitotic events. Selected frames
from this movie are shown in Fig. 2.8.
Movie 4
Chapter 1. FUCCI imaging of control BJ-SV40 cells
BJ human fibroblasts expressing SV40-LT transduced with FUCCI vectors
were imaged (phase contrast, GFP and rhodamine channels) every 15 min for
96 h (10X objective). Arrow highlights a representative cell dividing during
time.
Chapter 2. FUCCI imaging of BJ-SV40 cells treated with zeocin
BJ human fibroblasts expressing SV40-LT transduced with FUCCI vectors
were imaged as in Chapter 1 in the presence of zeocin. Arrows highlight repre-
sentative cells showing geminin and Cdt1 fluctuation in the absence of mitotic
events.
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Movie 5
Chapter 1. FUCCI imaging of synchronized control cells
POT1aF/-POT1bF/F MEFs transduced with FUCCI vectors were synchronized
in G1 by mitotic shake-off. Mitotic cells were plated and 10 h later, cells were
imaged as in Movie 3. Selected frames from this movie are shown in Fig. 2.10A.
Chapter 2. FUCCI imaging of synchronized cells treated with zeocin
POT1aF/-POT1bF/F MEFs transduced with FUCCI vectors were synchronized
in G1 by mitotic shake-off. Mitotic cells were imaged as in Chapter 1 in the
presence of zeocin (added 2 hours before the imaging session and maintained
throughout). Selected frames from this movie are shown in Fig. 2.10A.
Movie 6
Chapter 1. FUCCI imaging of cells treated with Cdh1 shRNA
POT1aF/-POT1bF/F MEFs transduced with FUCCI vectors were treated with
Cdh1 shRNA and imaged (phase contrast, GFP and rhodamine channels, 10X
objective) every 15 min over a period of 60 h. Arrow shows a representative
cell dividing during the imaging session.
Chapter 2. FUCCI imaging of POT1a/b DKO cells treated with
vector control for Cdh1 shRNA
POT1aF/-POT1bF/F MEFs transduced with FUCCI vectors were treated with
Cre and the day after with empty vector (pLK0.1) used for the Cdh1 shRNA.
Cells were imaged (at 72 h after introduction of Cre) as in Chapter 1. Arrows
highlight representative cells. Selected time points from this movie are shown
in Fig. 2.12A.
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Chapter 3. FUCCI imaging of POT1a/b DKO cells treated with
Cdh1 shRNA
POT1aF/-POT1bF/F MEFs transduced with FUCCI vectors were treated with
Cre and the day after with Cdh1 shRNA. At 72 h after introduction of Cre,
cells were imaged as in Chapter 1. Arrows highlight representative cells show-
ing prolonged arrest in G2 without geminin degradation. Selected time points
from this movie are shown in Fig. 2.12A.
Movie 7
Chapter 1. FUCCI imaging of zeocin-treated cells infected with vec-
tor control for Cdh1 shRNA
POT1aF/-POT1bF/F MEFs transduced with FUCCI vectors were treated
with the empty vector (pLK0.1) used for Cdh1 shRNA. Cells were imaged as
in Movie 6 in the presence of zeocin. Zeocin was added 2 h before the session
and maintained on the cells. Arrows highlight representative cells over time.
Selected time points from this movie are shown in Fig. 2.13A.
Chapter 2. FUCCI imaging of zeocin-treated cells infected with the
Cdh1 shRNA
POT1aF/-POT1bF/F MEFs transduced with FUCCI vectors were infected with
Cdh1 shRNA and imaged in the presence of zeocin as in Chapter 1. Arrows
highlight representative cells over time showing prolonged arrest in G2 with-
out geminin degradation. Selected time points from this movie are shown in
Fig. 2.13A.
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Movie 8
Chapter 1. FUCCI imaging of BJ-SV40 cells PD 45
BJ-SV40 cells at PD45 were stably transduced with FUCCI vectors and im-
aged (phase contrast, GFP and rhodamine channels) for 96 hours every 20
min (10X objective). Most of the cells perform a normal mitotic cell cycle
where the green geminin is degraded as the cell goes through mitosis. Selected
frames of this movie are shown in Fig. 2.22A.
Chapter 2. FUCCI imaging of BJ-SV40 cells PD 105
BJ-SV40 cells PD105 stably expressing the FUCCI markers were imaged as in
Chapter 1. Arrows highlight representative cells becoming tetraploid during
the imaging. White arrows highlight representative cells undergoing endoredu-
plication, and black arrows highlight cells undergoing mitotic failure. Selected
frames of this movie are shown in Fig. 2.22A.
Chapter 3. FUCCI imaging of BJ-SV40 cells PD 100
BJ-SV40 cells PD100 (experiment independent from the one shown in Chapter
2) stably expressing the FUCCI markers were imaged as in Chapter 1. Arrows
highlight representative cells becoming tetraploid during the imaging. White
arrows highlight representative cells undergoing endoreduplication, black ar-
rows highlight cells undergoing mitotic failure.
Movie 9
Chapter 1. FUCCI imaging of IMR90-SV40 cells PD 62
IMR90-SV40 cells PD62 were stably transduced with FUCCI vectors and an-
alyzed by live cell imaging as in Movie 8. Selected frames of this movie are
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shown in Fig. 2.22B.
Chapter 2. FUCCI imaging of IMR90-SV40 cells PD 90
IMR90-SV40 cells PD90 stably expressing FUCCI vectors were analyzed by
live-cell imaging as in Movie 8. Arrows highlight representative cells becoming
tetraploid during the imaging. White arrows highlight representative cells un-
dergoing endoreduplication and black arrows highlight cells undergoing mitotic
failure (as in Movie 8). Selected frames of this movie are shown in Fig. 2.22B.
Movie 10
Chapter 1. FUCCI imaging of hMECs 48RS-GSE22 p20
hMECs 48RS-GSE22 passage 20 (early passage) stably expressing FUCCI
markers were imaged as in Movie 8. Selected frames of this are shown in
Fig. 2.24.
Chapter 2. FUCCI imaging of hMECs 48RS-GSE22 p32
hMECs 48RS-GSE22 passage 32 ( telomere crisis) stably expressing FUCCI
markers were imaged as in Movie 8. White arrows highlight representative
cells undergoing endoreduplication, and black arrows highlight cells undergo-
ing mitotic failure Selected frames of this movie are shown in Fig. 2.24.
Chapter 3. FUCCI imaging of hMECs p20 48RS-GSE22 p20 treated
with zeocin
hMECs 48RS-GSE22 passage 20 stably expressing FUCCI markers were im-
aged in the presence of zeocin. White arrows highlight endocycle events and
black arrows highlight mitotic failure events. Selected frames of this movie are
shown in Fig. 2.24.
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Movie 11
Chapter 1. FUCCI imaging of G1-sorted BJ-p53dn cells treated
with zeocin
BJ-p53dn cells at PD35 transduced with the FUCCI vectors were FACS sorted
to isolate the cells in G1 (Cdt1, red). Sorted BJ-p53dn G1 cells were imaged
in the presence of zeocin. Selected frames are shown in Fig. 2.29.
Chapter 2. FUCCI imaging of G1-sorted BJ-SV40 cells treated with
zeocin
BJ-SV40 cells at PD40 transduced with the FUCCI vectors were FACS sorted
for the cells in G1 (Cdt1, red) and imaged as in Chapter1 in the presence of
zeocin. Selected frames are shown in Fig. 2.29.
Movie 12
Chapter 1. FUCCI imaging of G2-sorted BJ-p53dn cells treated
with zeocin
BJ-p53dn cells at PD35 transduced with the FUCCI vectors were FACS sorted
for selection of cells in late S/G2 (geminin, green). S/G2-sorted cells were im-
aged as in Movie 12 in the presence of zeocin. Selected frames are shown in
Fig. 2.29.
Chapter 2. FUCCI imaging of G2-sorted BJ-SV40 cells treated with
zeocin
BJ-SV40 cells at PD40 transduced with the FUCCI vectors were FACS sorted
for cells in late S/G2 (geminin, green). S/G2-sorted cells were imaged as in
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Movie 11 in the presence of zeocin. Selected frames are shown in Fig. 2.29.
Movie 13
Chapter 1 Imaging of sorted diploid cells after re-expression of POT1a
H2B-GFP expressing POT1a-tetOFF cell line 19 was treated as described in
Fig. 2.34A and after sorting diploid cells were imaged in the absence of doxy-
cycline (phase contrast and GFP channel) every 15 min for 72 hours. Arrows
highlight a representative cell dividing multiple times. Selected time points
from this movie are shown in Fig. 2.34B.
Chapter 2 Imaging of sorted tetraploid cells after re-expression of
POT1a
H2B-GFP expressing POT1a-tetOFF cell line 19 was treated as described in
Fig. 2.34A and after sorting tetraploid cells were imaged as in Chapter 1.
Arrows highlight representative cells dividing during time. Cells showing evi-
dence of multipolar spindles are marked with three red arrows. Selected time
points from this movie are shown in Fig. 2.34B.
Movie 14
Chapter 1. FUCCI imaging of BRCA2F/+ MEFs treated with Cre
BRCA2F/+ MEFs were treated with Cre as in Fig. 2.47 and analyzed by
FUCCI imaging at day 8 after Cre. Arrows indicate cells undergoing en-
doreduplication.
Chapter 2. FUCCI imaging of BRCA2F/- MEFs treated with Cre
BRCA2F/- MEFs were treated with Cre as in Fig. 2.47 and analyzed by FUCCI
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imaging at day 8 after Cre. Arrows indicate endoreduplicating cells.
Movie 15
Chapter 1. FUCCI imaging of RPE SV40 cells
RPE SV40 control cells were analyzed by FUCCI imaging.
Chapter 2. FUCCI imaging of RPE SV40 cells overexpressing RasV12
RPE SV40 cells were transduced to overexpress RasV12 as in Fig. 2.48 and
analyzed by FUCCI imaging after 8 days.
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Appendix B
Fusion PCR primers
The following figure shows the sequence of the primers used in the Fusion PCR
assay.
Figure B.1: Sequence of the primers used in the fusion PCR assay.
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Appendix C
List of cell Lines
The following list includes the the cell lines used in this work.
Figure C.1: List of the cell lines used. List of the cell lines used in this work
including the organism and organ of origin and the reference, if not produced in this
work.
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